204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

	Otatiotical Arialysis Flair Americanent
gsk GlaxoSmithKline	Statistical Analysis Plan
Detailed Title:	A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with <i>Prevenar13</i> in adults aged 50 years and older.
eTrack study number and Abbreviated Title	204487 (ZOSTER-059 PRI)
Scope:	All analyses planned per protocol.
Date of Statistical Analysis Plan	Final: 13 April 2018 Amendment 1: 11 June 2019 Amendment 2: 20 November 2019 Amendment 3 Final: 23 November 2020

APP 9000058193 Statistical Analysis Plan Template V4 (Effective date: 3 June 2019)

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

TABLE OF CONTENTS

				PAGE
LIS	ST OF A	BBREVIA	TIONS	10
1.	DOC	JMENT HI	STORY	12
2.	STUE	Y DESIGN	٧	13
3.	OR IE	CTIVES		15
J.	3.1.		ary objectives	
	3.2.		ry objective	
4.	ENDF	POINTS		16
	4.1.		endpoints	
	4.2.	•	ry endpoints	
5.	ANAL	YSIS SET	S	17
	5.1.		1	
		5.1.1.	Enrolled Set	
		5.1.2.	Randomized Set	
		5.1.3.	Exposed Set (ES)*	
	5.2.	5.1.4.	Per-protocol set (PPS)* for immunogenicity	
	5.2.	5.2.1.	or eliminating data from Analysis Sets Elimination from Enrolled Set	
		5.2.1. 5.2.2.	Elimination from Randomized Set	
		5.2.3.	Elimination from Exposed Set (ES)	
		5.2.4.	Elimination from Per-protocol analysis Set (PPS)	
	5.3.	Importan	t protocol deviation not leading to elimination from per-	
		protocor	analysis set	21
6.	STAT	ISTICAL A	NALYSES	21
	6.1.		aphy	
		6.1.1.	Analysis of demographics/baseline characteristics planned	
		0.4.0	in the protocol	
	0.0	6.1.2.	Additional considerations	
	6.2.	6.2.1.	Analysis of exposure planned in the protocol	22
		6.2.2.	Additional considerations	
	6.3.	-	genicity	
	0.5.	6.3.1.	Analysis of immunogenicity planned in the protocol	
		0.0.1.	6.3.1.1. Within group assessment	
			6.3.1.2. Between group assessment	
		6.3.2.	Additional considerations	
			6.3.2.1. Statistical considerations for confirmatory	0.4
	6.4	A malus!=	objectives	
	6.4.		of safety	
		6.4.1. 6.4.2.	Analysis of safety planned in the protocol	
		0.4.2.	6.4.2.1. Combined Solicited and Unsolicited Adverse	20
			Events	28

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3 8 1 82 10. NON-STANDARD DATA DERIVATION RULES AND STATISTICAL 12. ANNEX 1 STANDARD DATA DERIVATION RULE AND STATISTICAL 12.1.2. Safety 33 12.2. 12.3.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

LIST OF TABLES

		PAGE
Table 1	Study groups and epochs foreseen in the study	14
Table 2	Study groups and treatment foreseen in the study	14
Table 3	Blinding of study epochs	14
Table 4	Power to demonstrate VRR objective and non-inferiority of the immunogenicity of HZ/su and <i>Prevenar13</i> co-administered compared to Control group.	24
Table 5	Analysis and disclosure plan for the planned analysis	29
Table 6	Group Definitions to be used for the sub-group analysis by age (Analysis will be included in the clinical report)	31

20	4487	Statistical	Analysis Plan	Amendment 3 23 Nov	2020 LTMF-	6035255 2 (
20	440/	i Statistical i	AHAIVSIS ETAIL	AIDENUMENT 3 43 INOV		UU. 1. 1 Z. 1. 1 I Z. U

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

LIST OF FIGURES

		PAGE
Figure 1	Overview of Study Design	13

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

LIST OF TEMPLATES

		PAGE
Template 1	Number of subjects by country and center <exposed set=""></exposed>	37
Template 2	Number of enrolled subjects by country	37
Template 3	Number of enrolled subjects by age category	37
Template 4	Number of subjects by country and age category <exposed set=""></exposed>	38
Template 5	Number of subjects vaccinated, completed and withdrawn with reason for withdrawal – <end active="" end="" of="" phase,="" study=""> <exposed set=""></exposed></end>	38
Template 6	Visit attendance <exposed set=""></exposed>	38
Template 7	Summary of important protocol deviations leading to elimination from any analyses	39
Template 8	Percentage of subjects with serological results who were eliminated from PPS for immunogenicity	39
Template 9	Deviations from specifications for age and intervals between study visits for Co-Ad group <exposed set=""></exposed>	39
Template 10	Deviations from specifications for age and intervals between study visits - for Control group <exposed set=""></exposed>	40
Template 11	Summary of demographic characteristics <exposed for="" immunogenicity="" pps="" set,=""></exposed>	40
Template 12	Minimum and maximum activity dates <exposed set=""></exposed>	41
Template 13	Study Population <exposed set=""></exposed>	41
Template 14	Exposure to study vaccines <exposed set=""></exposed>	42
Template 15	Compliance in completing solicited adverse events information <exposed set=""></exposed>	42
Template 16	Incidence and nature of <grade 3="" 3,="" grade="" related,=""> adverse events (<unsolicited and="" only="" solicited="" solicited,="">) reported <during (days="" 1-7)="" 1-7),="" 7-day="" beyond="" the=""> post-vaccination period following each dose and overall <exposed set=""></exposed></during></unsolicited></grade>	43
Template 17	Incidence of solicited local adverse events reported during the 7-day (Days 1-7) post-vaccination period by study vaccine following each dose and overall <exposed set=""></exposed>	44

	204487 (ZOSTER- Statistical Analysis Plan Amer	
Template 18	Incidence of solicited general adverse events reported during the 7-day (Days 1-7) post-vaccination period following each dose and overall <exposed set=""></exposed>	45
Template 19	Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose <exposed set=""></exposed>	46
Template 20	Number and percentage of subjects reporting the occurrence of <grade 3=""> <non-serious> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with attended="" causal="" medically="" relationship="" to="" vaccination,="" visit="" with="">, within the 30-day (Days 1-30) post-vaccination period <,including numbers of events><exposed set=""></exposed></with></non-serious></grade>	47
Template 21	Global Summary of <grade 3=""> <non-serious>unsolicited signs and adverse events reported <with attended="" causal="" medically="" relationship="" vaccination,="" visit="" with=""> within the 30-day (Days 1-30) post-vaccination period <exposed set=""></exposed></with></non-serious></grade>	48
Template 22	Number and percentage of subjects starting a concomitant medication during the 30- day (Days 1-30) post vaccination period by dose and overall <exposed set=""></exposed>	48
Template 23	Number of days with solicited <local, general=""> adverse events <during (days="" 1-7)="" 7="" and="" days="" dose="" each="" following="" overall="" period="" post="" the="" vaccination=""> <- Prevenar 13 vaccine, - HZ/su vaccine> <exposed set=""></exposed></during></local,>	49
Template 24	Solicited and unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term within the 30-day (Days 1-30) post-vaccination period including number of events - SAE excluded <exposed set=""></exposed>	49
Template 25	Number (%) of subjects with serious adverse events from <first 30="" <database="" date(ddmmmyyyy)="" days="" dose="" end,="" first="" freeze="" last="" post="" study="" to="" up="" vaccination="" vaccination,=""><study end="">, including number of events reported <exposed set=""></exposed></study></first>	50
Template 26	Number (%) of subjects reported solicited local adverse events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <exposed set=""></exposed>	51
Template 27	Number (%) of subjects reported solicited general adverse events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <exposed set=""></exposed>	52
Template 28	Number and percentage of subjects with <anti-pneumococcal <x=""> antibody titres> equal to or above <cut-off> and GMT <pps exposed="" for="" immunogenicity,="" set=""></pps></cut-off></anti-pneumococcal>	53

	204487 (ZOSTER-0 Statistical Analysis Plan Amen	
Template 29	Seropositivity rate and geometric mean concentration for anti-gE ELISA antibody concentration <pps exposed="" for="" immunogenicity,="" set=""></pps>	53
Template 30	Adjusted ratios of GMCs between groups (Control group divided by Co-Ad group) for anti-gE antibody ELISA concentrations at one month post dose 2 of HZ/su vaccine < <i>PPS for immunogenicity</i> , Exposed Set>	54
Template 31	Adjusted ratios of GMTs between groups (Control group divided by Co-Ad group) for anti-pneumococcal <x> antibody titres at one month post Prevenar 13 vaccine <pps exposed="" for="" immunogenicity,="" set=""></pps></x>	54
Template 32	Mean Geometric Increase (MGI) of anti-gE antibody ELISA concentrations from baseline to one month post dose 2 of HZ/su vaccine < <i>PPS for immunogenicity</i> , Exposed Set>	54
Template 33	Descriptive statistics of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentration < <i>PPS for immunogenicity</i> , Exposed Set>	55
Template 34	Distribution of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentrations < PPS for immunogenicity, Exposed Set>	55
Template 35	Listing of potential Immune Mediated Diseases (pIMDs) reported as identified by predefined list of preferred terms and/or by investigator assessment up to end of study by age subgroup <exposed set=""></exposed>	56
Template 36	Listing of all SAEs up to end of study by age subgroup <exposed set=""></exposed>	56
Template 37	Listing of suspected HZ cases from first administered dose up to end of study by age subgroup <exposed set=""></exposed>	56
Template 38	Listing of (S)AEs and solicited adverse events leading to study or treatment discontinuation <up 5="" month="" to=""><up end="" of="" study="" to=""> by age subgroup <exposed set=""></exposed></up></up>	57
Template 39	Maximum intensity of solicited <local, general=""> adverse event ongoing beyond the 7-day (Days 1-7) post-vaccination period following each dose and overall <exposed set=""></exposed></local,>	57
Template 40	Number and percentage of doses reporting the occurrence of <grade 3=""> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal="" relationship="" to="" vaccination=""> within the 30-day (Days 1-30) post-vaccination period <exposed set=""></exposed></with></grade>	58
Template 41	Number and percentage of subjects reporting the occurrence of <serious adverse="" disease="" events,="" immune="" mediated="" potential=""></serious>	

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3 classified by MedDRA Primary System Organ Class and Preferred Term from <first vaccination up to 30 days post last vaccination, from 30 days post last vaccination dose up to end of study, from first vaccination up to study end> < including number Global Summary of <serious adverse events, potential Immune Template 42 Mediated Disease> < with causal relationship with vaccination> reported from <first vaccination up to 30 days post last vaccination, from 30 days post last vaccination dose up to end of study, from first vaccination up to study end> <Exposed Set>.................59 Template 43 Vaccine response rates for anti-gE antibody concentrations at one month post dose 2 of HZ/su vaccine <PPS for immunogenicity, Exposed Set>.....60 Template 44 Reverse cumulative distribution curves for <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> in each group at baseline and <post dose 2 of HZ/su vaccine, post dose of Prevenar 13> <PPS for immunogenicity, Exposed Set>......61 Number and percentage of subjects <with><experiencing> fatal Template 45 SAEs classified by MedDRA Primary System Organ Class and Preferred Term <who died><with onset of fatal SAE> <during the period starting> <from first vaccination up to 30 days post last vaccination dose > <after 30 days post last vaccination dose up to study end><from first vaccination until the study end><during the entire study period> <Exposed Set>......62 Summary of subject disposition from Enrolled Set to Randomized Template 46 Summary of subject disposition from Randomized Set to Per Template 47 Template 48 Listing of subjects who died during the entire study period and their fatal SAEs by age subgroup < Enrolled Set>......64 Summary of subjects by unsolicited adverse event category, with Template 49 onset within 30 days of each vaccination65 Template 50 Summary of subjects by serious adverse event and potential Immune Mediated Disease categories, with onset <from first vaccination to 30 days post last vaccination, after 30 days post last vaccination until study end>......65

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

LIST OF ABBREVIATIONS

AE Adverse event

AES Adverse Event Screen

ANCOVA Analysis of Covariance

AS01_B: MPL, QS21, liposome based Adjuvant System (50 µg MPL and 50

μg QS21)

BS Blood Sampling

CDR Clinical Data Reviewer

CI Confidence Interval

Co-Ad Co-administration

CRDL Clinical Research and Development Lead

CRF Case Report Form

CSR Clinical Study Report

CTRS Clinical Trial Registry Summary

EL.U/ml ELISA unit per milliliter

Eli Type Internal GSK database code for type of elimination code

ELISA Enzyme-linked immunosorbent assay

EoS End of Study

ES Exposed Set (formally called 'Total Vaccinated Cohort')

GMC Geometric mean antibody concentration

GMT Geometric mean antibody titre

GSK GlaxoSmithKline

IU/ml International units per milliliter

LL Lower Limit of the confidence interval

LLOQ Lower Limit of Quantification

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

MedDRA Medical Dictionary for Regulatory Activities

MGI Mean Geometric Increase

MOPA Multiplex Opsonophagocytosis Assay

PCD Primary Completion Date

PD Protocol Deviation

PDMP Protocol Deviation Management Plan

PPS Per-Protocol Set (formally called 'According to Protocol')

PT Preferred Term

SAE Serious adverse event

SAP Statistical Analysis Plan

SBIR GSK Internet Randomization System

SD Standard Deviation

SHS Study Headline Summary

SOC System Organ Class

SUSAR Suspected Unexpected Serious Adverse Reactions

TFL Tables Figures and Listings

TOC Table of Content

UL Upper Limit of the confidence interval

ULOQ Upper Limit of Quantification

VRR Vaccine response rate

YOA Years of Age

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

1. DOCUMENT HISTORY

Date	Description	Protocol
		Version
13 APR	First Version	Amendment 2:
2018		30 JAN 2018
11 JUN	Amendment 1 - Summary of changes as below:	Amendment 2:
2019	- As per new process applicable, the front page has been	30 JAN 2018
	modified to remove the names of all the contributing author	
	and reviewers. Also, sign-off is only required to be done by	
	Lead Statistician	
	- Updated LLOQ and newly calculated ULOQ for the 13	
	pneumococcal serotypes tested by MOPA have been added	
	and accordingly analysis of immunogenicity section has been	
	updated.	
	- Consort table have been added for subject disposition.	
	- Additional tables for fatal serious adverse events (SAEs) and	
	grade 3 non-serious unsolicited adverse events (AEs) have	
	been added.	
	- The term "symptom" has been changed to "adverse event	
	(AE)" in endpoints, table titles and content for solicited AEs,	
	unsolicited AEs, SAEs, and potential immune mediated	
	diseases (pIMDs).	
	- Table 'Summary of temperature value by half degree	
	increment reported during the 7-day (Days 1-7) post-	
	vaccination following each dose' has been removed	
	- Sequence of analysis has been updated	
	- Inclusion of Enrolled and Randomized Set definition	
	- Code 1500 in elimination codes has been removed and added	
	under code 1070. Also, mandatory columns have been added	
	in the elimination table under 'Elimination from PPS section.	
20-	Amendment 2 - Summary of changes as below:	Amendment 2:
NOV-	- The active phase analysis has been removed as a request for	30 JAN 2018
2019	a CTRS posting extension has been submitted to NIH;	
	complete CTRS posting will be done at Last Subject Last Visit	
	(LSLV) + 12 months rather than Primary Completion Date	
	(PCD) +12 months as previously planned	
	- Titles and Footnotes of selected templates have been updated	
	following the Dry run kick-off meeting	
	- Two new safety templates have been added (Templates 49	
	and 50)	
23-	Amendment 3 – Summary of changes: -	Amendment
NOV-	Few templates have been edited for better presentation	2: 30 JAN
2020	Removal of template for vaccine response table with only one	2018
	group for primary objective assessment; Addition of separate	
	template for anti-gE seropositivity rate and GMC, list of PT	
	codes to identify suspected HZ episode	

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

2. STUDY DESIGN

Figure 1 Overview of Study Design



Vacc: vaccination; BS: blood sample; Pre-Vacc: pre-vaccination; FU: follow-up

Experimental design: Phase IIIB, open-label, randomized, controlled, multi-centric, and multi-country, with two parallel groups.

Duration of the study: The intended duration of the study per subject is approximately 14 months for subjects from the Co-Ad group and approximately 16 months for subjects from the Control group.

• Epoch 001: Primary starting at Visit Day 1 and ending with the phone contact at Month 16.

Primary completion date (PCD): Visit Month 5.

End of Study (EoS): Last testing results released of samples collected at Visit Month 3 (Co-Ad group) or at Visit Month 5 (Control group).

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Study groups:

Table 1 Study groups and epochs foreseen in the study

Study groups	Number of subjects	Age	Epochs Epoch 001
Co-Ad	456	≥ 50 years	Х
Control	456	≥ 50 years	Х

Table 2 Study groups and treatment foreseen in the study

Treatment name	Vaccine/Product name	Study	Groups
		Co-Ad	Control
HZ/su	VZV gE	Х	Х
	AS01B	Х	Х
Prevenar13	Prevenar 13	Х	х

Control: active control.

Vaccination schedule(s):

- Co-Ad Group:
 - at Visit Day 1: first dose of HZ/su and one dose of Prevenar13,
 - at Visit Month 2: second dose of HZ/su.
- Control Group:
 - at Visit Day 1: one dose of *Prevenar13*,
 - at Visit Month 2: first dose of HZ/su,
 - at Visit Month 4: second dose of HZ/su.

Treatment allocation: Subjects to be randomized in a 1:1 ratio at Visit Day 1 to either Co-Ad or Control group. Subjects in each group will be stratified by age with the following approximate distribution (not less than 25% in each age strata):

- 171 subjects in the 50-59 Years of Age (YOA) stratum,
- 171 subjects in the 60-69 YOA stratum, and
- 114 subjects in the \geq 70 YOA stratum.

Blinding: open-label.

Table 3 Blinding of study epochs

Study Epochs		Blinding	
Ī	Epoch 001	open	

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

3. OBJECTIVES

3.1. Co-Primary objectives

To determine the vaccine response rate (VRR) to HZ/su (based on humoral immune response) one month after the second vaccine dose, when the first dose of HZ/su is co-administered with *Prevenar13* (Co-Ad group).

Criterion to be used:

The objective is met if the lower limit (LL) of the 95% CI of the VRR for anti-gE antibody concentrations in the Co-Ad group one month after the second vaccine dose is $\geq 60\%$.

If the above objective is met in the Co-Ad group, then the following objective will be evaluated:

To demonstrate non-inferiority of the humoral immune response to two doses of HZ/su at one month after the last vaccine dose, when the first dose of HZ/su is co-administered with *Prevenar13* (Co-Ad group) compared to when two doses of HZ/su are administered subsequent to *Prevenar13* (Control Group).

Criterion for non-inferiority:

One month after the last vaccine dose in each study group, the upper limit (UL) of the 95% confidence interval (CI) for the anti-gE antibodies Geometric Mean Concentration (GMC) ratio between the Control group and the Co-Ad group is <1.5.

If the above non-inferiority objective is met, then the following objective will be evaluated:

To demonstrate non-inferiority of the humoral immune response to *Prevenar13* at one month after the vaccine dose, when *Prevenar13* is co-administered with the first HZ/su dose (Co-Ad group) compared to when *Prevenar13* is administered separately from HZ/su (Control group), for the 13 serotypes included in *Prevenar13* analyzed sequentially.

Criterion for non-inferiority:

One month after the Prevenar13 vaccine dose in each study group, the UL of the 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group is <2.

For the co-primary objectives, fixed sequence testing which allows for full alpha propagation in pre-ordered hypotheses families will be used (see section 6.3.2.1).

3.2. Secondary objective

To evaluate the safety and reactogenicity following administration of HZ/su and *Prevenar13* vaccines, up to one month post last vaccination and during the whole follow-up period, in the Control group and the Co-Ad group.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

4. ENDPOINTS

4.1. Primary endpoints

HZ/su immunogenicity:

- Vaccine response for anti-gE humoral immunogenicity, as determined by ELISA, in subjects from the Co-Ad group at one month post-dose 2, at Visit Month 3.
- Anti-gE antibody concentrations as determined by ELISA at one month post-dose 2, at Visit Month 3 for the Co-Ad group and Visit Month 5 for the Control group.

Pneumococcal vaccine immunogenicity:

• Anti-pneumococcal antibody titers for the 13 following serotypes as determined by MOPA at one month post-dose at Visit Month 1: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

The criteria used to define the VRR is given in Section 12.1.2.

4.2. Secondary endpoints

Occurrence of solicited local and general adverse events:

- Occurrence, duration and intensity of each solicited local adverse event within 7 days (Days 1 7) after each vaccination,
- Occurrence, duration, intensity and relationship to vaccination of each solicited general adverse event within 7 days (Days 1 7) after each vaccination.

Occurrence of unsolicited AEs:

Occurrence, intensity and relationship to vaccination of unsolicited AEs within 30 days (Days 1 - 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.

Occurrence of SAEs:

- Occurrence and relationship to vaccination of all SAEs from first vaccination at Day 1 up to 30 days post last vaccination.
- Occurrence and relationship to vaccination of all SAEs during the period starting after 30 days post last vaccination up to study end.

Occurrence of pIMDs:

- Occurrence and relationship to vaccination of any pIMDs from first vaccination at Day 1 up to 30 days post last vaccination.
- Occurrence of any pIMDs during the period starting after 30 days post last vaccination up to study end.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

5. ANALYSIS SETS

5.1. Definition

5.1.1. Enrolled Set

The Enrolled Set will include all the subjects for whom valid signed informed consent form is available

5.1.2. Randomized Set

The Randomized Set will include all the subjects for whom valid signed informed consent form is available and treatment is allocated.

5.1.3. Exposed Set (ES)*

The Exposed set (ES) will include all subjects with at least one vaccine administration documented:

- The ES for analysis of solicited adverse events will include all subjects with at least one documented administered vaccine.
- The ES for analysis of unsolicited AEs, SAEs and pIMDs will include all subjects with at least one vaccine administered.
- The ES for analysis of immunogenicity will include vaccinated subjects for whom immunogenicity data are available.

The ES analysis will be performed per treatment actually administered (at Dose 1).

5.1.4. Per-protocol set (PPS)* for immunogenicity

The Per-protocol set for immunogenicity will include all evaluable subjects:

- who meet all eligibility criteria,
- who comply with the procedures and intervals allowed for the analysis,
- who do not meet any of the criteria for elimination during the study,
- for whom data concerning immunogenicity endpoint measures are available.

17

^{*} Note that in order to align to ICH and cDISC terminology the Total Vaccinated Cohort and the Per- Protocol cohort have been renamed Exposed Set (ES) and Per-Protocol Set (PPS) respectively.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

The intervals allowed for the inclusion in the *PPS for immunogenicity* are defined as follows:

	Group	Interval	Allowed interval for PPS analysis of immunogenicity
Interval between	Co-Ad	HZ/su (Dose 1) – HZ/su (Dose 2)	49-83 Days
vaccinations	Control	Prevenar13 (Dose 1) – HZ/su (Dose 2)	>= 60 days*
	Control	HZ/su (Dose 2) – HZ/su (Dose 3)	49-83 Days
Interval between vaccination and blood sample	Co-Ad	Prevenar13 (Dose 1) – Visit Month 1 for BS	28-48 Days*
taken	Co-Ad	HZ/su (Dose 2) – Visit Month 3 for BS	28-48 days*
	Control	Prevenar13 (Dose 1) – Visit Month 1 for BS	28-48 Days*
	Control	HZ/su (Dose 3)– Visit Month 5 for BS	28-48 days*

BS= blood sampling taken; *please note these intervals differ from protocol amendment 2 Table 8 and 9 to increase the number of evaluable subjects while not compromising the interpretation of immunogenicity data

5.2. Criteria for eliminating data from Analysis Sets

Elimination codes are used to identify subjects to be eliminated from analysis. Detail is provided below for each set.

5.2.1. Elimination from Enrolled Set

Code 900 (invalid informed consent or fraud data) will be used for identifying subjects eliminated from Enrolled Set.

5.2.2. Elimination from Randomized Set

Code 900 (invalid informed consent or fraud data) and code 1010 (vaccine number not allocated) will be used for identifying subjects eliminated from Randomized Set.

5.2.3. Elimination from Exposed Set (ES)

Code 1030 (Study vaccine not administered at all), code 1010 (vaccine number not allocated) and code 900 (invalid informed consent or fraud data) will be used for identifying subjects eliminated from ES.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

5.2.4. Elimination from Per-protocol analysis Set (PPS)

A subject will be excluded from the PPS analysis under the following conditions:

Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set
900	Invalid informed consent or fraudulent data. Subjects excluded from all stat analysis Note: Subjects receiving a code 900 should not receive any other elimination codes.	All	All
1010	Vaccine number not allocated Note: Subjects receiving a code 1010 should not receive any other elimination codes	Day 1	Randomized Set, ES, PPS
1030	Study vaccine not administered AT ALL but subject number allocated Note: Subjects receiving a code 1030 should not receive any other elimination codes	Day 1	ES, PPS
1040*	Administration of concomitant vaccine(s) forbidden in the protocol Comment: Co-Ad group: From 30 days before 1st vaccination up to Month 3 blood sampling Control group: From 30 days before 1st vaccination up to Month 5 blood sampling	Co-Ad group: Day -30 to Month 3 Control group: Day -30 to Month 5	PPS
1050	Randomization failure (subject not randomized in the correct group) Comment: To check for manual randomisation, treatment not compatible with one assigned by SBIR	Day 1	PPS
1070	 Side, site or route of study vaccine administration wrong or unknown Administration not according to protocol for reason specified by the investigator, other than side, site and route Wrong replacement or study vaccine administered (not compatible with the vaccine regimen associated to the treatment number) Administered study vaccine reported as being the correct one but is not compatible with the vaccine regimen associated to the treatment number. 	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
1080	Vaccine has been administered (effective treatment number) despite a temperature deviation qualified by Status QA GMP NON Use	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
1090	Expired vaccine administered	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
2010	Protocol violation (inclusion/exclusion criteria)	Day 1	PPS
2040*	Administration of any medication forbidden by the protocol Co-Ad group: From 1st vaccination up to Month 3 blood sampling Control group: From 1st vaccination up to Month 5 blood sampling	Co-Ad group – Day 1 up to Month 3 Control group – Day 1 up to Month 5	PPS

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

	Statistical Analysis Plan Amendment				
Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set		
2050*	Underlying medical condition forbidden by the protocol Co-Ad group: From 1st vaccination up to Month 3 blood sampling	Co-Ad group – Day 1 up to Month 3	PPS		
	Control group: From 1st vaccination up to Month 5 blood sampling	Control group – Day 1 up to Month 5			
2060*	Concomitant infection related to the vaccine which may influence immune response Co-Ad group: From 1st vaccination up to Month 3 blood sampling	Co-Ad group – Day 1 up to Month 3 Control group – Day 1 up	PPS		
	Control group: From 1st vaccination up to Month 5 blood sampling	to Month 5			
2070*	Concomitant infection not related to the vaccine which may influence immune response Comment:	Co-Ad group – Day 1 up to Month 3	PPS		
	Co-Ad group: From 1st vaccination up to Month 3 blood sampling Control group: From 1st vaccination up to Month 5 blood sampling	Control group – Day 1 up to Month 5			
2080	Subjects did not comply with vaccination schedule (dates of vaccination not corresponding to adapted protocol intervals provided in SAP or unknown	Co-Ad group: Day 1, Month 2	PPS		
	vaccination dates) Comment: Co-Ad group: DOSE 1 – DOSE 2 Control group: DOSE 1 – DOSE 2 DOSE 2 – DOSE 3	Control group: Day 1, Month 2, Month 4			
2090	Subjects did not comply with blood sample schedule (dates of BS not corresponding to adapted protocol intervals provided in SAP or unknown BS/vaccination	Co-Ad group: Month 1, Month 3	PPS		
	dates) Comment: Co-Ad group: DOSE 1 – MONTH 1 BS	Control group: Month 1, Month 5			
	DOSE 2 – MONTH 1 BS Control group: DOSE 1 – MONTH 1 BS DOSE 3 – MONTH 5 BS				
2100	Serological results not available post-vaccination (including lost samples, blood sample not done, unable to test, absence of parallelism). Please specify the applicable rule: elimination code if ALL are missing for a subject Comment:	Co-Ad – Month 1, Month 3 Control – Month 1, Month 5	PPS		
	Co-Ad group: Check for availability of anti-gE serological result at Month 3 and for pneumococcal serological results at Month 1 Control group: Check for availability of anti-gE serological result at Month 5 and for pneumococcal serological results at Month 1				
2120	Obvious incoherence or abnormality or error in data (incoherence between CRF and results, wrong labelling) Comment: Co-Ad group: Check for above condition on anti-gE	Co-Ad – Month 1, Month 3 Control – Month 1, Month 5	PPS		
	serological result at Month 3 and on pneumococcal serological results at Month 1				

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set
	Control group: Check for above condition on anti-gE serological result at Month 5 and on pneumococcal serological results at Month 1		
2500	Incomplete vaccination course. Comment: The subject should receive one dose of Prevenar 13 vaccine and 2 doses of Hz/su vaccine	Co-Ad – Day 1, Month 2 Control – Day 1, Month 2, Month 4	PPS

BS = Blood sample

5.3. Important protocol deviation not leading to elimination from per-protocol analysis set

For information on important protocol deviation not leading to elimination from the PPS set, refer to the study protocol deviation and management plan (PDMP).

6. STATISTICAL ANALYSES

Note that standard data derivation rule and stat methods are described in Section 12 and will not be repeated below. All analyses will be presented by study phase when there are data for both active and follow up phases.

6.1. Demography

6.1.1. Analysis of demographics/baseline characteristics planned in the protocol

Demographic characteristics (age at first vaccination, sex, race and ethnicity) will be tabulated per treatment group.

The mean age (plus range and standard deviation [SD]) of the subjects, as a whole, and per treatment group will be calculated for ES and PPS. The distribution of subjects enrolled among the study sites will be tabulated, as a whole, and per treatment group.

The same tabulations might be performed by age strata (50-59, 60-69 and \geq 70 YOA) if deemed necessary.

6.1.2. Additional considerations

- The following additional tables will be generated:
 - The number of subjects enrolled into the study as well as the number of subjects excluded from PPS analyses will be presented through two consort tables:
 - Consort table 1 Showing the subjects disposition from Enrolled Set to Randomized Set
 - Consort table 2 Showing the subjects disposition from Randomised Set to *Per Protocol Set for immunogenicity*
 - Withdrawal status will be summarized by group. The numbers of withdrawn subjects will be tabulated according to the reason for withdrawal

^{*} Attribution of these elimination codes are responsibility of CRDL following review of individual data listings

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

- The following table will be generated for CTRS:
 - Percentage of Enrolled subjects by country will be tabulated by group.
 - Percentage of Enrolled subjects in the following age categories ≤64, 65-84, ≥85 will be tabulated by group.
- For computation of age, following rule need to be considered:
 - Age will be calculated as the number of years between the date of birth and the date of first vaccination.
 - To ensure that the collection of date of birth will not jeopardise the privacy of Personally Identifiable Information (PII), only a partial date of birth (MMYYYY) will be collected.
 - Therefore, the 15th of the month will be used to replace the missing date.
 - In case the month is missing, the date will be replaced by the June 30th of the year.
- Summary of important protocol deviations leading to elimination will be presented.

6.2. Exposure

6.2.1. Analysis of exposure planned in the protocol

None

6.2.2. Additional considerations

The number of doses administered will be tabulated. The number of doses administered will be tabulated by age sub-group.

6.3. Immunogenicity

6.3.1. Analysis of immunogenicity planned in the protocol

The primary analysis will be based on the *Per-protocol set (PPS) for immunogenicity*. A second analysis based on the Exposed set will be performed to complement the per-protocol analysis (see section 9 for changes in the planned analysis).

Immunogenicity analyses for confirmatory objectives will be performed by age stratum (50-59, 60-69 and \geq 70 YOA) on PPS, if the number of subjects enrolled is sufficient in each stratum.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

6.3.1.1. Within group assessment

The following parameters will be tabulated by vaccine group at each time point when a blood sample result is available:

- Seropositivity with exact 95% CI for all antigens
- GMC/GMT with 95% CI for all antigens
- VRR with exact 95% CI for anti-gE
- Mean Geometric Increase (MGI) with exact 95% CI for anti-gE
- Descriptive statistics (N, mean, SD, min, Q1, median, Q3, max) of Mean Geometric Increase (MGI) for anti-gE
- Distribution of the fold increase i.e. Percentage of subjects with a more than X-fold (e.g. >2, >4, >6, -fold) increase will be tabulated for anti-gE per group with 95% CI.
- Antibody titre/concentration will be displayed using reverse cumulative curves.

6.3.1.2. Between group assessment

The following between group comparison will be performed:

- For the second co-primary objective for non-inferiority of the anti-gE humoral response, at one-month post-dose 2 of HZ/su vaccine:
 - The 95% CI of the group GMCs ratio (Control divided by Co-Ad) will be computed using an ANCOVA model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.
- For the third co-primary objective for non-inferiority of the humoral response to each vaccine pneumococcal serotype (according to the pre-specified order in the protocol), one month post-dose of *Prevenar13*:
 - The 95% CI of the group MOPA GMT ratios (Control divided by Co-Ad) will be computed using an ANCOVA model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

6.3.2. Additional considerations

The following additional points need to be considered for immunogenicity analysis:

- Percentage of subjects above the pneumococcal serotype specific LLOQ will be calculated for each serotype with exact 95% Cis.
- Immunogenicity descriptive analyses will be performed by age stratum (50-59, 60-69 and \geq 70 YOA), if the number of subjects enrolled is sufficient in each stratum.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

- Two-sided 95% CIs for Seropositivity and VRR will be computed by Clopper-Pearson method [Clopper, 1934].
- The two-sided 95% CI for the mean of log-transformed titre/concentration will be first obtained assuming that log-transformed values were normally distributed with unknown variance. The 95% CI for the GMTs/GMCs/MGIs will be then obtained by exponential-transformation of the 95% CI for the mean of log-transformed titre/concentration.

6.3.2.1. Statistical considerations for confirmatory objectives

For the multiplicity adjustment, all hypotheses have been ranked into three families and one sub-family according to the following power of test:

Table 4 Power to demonstrate VRR objective and non-inferiority of the immunogenicity of HZ/su and *Prevenar13* co-administered compared to Control group

Endpoint	Threshold	VR assumed	Total β	Power
VRR in Co-Ad group	0.60	95%	0.001%	99.99%
Family 2: HZ/su: non-inferi				
Endpoint	Standard deviation	δ	Total β	Power
Anti-gE GMC ratio	0.35	1.5	0.001 %	99.99 %
Family 3: Prevenar13: Non	-inferiority* (1-sided test	with alpha = 2.5%)	N=410	
Endpoint (13 vaccine pneumococcal serotypes)	Standard deviation	δ	Total β	Power
3 GMT ratio	0.660	2	0.001%	99.99%
19A GMT ratio	0.644	2	0.001%	99.99%
1 GMT ratio	0.798	2	0.029%	99.97%
18C GMT ratio	0.891	2	0.203%	99.80%
4 GMT ratio	0.906	2	0.260%	99.74%
6A GMT ratio	0.919	2	0.320%	99.68%
5 GMT ratio	0.931	2	0.383%	99.62%
19F GMT ratio	0.971	2	0.664%	99.33%
6B GMT ratio	0.995	2	0.891%	99.11%
7F GMT ratio	1.014	2	1.107%	98.89%
9V GMT ratio	1.021	2	1.194%	98.81%
14 GMT ratio	1.045	2	1.530%	98.47%
23F GMT ratio	1.094	2	2.398%	97.60%
Global β to show non-inferio	ority		~9%	
Global power	~91%			

VRR: vaccine response rate; gE: Varicella Zoster Virus glycoprotein E; GMT: geometric mean titer; GMC: geometric mean concentration.

For gE: non-inferiority limit = 0.176 (=log10(1.5)), power under equal GMC

For each pneumococcal serotype: non-inferiority limit = 0.301 (=log10(2)), variability for each of the 13 vaccine pneumococcal serotype taken from the EMA assessment report for *Prevenar13* and multiplied by 1.1, power under equal GMT.

^{*} Pass 12, alpha = 2.5%, for VRR: Exact test, for non-inferiority one-sided equivalence of means.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Fixed sequence testing which allows for full alpha propagation in pre-ordered hypotheses families will be applied in the following manner:

Family 1:

In the Co-Ad group, for anti-gE, at one month post-dose 2 of HZ/su vaccine:

• The VRR and 95% CI will be computed.

The objective is met if the LL of the 95% CI is \geq 60%.

Family 2:

For anti-gE, at one month post-dose 2 of HZ/su vaccine:

• The 95% CI of the group GMCs ratio will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

In terms of concentrations, the Co-Ad group will be considered non-inferior to the Control group if the UL of the 95% CI for the GMC ratio of the Control group to the Co-Ad group is <1.5.

Family 3:

For each vaccine pneumococcal serotype (according to the pre-specified order), one month post-dose of *Prevenar13*:

The 95% CI of the group MOPA GMT ratios will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations.
 The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model

In terms of MOPA GMTs, the Co-Ad group will be considered non-inferior to the Control group if the UL of the 95% CI for the MOPA GMTs ratio of the Control group to the Co-Ad group is <2 for each of the 13 vaccine serotypes.

In the ANCOVA models Adjusted Least Squares (LS) means and difference of LS means between the groups will be calculated together with the 2-sided 95% CIs and backtransformed to the original units to provide GMCs and GM ratios.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

6.4. Analysis of safety

6.4.1. Analysis of safety planned in the protocol

The analysis for safety will be based on the Exposed set. All safety analyses may also be performed by age strata (50-59, 60-69 and \geq 70 YOA), if deemed necessary.

When appropriate, tabulations will be presented overall and by time of occurrence relative to last vaccination (e.g. using windows such as Days 1 to 7, Days 1 to 30 and more than 30 days post-vaccination).

The results for the analysis of safety will be tabulated as follows:

- The number and percentage of subjects with at least one local solicited AE, with at least one general solicited AE, and with any solicited AE during the 7-day follow-up period with exact 95% CIs after each vaccine dose and overall by vaccination group will be provided;
- The percentage of subjects reporting each individual solicited local and general AE during the solicited 7-day follow-up period will be tabulated with exact 95% CI;
- For all solicited adverse events, the same tabulation will be performed for grade 3 solicited AEs and for solicited general AEs with relationship to vaccination;
- Number of days with each individual solicited local and general AE during the solicited 7-day follow-up period;
- The proportion of subjects with at least one report of unsolicited AE (containing both serious and non-serious unsolicited AEs) classified by the MedDRA Primary System Organ Class (SOC) and Preferred Terms (PTs) and reported up to 30 days after each vaccination will be tabulated with exact 95% CI;
- The same tabulation will be performed for grade 3 unsolicited AEs and for unsolicited AEs with a relationship to vaccination reported up to 30 days after each vaccination with exact 95% CI. The proportion of AEs resulting in a medically attended visit will also be tabulated;
- Total number/percentages of doses (per dose and overall) followed by AEs will be tabulated:
- Number of subjects with pIMDs will be tabulated;
- SAEs, including fatalities and withdrawal due to AE(s) will be described in detail.

6.4.2. Additional considerations

- The following additional tables will be generated:
 - The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE (solicited and unsolicited) during the 7-day follow-up period will be tabulated with exact 95% CI after each vaccine dose and overall. The same computations

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

- will be done for Grade 3 AEs, for any AEs considered related to vaccination and for any Grade 3 AEs considered related to vaccination.
- The percentage of subjects with at least one local solicited AE, with at least one general solicited AE and with any solicited AE will also be done for Grade 3 solicited AEs, for any solicited AEs considered related to vaccination and for any Grade 3 solicited AEs considered related to vaccination.
- The percentage of subjects reporting each individual solicited local AE during the solicited 7-day follow-up period will be tabulated by study vaccine with exact 95% CI.
- Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose.
- For fever, the number and percentage of subjects reporting fever by half degree (°C) cumulative increments during the 7-day follow-up period (Day 1-7) will be tabulated for each group after each vaccine dose and overall. Similar tabulations will be performed for Grade 3 (> 39.0°C) causally related fever.
- List of suspected HZ cases identified during the study will be presented.
- The number and percentage of subjects starting a concomitant medication during the 30-day post-vaccination period by dose and overall will be presented.
- The duration of solicited local adverse events (in days), not limited to the 7-day post-vaccination period, following each dose and overall/dose. The same tabulations after Prevenar13 and HZ/su vaccinations.
- The duration of solicited general adverse events (in days), not limited to the 7day post-vaccination period, following each dose and overall/dose.
- Solicited local adverse events ongoing beyond the 7-day (Days 1-7) post-vaccination period, following each dose and overall/dose. The same tabulations after Prevenar13 and HZ/su vaccinations.
- Solicited general adverse events ongoing beyond the 7-day (Days 1-7) post-vaccination period, following each dose and overall/dose.
- Number and percentage of subjects with at least one report of a grade 3 non-serious unsolicited AE during the 30-day (Days 0-29) follow-up period after each vaccination classified according to the MedDRA Primary SOC and PTs will be tabulated, with exact 95% CI. The same will be generated for grade 3 non-serious unsolicited AE considered related to vaccination.
- Number and percentage of subjects with fatal SAEs, classified by MedDRA
 Primary SOC and PTs will be presented with exact 95% CI in two ways:
- With onset of fatal SAE during the period starting from first vaccination to 30 days post last vaccination dose, after 30 days post last vaccination dose to study end and from first vaccination to study end.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

- Who died during the period starting from first vaccination to 30 days post last vaccination dose, after 30 days post last vaccination dose to study end and entire study period.
- The listing of all subjects who died during the entire study period and their fatal SAEs in the Enrolled Set

6.4.2.1. Combined Solicited and Unsolicited Adverse Events

A summary of subjects with all combined solicited (regardless of their duration) and unsolicited adverse events will be provided. Solicited adverse events will be coded by MedDRA as per the following codes:

Solicited adverse event	Lower level term name	Corresponding Lower level term code
Pain	Injection site pain	10022086
Redness	Redness at injection site	10022098
Swelling	Swelling at injection site	10053425
Fatigue	Fatigue	10016256
Gastrointestinal symptoms	Gastrointestinal disorder	10017944
Headache	Headache	10019211
Myalgia	Myalgia	10028411
Shivering	Shivering	10040558
Temperature	Fever	10016558

For clintrial gov and EudraCT posting purposes, a summary of combined solicited and unsolicited non-serious adverse events will be produced by SOC and PTs and according to occurrence of each event

7. ANALYSIS INTERPRETATION

All co-primary objectives will be evaluated using a one-sided Type I error of 2.5% (as already justified by fixed sequential testing procedure, no alpha adjustment needed). The trial will be considered conclusive if all co-primary objectives criteria are met.

8. CONDUCT OF ANALYSES

8.1. Sequence of analyses

The analysis will be performed in the following steps:

• The final analysis on immunogenicity, reactogenicity and safety data will be performed when all data up to study end (i.e., phone contact at Month 14 for Co-Ad group and phone contact at Month 16 for Control group) will be available and cleaned. Individual data listings will also be provided.

An integrated clinical study report containing all data will be written and made available to the investigators following the final analysis.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Table 5 Analysis and disclosure plan for the planned analysis

Description	Analysis ID	Disclosure Purpose (CTRS=public posting, CSR=clinical study report, internal)	Dry run review needed (Y/N)	Reference for TFL
Final analysis	E1_01	CTRS CSR	Y	All tables from Section 13 of the SAP Amendment 3 23NOV2020

8.2. Statistical considerations for interim analyses

Not applicable

9. CHANGES FROM PLANNED ANALYSES

- In Protocol Amendment 2 Final (30 Jan 2018), it was specified that a second analysis for immunogenicity of the ES would be performed only if, in any study group, the percentage of enrolled subjects with serological results excluded from the PPS for immunogenicity is 5% or more. At the request of Paul Ehrlich Institute, Germany (PEI), an analysis of the ES will be performed to complement the per-protocol analysis regardless of the percentage of enrolled subjects excluded from the PPS for immunogenicity.
- Updated LLOQ values (i.e. assay cut-off values) for the pneumococcal serotypes are provided in this version of SAP (section 12.1.2). The cut-off values presented in this SAP will be used to determine seropositivity rather than those presented in Protocol Amendment 2 Final (30 Jan 2018). Analysis of immunogenicity section has been updated accordingly.
- Additional tables on presentation of grade 3 non-serious unsolicited adverse events and fatal SAEs has been added based on CBER request.
- The sequence of analysis was updated from SAP amendment 1 to accommodate a delay in the availability of immunogenicity results. The active phase analysis has been removed as a request for a CTRS posting extension has been submitted to NIH; complete CTRS posting will be done at Last Subject Last Visit (LSLV) + 12 months rather than Primary Completion Date (PCD) +12 months as previously planned
- Two new cohorts Enrolled Set and Randomized Set has been defined as required for web disclosure and SAE tables presentation.
- Analysis of demography section has been updated to add consort table and summary of important protocol deviations.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

10. NON-STANDARD DATA DERIVATION RULES AND STATISTICAL METHODS

10.1. Statistical Method

10.1.1. Safety

For the listing of suspected HZ episode, following list of PT CODE has to be considered:-

PT_CODE	PT_NAME
10076667	Disseminated varicella zoster vaccine virus infection
10084396	Disseminated varicella zoster virus infection
10072210	Genital herpes zoster
10019974	Herpes zoster
10074297	Herpes zoster cutaneous disseminated
10061208	Herpes zoster infection neurological
10074259	Herpes zoster meningitis
10074248	Herpes zoster meningoencephalitis
10074251	Herpes zoster meningomyelitis
10079327	Herpes zoster meningoradiculitis
10074253	Herpes zoster necrotising retinopathy
10063491	Herpes zoster oticus
10074245	Herpes zoster pharyngitis
10080516	Herpes zoster reactivation
10030865	Ophthalmic herpes zoster
10074241	Varicella zoster gastritis
10074243	Varicella zoster oesophagitis
10074254	Varicella zoster pneumonia
10074298	Varicella zoster sepsis
10075611	Varicella zoster virus infection

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

11. LIST OF FINAL REPORT TABLES, LISTINGS AND FIGURES

The TFL TOC provides the list of tables/listings and figures to be included in the study report.

The following group names will be used in the TFLs, in line with the T-domains:

Group order in tables	Group label in tables	Group definition for footnote	
1	Co-Ad	Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su	
2	Control	Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su	

The following sub-groups will be used in the TFL, in line with the T-domains:

Table 6 Group Definitions to be used for the sub-group analysis by age (Analysis will be included in the clinical report)

Sub-group order in tables	Sub-group label in tables	Sub-group definition for footnote
1	50-59YOA	Subjects aged 50-59 years
2	60-69YOA	Subjects aged 60-69 years
3	≥70YOA	Subjects aged 70 years and over

YOA = Year of age

Please note that for table presentation in the sub-group analysis, the sequence maintained has to be each treatment group within each age sub-group.

12. ANNEX 1 STANDARD DATA DERIVATION RULE AND STATISTICAL METHODS

12.1. Standard data derivation

12.1.1. Dose number

The study dose number is defined in reference to the number of study visits at which vaccination occurred. More specifically dose 1 refers to all vaccines administered at the first vaccination visit while dose 2 corresponds to all vaccinations administered at the second vaccination visit even if this is the first time a product is administered to the subject.

Associated dose: the associated dose for an event (AE, medication, vaccination) is the most recent study dose given before an event. In case the event takes place on the day a study dose is given, the associated dose will be that of the study dose, even if the event actually took place before vaccination. For instance, if an adverse event begins on the day of the study vaccination but prior to administration of the vaccine, it will be assigned to this dose. In case a study dose is not administered and an event occurs after the

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

subsequent study dose (e.g. 2nd study dose), the associated dose of the event will be study dose associated to the subsequent study dose (e.g. dose 2).

The number of doses for a product is the number of times the product was administered to a subject.

The incidence per dose is the number of visits with vaccine administered at which an event was reported among all visits with vaccine administered.

12.1.2. Immunogenicity

- For a given subject and given immunogenicity measurement, missing or nonevaluable measurements will not be replaced. Therefore, an analysis will exclude subjects with missing or non-evaluable measurements.
- A seronegative subject is a subject whose antibodies concentration/titer is below the cut-off value (cut-off value is defined by the laboratory prior to the analysis).
- A seropositive subject is a subject whose antibodies concentration/titer is greater than or equal to the assay cut-off value.
- The seropositivity rate is defined as the percentage of seropositive subjects.
- The VRR for anti-gE is defined as the percentage of subjects who have at least:
 - a 4-fold increase in the anti-gE antibodies concentration as compared to the prevaccination anti-gE antibodies concentration, for subjects who are seropositive at baseline, or,
 - a 4-fold increase in the anti-gE antibodies concentration as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who are seronegative at baseline.
- The GMC calculations for anti-gE antibody concentration are performed by taking the anti-log of the mean of the log base 10 concentration transformations. Antibody concentrations below the cut-off of the assay will be given an arbitrary value equal to half the cut-off for the purpose of GMC/GMT calculation.
- All CI computed will be two-sided 95% CI.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

• Updated LLOQ and ULOQ values for the MOPA assay are described below for each of the 13 pneumococcal serotypes:

Pneumococcal serotype	Method	Unit	LLOQ1	ULOQ	Laboratory
Streptococcus pneumoniae Serotype 01/37 Brugmann Hospital Ab			14	3504	
Streptococcus pneumoniae Serotype 03/1 Statens Serum Institut Ab			11	2822	
Streptococcus pneumoniae Serotype 04/2656 Brugmann Hospital Ab			40	18042	
Streptococcus pneumoniae Serotype 05 Ambrose- Statens Serum Institut Ab			15	13304	
Streptococcus pneumoniae Serotype 06A Centers for Disease Control Ab			45	15305	
Streptococcus pneumoniae Serotype 06B/DS2212/94 Centers for Disease Control Ab			29	20806	University of
Streptococcus pneumoniae Serotype 07F/46 Brugmann Hospital Ab	MOPA	1/ dilution	28	59809	University of Alabama at
Streptococcus pneumoniae Serotype 09V/112 161/95 Statens Serum Institut Ab			39	28095	Birmingham
Streptococcus pneumoniae Serotype 14/58 Brugmann Hospital Ab			16	47856	
Streptococcus pneumoniae Serotype 18C/4593/40 Statens Serum Institut Ab			40	13318	
Streptococcus pneumoniae Serotype 19A/DB18 Kansanterveyslaitos Folkhalsoinstitutet Ab			13	34881	
Streptococcus pneumoniae Serotype 19F/2737 Brugmann Hospital Ab			33	29352	
Streptococcus pneumoniae Serotype 23F Mac- Statens Serum Institut Ab			40	10662	

¹LLOQ corresponds to serotype-specific assay cut-off value.

• The Geometric Mean Titres (GMTs) calculations for pneumococcal serotypes are performed by taking the anti-log of the mean of the log base 10 titre transformations. For GMT calculation for pneumococcal serotypes, antibody titres below the LLOQ of the assay will be given an arbitrary value of half the cut-off for GMT calculation. Antibody titres above the ULOQ of the assay will be given the value of ULOQ for GMT calculation.

12.1.3. Safety

For a given subject and the analysis of solicited adverse event during the 7 day follow-up period after vaccination, missing or non-evaluable measurements will not be replaced. Therefore, the analysis of the solicited adverse events based on the ES will include only vaccinated subjects with documented safety data (i.e., symptom screen completed). More specifically the following rules will be used:

- Subjects who documented the absence of a solicited adverse event after one dose will be considered not having that adverse event after that dose.
- Subjects who documented the presence of a solicited adverse event and fully or
 partially recorded daily measurement over the solicited period will be included in the
 summaries at that dose and classified according to their maximum observed daily
 recording over the solicited period.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

- Subjects who documented the presence of a solicited adverse event after one dose
 without having recorded any daily measurement will be assigned to the lowest
 intensity category at that dose (i.e., 38°C for fever or grade 1 for other adverse
 events). The subject will only be presented in the subject with adverse event
 experienced and not in specific grade information.
- Doses without adverse event sheets documented will be excluded.

For analysis of unsolicited AEs, such as SAEs or adverse events by MedDRA Primary SOC and PTs term, and for the analysis of concomitant medications, all vaccinated subjects will be considered. Subjects who did not report the event or the concomitant medication will be considered as subjects without the event or the concomitant medication respectively.

Associated dose: The associated dose for an event (e.g., AE, medication, vaccination,...) is the study dose given before an event. In case the event takes place on a day a study dose is given, the associated dose will be that of the study dose even if the event actually took place before. For instance, for a conc. medication started on the day of study dose 2 but before dose 2 administrations, the associated dose will be dose 2

The way the percentage of subjects will be derived will depend on the event analysed (see the following table for details). As a result, the denominator (N) will differ from one table to another.

Event	N used for deriving %	Terminology used in the tables for N
Concomitant	All vaccinated subjects	Number of subjects with at least one
medication		administered dose
Solicited local	All vaccinated subjects with at least one	For each dose and overall/subject:
adverse event	solicited local adverse event	N= number of subjects with at least one
	documented as either present or absent	documented dose
		For overall/dose:
		N= number of documented doses
Solicited general	All vaccinated subjects with at least one	For each dose and overall/subject:
adverse event	solicited general adverse event	N= number of subjects with at least one
	documented as either present or absent	documented dose
		For overall/dose:
		N= number of documented doses
Unsolicited adverse	All vaccinated subjects	Number of subjects with at least one
event from day 0 to		administered dose
day X		
SAE	All vaccinated subjects	Number of subjects with at least one
		administered dose

- The maximum intensity of local injection site redness and swelling will be scored at GSK Biologicals as follows:
 - 0 : <20 mm
 - 1 : > 20 mm to < 50 mm diameter
 - 2: > 50 mm to \leq 100 mm diameter
 - 3 : > 100 mm diameter

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Fever is defined as temperature $\geq 38.0 \text{ C} / 100.4 \text{ F}$ for oral, axillary, tympanic or rectal route. The preferred route for recording temperature in this study will be oral. For the analysis, temperatures will be coded as follows:

Grade	Temperature (oral, axillary, tympanic or rectal route)	
0	< 38°C	
1	≥ 38°C - ≤ 38.5°C	
2	> 38.5°C - ≤ 39°C	
3	> 39°C	

• Conversion of temperature to °C -

The following conversion rule is used for the conversion of temperature to °C

Temperature in °Celsius = ((Temperature in °Fahrenheit -32) *5)/9

The result is rounded to 1 decimal digit.

12.2. Statistical Method References

Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. *Biometrika*. 1934; 26:404-413.

12.3. Number of decimals displayed:

The following decimal description from the decision rules will be used for the demography, immunogenicity and safety/reactogenicity.

Display Table	Parameters	Number of decimal digits
Demographic characteristics	Mean, median age	1
Demographic characteristics	SD (age)	1
Immunogenicity	Ratio of GMT/C	2
All summaries	% of count, including LL & UL of CI	1
All summaries	% of difference, including LL & UL of CI	2

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

13. ANNEX 2: STUDY SPECIFIC MOCK TFL

The study specific mocks are annexed to this SAP in a separate document.

The data display, title and footnote are for illustration purpose and will be adapted to the study specificity as indicated in the TFL TOC. Note that there may be few changes between the study specific SAP mock TFL and the final TFLs as editorial/minor changes do not require a SAP amendment

13.1. List of individual data listing

Following individual data listing will be generated. *Please refer to TFL TOC for the numbering of these Appendices*.

- Elimination codes
- Demography
- Physical examination/vital signs
- Dates of birth, Informed consent, Vaccination and blood sampling, Contact
- Reason for visit not done
- General medical history Physical examination
- Study Conclusion
- Notes (this appendix is provided for info only and should not be used for the clinical report)
- Vaccination procedure
- Reason for not administration of vaccine
- Reason for non-eligibility
- Previous history of vaccination
- Previous history of disease
- Solicited local adverse events
- Solicited general adverse events
- Unsolicited adverse events within (30) days post-vaccination
- Unsolicited adverse events after (30) days post-vaccination
- Concomitant medications
- Concomitant vaccinations
- Immunogenicity

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

13.2. Template of Tables and Figures

Template 1 Number of subjects by country and center < Exposed Set>

			<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>		otal (XXX
Country	Center	n	%	n	%	n	%
<each country=""></each>	<each center=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X
,	All	XXX	XX.X	XXX	XX.X	XXX	XX.X

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

Center = GSK Biologicals assigned center number

Template 2 Number of enrolled subjects by country

		ach group> N=XXXX		ich group> N=XXXX		otal XXXX
Country	n	%	n	%	n	%
<each country=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X

<each group>:

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

No Group= enrolled not vaccinated

n = number of subjects in a given country

N = total number of subjects

 $% = n/N \times 100$

Template 3 Number of enrolled subjects by age category

		ich group> N=XXXX		ich group> N=XXXX		otal KXXX
Age category	n	%	n	%	n	%
Adults [18-64 years]	XXX	XX.X	XXX	XX.X	XXX	XX.X
From 65-84 years						
85 years and over						

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of enrolled subjects

n = number of enrolled subjects included in each group or in total for a given age category or for all age categories

 $% = n/N \times 100$

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 4 Number of subjects by country and age category <Exposed Set>

			ach group> N=XXXX	<each group=""> N=XXXX</each>		Total N=XXXX	
Country	Age category	n	%	n	%	n	%
<each country=""></each>	50-59YOA	XXX	XX.X	XXX	XX.X	XXX	XX.X
·	60-69YOA						
	≥70YOA						
	All	XXX	XX.X	XXX	XX.X	XXX	XX.X

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

50-59YOA = subjects aged 50-59 years; 60-69YOA = subjects aged 60-69 years; ≥70YOA = subjects aged 70 years and over

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

Template 5 Number of subjects vaccinated, completed and withdrawn with reason for withdrawal – <end of active phase, study end> <Exposed set>

	<each group=""> N=XXXX</each>	<each group=""> N=XXXX</each>	Total N=XXXX
	n	n	n
Number of subjects vaccinated	XXX	XXX	XXX
End of study status			
[EACH CATEGORY]	XXX	XXX	XXX
Reasons for withdrawal:			
[REASONS]	XXX	XXX	XXX

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Vaccinated = number of subjects who were vaccinated in the study

Completed = number of subjects who completed <end of active phase visit, last study visit>
Withdrawn = number of subjects who did not come for the <end of active phase visit, last study visit>
Unknown = number/percentage of subjects who have not come for the <end of active phase visit, last study visit> yet

Template 6 Visit attendance < Exposed set>

		<each< th=""><th>group> N=XXX</th></each<>	group> N=XXX
Visit	Status	n	%
INFORMED CONSENT	Completed		
RANDOMIZATION	Completed		
<each visit=""></each>	Attended		
	Not attended yet		
	Permanent discontinuation prior to this visit		
	Not attended		
CONCLUSION	Completed		

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Number of subjects in each group or in total

Conclusion = date of last visit or withdrawal

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 7 Summary of important protocol deviations leading to elimination from any analyses

Category Sub-category	•	<each group=""> N=XXXX</each>			Total N=XXXX		
	осс	n	%	осс	n	%	
At least one important protocol	XXX	XXX	XX.X	XXX	XXX	XX.X	
deviation							
<category 1=""></category>	XXX	XXX	XX.X	XXX	XXX	XX.X	
<sub-category 1=""></sub-category>	XXX	XXX	XX.X	XXX	XXX	XX.X	
<sub-category 2=""></sub-category>	XXX	XXX	XX.X	XXX	XXX	XX.X	
<category 2=""></category>	xxx	XXX	XX.X	xxx	XXX	XX.X	

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Total number of subjects

Occ = number of occurrences = number of important protocol deviations

n/% = number / percentage of subjects with important protocol deviations

Template 8 Percentage of subjects with serological results who were eliminated from PPS for immunogenicity

	[each group]
Number of subjects in Exposed Set with serological results available	
Number of subjects with serological results eliminated from PPS for immunogenicity	
Percentage of subjects with serological results eliminated from PPS for immunogenicity	

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 9 Deviations from specifications for age and intervals between study visits for Co-Ad group <Exposed Set>

		, ,		Dose:1- Dose:2	Dose:2-PII (M3)		Dose:2- PHC (M14)	
Group		Protocol from ≥ 50	Protocol from 30 to		Protocol from 49 to 83	Protocol from 30 to	Adapted from 28 to 48	Protocol from 335
		years	42 days	days	days	48 days	days	to 395 days
Co-Ad	N							
	n							
	%							
	range							

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Adapted = interval used for defining PPS for immunogenicity

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PI (M1) = Blood sample at Month 1, post-vaccination Dose 1; PII (M3) = Blood sample at Month 3, post-vaccination

Dose 2; PHC (M14) = Phone Contact MONTH 14

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 10 Deviations from specifications for age and intervals between study visits - for Control group <Exposed Set>

		Age	Dose:1-PI(M1)	Dose:1-Do	se:2	Dose:2- Dose:3	Dose:3-PII	` ,	Dose:3- PHONE CONT M16
Group		Protocol	Protocol	Adapted	Protocol	Adapted	Protocol	Protocol	Adapted	Protocol
		from ≥ 50	from 30 to	from 28 to	from 60 to	≥ 60	from 49 to	from 30 to	from 28 to	from 335 to
		years	42 days	48 days	83 days	days	83 days	48 days	48 days	395 days
Control	N			_			_	-	-	•
	n									
	%									
	range									

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adapted = interval used for defining the **PPS for immunogenicity**

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PI(M1) = Blood sample at Month 1, post-vaccination Dose 1; PIII(M5) = Blood sample at Month 5, post-vaccination

Dose 3; PHC (M16) = Phone Contact Month 16

Template 11 Summary of demographic characteristics <Exposed Set, PPS for immunogenicity>

	<each group=""> N=XXXX</each>			<each group=""> N=XXXX</each>		otal XXXX
	Value or n	%	Value or n	%	Value or n	%
Age in Years at <timepoint></timepoint>						
N with data	xxx		XXX		XXX	
Mean	XXX.X		XXX.X		XXX.X	
SD	XXX.X		XXX.X		XXX.X	
Median	xxx.x		XXX.X		XXX.X	
Minimum	xxx		XXX		XXX	
Maximum	XXX		XXX		XXX	
Gender						
<each gender=""></each>	xxx	XX.X	XXX	XX.X	XXX	XX.X
	XXX	XX.X	XXX	XX.X	XXX	XX.X
Ethnicity						
<each ethnicity=""></each>	xxx	XX.X	XXX	XX.X	XXX	XX.X
	xxx	XX.X	xxx	XX.X	XXX	XX.X
Geographic Ancestry						
<each ancestry="" geographic=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X
	XXX	XX.X	XXX	XX.X	XXX	XX.X
Age category						
<each age="" category=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X
Country						
<each country=""></each>	xxx	XX.X	XXX	XX.X	xxx	XX.X
	xxx	XX.X	XXX	XX.X	xxx	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = total number of subjects

n/% = number / percentage of subjects in a given category

Value = value of the considered parameter

N with data = number of subjects with documentation of the corresponding data

SD = standard deviation; <u>YOA = years of age</u>

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 12 Minimum and maximum activity dates <Exposed Set>

Group	Activity number	Activity Description	Minimum date	Maximum date
Co-Ad	10	VISIT DAY 1		
	20	VISIT MONTH 1		
	30	VISIT MONTH 2		
	40	VISIT MONTH 3		
	70	PHONE CONTACT MONTH 14		
Control	10	VISIT DAY 1		
	20	VISIT MONTH 1		
	30	VISIT MONTH 2		
	50	VISIT MONTH 4		
	60	VISIT MONTH 5		
	80	PHONE CONTACT MONTH 16		

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 13 Study Population < Exposed Set>

	<each group=""> N=XXXX</each>	<each group=""> N=XXXX</each>	Total N=XXXX
Number of subjects			
Planned, N	XXX	XXX	xxx
Randomised, N <cohort name=""></cohort>	XXX	XXX	xxx
Completed to visit Month 3, n (%)*	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
Completed to visit Month 5, n (%)**	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
Completed to Phone contact Month 14, n (%)*	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
Completed to Phone contact Month 16, n (%)**	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<unknown></unknown>	XXX	XXX	XXX
Demographics			
N <cohort name=""></cohort>	XXX	XXX	XXX
Females:Males	xxx:xxx	XXX:XXX	xxx:xxx
Mean Age, <unit> (SD)</unit>	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median Age, <unit> (minimum, maximum)</unit>	xxx (xxx,xxx)	xxx (xxx,xxx)	xxx (xxx,xxx)
<most category="" frequent="" of="" race=""></most>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<second category="" frequent="" most="" of="" race=""></second>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<third category="" frequent="" most="" of="" race=""></third>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Total number of subjects

SD = Standard deviation

*applicable for Co-Ad group and ** applicable for Control group

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 14 Exposure to study vaccines <Exposed Set>

	<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>		Total N=XX	xx
Number of subjects receiving	n	%	n	%	n	%
Exactly 1 Dose						
Exactly 2 Doses						
Exactly 3 Doses						
At least 1 Dose						
Total number of doses administered during the study						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects in each group or in total included in the considered cohort

n = number of subjects/doses in the given category

% = percentage of subjects in the given category

Template 15 Compliance in completing solicited adverse events information <Exposed Set>

	Adverse event information		<each gro<="" th=""><th>oup></th><th colspan="5"><each group=""></each></th></each>	oup>	<each group=""></each>				
DOSE						Compliance (%)	N	n	Compliance (%)
DOSE <each dose<="" td=""><td>General AES</td><td></td><td></td><td></td><td></td><td></td><td></td></each>	General AES								
	Local AES								
TOTAL	General AES Local AES								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N=Number of administered doses

n = number of doses with AES returned

General AES = **AE** screens used for the collection of general solicited AEs

Local AES = **AE** screens used for the collection of local solicited AEs

Compliance (%) = $(n / N) \times 100$

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 16 Incidence and nature of <grade 3, related, grade 3 related, > adverse events (<unsolicited and solicited, solicited only>) reported <during the 7-day (Days 1-7), beyond the 7-day (Days 1-7)> post-vaccination period following each dose and overall <<u>Exposed Set></u>

		<e< th=""><th>ach</th><th>gro</th><th>up></th><th></th><th><e< th=""><th>ach</th><th>gro</th><th>up></th><th></th></e<></th></e<>	ach	gro	up>		<e< th=""><th>ach</th><th>gro</th><th>up></th><th></th></e<>	ach	gro	up>	
					95%	CI			_	95%	CI
Dose	Adverse event	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Any adverse event										
	General adverse events										
	Local adverse events										
Dose 2	Any adverse event										
	General adverse events										
	Local adverse events										
Dose 3	Any adverse event										
	General adverse events										
	Local adverse events										
Overall/dose	Any adverse event										
	General adverse events										
	Local adverse events										
Overall/subject	Any adverse event										
•	General adverse events										
	Local adverse events										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose and overall/subject: N = number of subjects with at least one documented dose; n/% =

number/percentage of subjects presenting at least one type of adverse event

For overall/dose: N = number of documented doses; n/% = number/percentage of doses followed by at least one type of adverse event

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 17 Incidence of solicited local adverse events reported during the 7-day (Days 1-7) post-vaccination period by study vaccine following each dose and overall <Exposed Set>

						Co-A	d			(Contr	ol	
							95%	6 CI				95%	% CI
Dose	Adverse event	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Pain	HZ/su	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
		Prevenar13	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
	Redness (mm)	HZ/su	All										
	, ,		>50										
			>100										
			Medical advice										
		Prevenar 13	All										
			>50										
			>100										
			Medical advice										
	Swelling (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar 13	All										
			>50										
			>100										
			Medical advice										
Dose 2													
Dose 3													
Overall/Dose													
Overall/Subject													
	Drayonar 12 - H7/	D 0 117	1.										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose: N = number of subjects with the corresponding documented dose; n/% = number/percentage of subjects reporting the type of adverse event at least once following the corresponding dose

For Overall/dose: N = number of documented dose; n/% = number/percentage of doses followed by at least one type of adverse event

For Overall/subject: N = number of subjects with at least one documented dose; n/% = number/percentage of subjects reporting the type of adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 18 Incidence of solicited general adverse events reported during the 7day (Days 1-7) post-vaccination period following each dose and overall <Exposed Set>

					<each gr<="" th=""><th></th><th></th></each>		
							5 % CI
Dose	Adverse event	Туре	N	n	%	LL	UL
Dose 1	Fatigue	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Gastrointestinal symptoms	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Headache	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Myalgia	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Shivering	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Fever (Oral) (°C)	All (≥38.0)					
		>38.0					
		>38.5					
		>39.0					
		>39.5					
		>40.0					
		Related					
		>39.0*Related					
		Medical advice					
Dose 2							
Dose 3							
Overall/Dose							
Overall/Subject							
	/enar 13+ H7/su Dose 2: H7/su						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose: N = number of subjects with the corresponding documented dose; n/% = number/percentage of subjects reporting the adverse event at least once following the corresponding dose

<u>For Overall/dose: N = number of documented dose; n/% = number/percentage of doses followed by at least one type of adverse event</u>

For Overall/subject: N = number of subjects with at least one documented dose; n/% = number/percentage of subjects reporting the type of adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 19 Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) postvaccination following each dose < Exposed Set>

						С	o-Ad				Co	ntrol	
							95	% CI				95	% CI
Dose	Symptom	Route	Type	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Temperature (°C)	Oral	≥35.0										
			>35.5										
			>36.0										
			>36.5										
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
		Axillary	≥35.0										
		,	>35.5										
			>36.0										
		>36.5											
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
Dose 2	Temperature (°C)	Oral	≥35.0										
			>35.5										
			>36.0										
			>36.5										
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
Dose 3			10.0		t	1	1					1	

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose: N = number of subjects with at least one documented dose; n/% = number/percentage of subjects

reporting the temperature at least once

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 20 Number and percentage of subjects reporting the occurrence of <grade 3> <non-serious> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination, with medically attended visit>, within the 30-day (Days 1-30) post-vaccination period <,including numbers of events><Exposed Set>

		Ea N		gro	oup	
						5% CI
Primary System Organ Class (CODE)	SOC Diarrhoea (10012735) Teething (10043183) Vomiting (10047700) At least one PT related to the corresponding SOC Pyrexia (10037660) Seasonal allergy (10048908) Conjunctivitis (10010741) Otitis media (10033078) Paronychia (10034016)	n*	n	%	LL	UL
	At least one adverse event					
Gastrointestinal disorders (10017947)	At least one PT related to the corresponding SOC					
	Diarrhoea (10012735)					
	Teething (10043183)					
General disorders and administration site conditions	At least one PT related to the corresponding					
(10018065)	SOC					
	Pyrexia (10037660)					
Immune system disorders (10021428)	, , , , , , , , , , , , , , , , , , , ,					
Infections and infestations (10021881)	Conjunctivitis (10010741)					
	Otitis media (10033078)					
	Paronychia (10034016)					
	Tonsillitis (10044008)					
	Tonsillitis streptococcal (10044013)					
	Viral upper respiratory tract infection (10047482)					
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)					
,	Face injury (10050392)					
	Head injury (10019196)					
Skin and subcutaneous tissue disorders (10040785)	Miliaria (10027627)					

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

n* = number of events reported

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Please note the n* will only be presented for the CTRS posting with the time interval as per the secondary endpoint

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 21 Global Summary of <grade 3> <non-serious>unsolicited signs and adverse events reported <with causal relationship with vaccination, with medically attended visit> within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

	Co-Ad	Control	Total
Number of subjects with at least one unsolicited adverse event reported			
Number of doses followed by at least one unsolicited adverse event			
Number of unsolicited adverse events classified by MedDRA Preferred Term*			
Number of unsolicited adverse events reported**			

Co-Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

N = number of subjects included in the considered cohort in each group

Template 22 Number and percentage of subjects starting a concomitant medication during the 30- day (Days 1-30) post vaccination period by dose and overall <Exposed Set>

				<each g<="" th=""><th>group></th><th></th></each>	group>	
				•		95% CI
Dose	Туре	N	n	%	LL	UL
Dose 1	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Dose 2	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Dose 3	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Overall/Dose	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Overall/Subject	Any					
overall/oubject	Any in anticipation of study vaccine reaction					
	Any chronic use					

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13. Dose 2: HZ/su. Dose 3: HZ/su

For each dose: N = total number of subjects with the corresponding administered dose; n/% = number/percentage of subjects who took the specified type of concomitant medication at least once during the considered period

For Overall/dose: N = number of administered doses; n/% = number/percentage of doses after which the specified type of concomitant medication was taken at least once during the considered period

For Overall/subject: N = total number of subjects with at least one administered dose; n/% = number/percentage of subjects who took the specified type of concomitant medication at least once during the considered period

^{*} Adverse events reported by a subject after a given dose and classified by the same Preferred Term are counted once
** Adverse events reported by a subject after a given dose and classified by the same Preferred Term and the same
start date of the event, are counted once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 23 Number of days with solicited <local, general> adverse events <during the 7 days (Days 1-7) post vaccination period following each dose and overall> <- Prevenar 13 vaccine, - HZ/su vaccine> <Exposed Set>

			<co-ad group=""></co-ad>	<control group=""></control>
Dose	Adverse event	Statistic	value	value
<each dose=""></each>	<each adverse="" event=""></each>	n	XXXX	XXXX
		Mean	XX.X	XX.X
		Minimum	XX.X	XX.X
		Q1	XX.X	XX.X
		Median	XX.X	XX.X
		Q3	XX.X	XX.X
		Maximum	XX.X	XX.X
Overall/Dose	<each adverse="" event=""></each>	n	XXXX	XXXX
		Mean	XX.X	XX.X
		Minimum	XX.X	XX.X
		Q1	XX.X	XX.X
		Median	XX.X	XX.X
		Q3	XX.X	XX.X
		Maximum	XX.X	XX.X

Co-Ad group = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control group = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

n= number of doses with adverse event Q1= 25th percentile; Q3= 75th percentile

Please note the table by vaccine type will only be done for local solicited adverse events.

Template 24 Solicited and unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term within the 30-day (Days 1-30) post-vaccination period including number of events - SAE excluded <Exposed Set>

		<each group=""> N =</each>					
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%			
	At least one adverse event						
<each soc=""></each>	<each pt="" term=""></each>						

<each group>:

Co-Ad group = Dose 1: Prevenar+ HZ/su, Dose 2: HZ/su

Control group = Dose 1: Prevenar, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n* = number of events reported

n/% = number/percentage of subjects reporting the adverse event at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 25 Number (%) of subjects with serious adverse events from <first vaccination dose up to 30 days post last vaccination, 30 days post last vaccination up to study end, first vaccination dose up to <database freeze date(DDMMMYYYY)><study end>, including number of events reported <Exposed Set>

			<ea< th=""><th>ch gro N =</th><th>up></th></ea<>	ch gro N =	up>
Type of Event	Primary System Organ Class	Preferred Term (CODE)	n*	n	%
SAE	At least one adverse event				
	<each soc=""></each>	<each pt="" term=""></each>			
Related SAE	At least one adverse event				
	<each soc=""></each>	<each pt="" term=""></each>			
Fatal SAE	At least one adverse event				
	<each soc=""></each>	<each pt="" term=""></each>			
Related fatal SAE	At least one adverse event				
	<each soc=""></each>	<each pt="" term=""></each>			

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with the administered dose

n* = number of events reported

n/% = number/percentage of subjects reporting the adverse event at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 26 Number (%) of subjects reported solicited local adverse events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <Exposed Set>

						Co-A	νd			(Contr	ol 💮	
							95%	6 CI				95%	6 CI
Dose	Adverse event	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Pain	HZ/su	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
		Prevenar	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
	Redness (mm)	HZ/su	All										
	, ,		>50										
			>100										
		Prevenar	Medical advice										
			All										
			>50										
			>100										
			Medical advice										
	Swelling (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar	All										
			>50										
			>100										
			Medical advice										
Dose 2													
Dose 3													
Across dose													

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

<u>For each dose:</u> N = number of subjects with the corresponding documented dose; n/% = number/percentage of subjects reporting the type of adverse event at least once following the corresponding dose

For Across dose: N = number of subjects with at least one documented dose; n/% = number/percentage of subjects reporting the adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 27 Number (%) of subjects reported solicited general adverse events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <Exposed Set>

					<each gr<="" th=""><th>oup></th><th></th></each>	oup>	
						9:	5 % CI
Dose	Adverse event	Туре	N	n	%	LL	UL
Dose 1	Fatigue	All					
		Grade 3					
		Related					
	Gastrointestinal symptoms	All					
		Grade 3					
		Related					
	Headache	All					
		Grade 3					
		Related					
	Myalgia	All					
	, ,	Grade 3					
		Related					
	Shivering	All					
		Grade 3					
		Related					
	Fever (Oral) (°C)	All (≥38.0)					
		>39.0					
		Related					
Dose 2	Fatigue						
	Gastrointestinal symptoms						
	Headache						
	Myalgia						
	Shivering						
	Fever (Oral) (°C)						
Across Dose							

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose: N = number of subjects with the corresponding documented dose; n/% = number/percentage of subjects reporting the adverse event at least once following the corresponding dose

For Across dose: N = number of subjects with at least one documented dose; n/% = number/percentage of subjects reporting the adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 28 Number and percentage of subjects with <anti-pneumococcal <X> antibody titres> equal to or above <cut-off> and GMT <PPS for immunogenicity, Exposed Set>

				<	≥each LL	serot OQ>	ype		<gm<sup>-</gm<sup>	Γ>		
						95	% CI		9	95% CI		
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL	Min	Max
<anti-< td=""><td>Co-Ad</td><td>PRE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></anti-<>	Co-Ad	PRE										
pneumococcal <x> antibody></x>		PI(M1) or PII(M3)										
	Control	PRE or PI(M2)										
		PI(M1) or PIII(M5)										

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13. Dose 2: HZ/su. Dose 3: HZ/su

GMT = geometric mean antibody titre calculated on all subjects

N = number of subjects with available results

95% CI = 95% confidence interval; LL = lower limit, UL = upper limit

n/% = number/percentage of subjects with <concentration, titre> equal to or above specified value

MIN/MAX = Minimum/Maximum

PRE= Pre-vaccination at Day 1; PII(M3) = Post-vaccination dose 2 at Month 3; PI(M1) = Post-vaccination dose 1 at

Month 1; PI(M2) = Post-vaccination dose 1 at Month 2; PIII(M5) = Post-vaccination dose 3 at Month 5

Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3) for Co-Ad and PI(M2) and PIII(M5) for Control group.

Template 29 <u>Seropositivity rate and geometric mean concentration for anti-gE</u>
<u>ELISA antibody concentration <PPS for immunogenicity, Exposed</u>
Set>

					≥cut-c	off un	it		GMC			
				95% CI			959	% CI				
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL	Min	Max
Anti-gE antibody	Co-Ad	PRE										
		PI(M1) or PII(M3)										
	Control	PRE or PI(M2)										
		PI(M1) or PIII(M5)										

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

GMC = geometric mean antibody concentration calculated on all subjects

N = *number of subjects with available results*

95% CI = 95% confidence interval; LL = lower limit, UL = upper limit

n/% = number/percentage of subjects with concentration equal to or above specified value

MIN/MAX = Minimum/Maximum

PRE= Pre-vaccination at Day 1; PII(M3) = Post-vaccination dose 2 at Month 3; PI(M1) = Post-vaccination dose 1 at

Month 1; PI(M2) = Post-vaccination dose 1 at Month 2; PIII(M5) = Post-vaccination dose 3 at Month 5

<u>Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3)</u> for Co-Ad and PI(M2) and PIII(M5) for Control group.

53

23-NOV-2020

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 30 Adjusted ratios of GMCs between groups (Control group divided by Co-Ad group) for anti-gE antibody ELISA concentrations at one month post dose 2 of HZ/su vaccine <PPS for immunogenicity, Exposed Set>

	Control				Co-Ad			•	ed GMC i rol / Co-/	
		95	% CI*			95%	CI*		95	% CI
N	Adjusted GMC	LL	UL	N	Adjusted GMC	LL	UL	Value	LL	UL

Co-Ad = Dose 1: Prevenar 13+ HZ/su. Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adjusted GMC = geometric mean antibody concentration adjusted for vaccine group, age and baseline concentration N = number of subjects with both pre- and post-vaccination results available

95% CI* = 95% confidence interval for the adjusted GMC (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

95% CI = 95% confidence interval for the adjusted GMC ratio (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

Template 31 Adjusted ratios of GMTs between groups (Control group divided by Co-Ad group) for anti-pneumococcal <X> antibody titres at one month post Prevenar 13 vaccine <PPS for immunogenicity, Exposed Set>

	Contro	ol			Co-Ad			Adjuste (Conti	d GMT ol / Co	
		95	% CI*			95%	CI*		95	% CI
N	Adjusted GMT	LL	UL	N	Adjusted GMT	LL	UL	Value	LL	UL

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adjusted GMT = geometric mean antibody titre adjusted for vaccine group, age and baseline concentration N = number of subjects with both pre- and post-vaccination results available

95% CI* = 95% confidence interval for the adjusted GMT (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

95% CI = 95% confidence interval for the adjusted GMT ratio (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

Template 32 Mean Geometric Increase (MGI) of anti-gE antibody ELISA concentrations from baseline to one month post dose 2 of HZ/su vaccine <PPS for immunogenicity, Exposed Set>

								MGI		
									9	5% CI
Antibody	Group	N	Time point description	GMC	Time point description	GMC	Ratio order	Value	LL	UL
<antibody></antibody>	Co-Ad		PII(M3)		PRE		PII(M3)/PRE			
-	Control		PIII(M5)		PI(M2)		PIII(M5)/PI(M2)			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = **n**umber of subjects with available results at the two considered time points

GMC = geometric mean antibody concentration

95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit

PRE= Pre-vaccination at Day 1; PII(M3) = Post-vaccination dose 2 at Month 3 for Co-Ad group

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

PI(M2) = Post-vaccination dose 1 at Month 2 for Control group (considered as pre-vaccination for HZ/su in Control group)

PIII(M5) = Post-vaccination dose 3 at Month 5 for Control group (considered as post dose 2 for HZ/su in Control group)

Template 33 Descriptive statistics of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentration <PPS for immunogenicity, Exposed Set>

			Each Grou N=	р
				95% CI
Antibody	Parameter	Value	LL	UL
Anti-gE antibody	n			
	Nmiss			
	Mean			
	SD			
	Min			
	Q1			
	Median			
	Q3			
	Max			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = total number of subjects

<u>n = number of subjects with available results;</u> Nmiss = number of subjects with missing results

SD = Standard Deviation; Q1, Q3 = First and third quartiles; Min/Max = Minimum/Maximum

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to PI(M2) for Control group has to be considered

Template 34 Distribution of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentrations <PPS for immunogenicity, Exposed Set>

				< E	ach gr	oup>			< E	ach gr	oup>	
					_	95	% CI			_		% CI
Antibody	Timing	Fold change	N	n	%	LL	UL	N	n	%	LL	UL
<each antibody=""></each>	<pii(m3)></pii(m3)>	≥2	XX	XX	XX.X	XX.X	XX.X	XX	XX	XX.X	XX.X	XX.X
-		≥4										
	Ì	≥6										
	İ	≥8										
	Ì	≥10		İ	İ							Ì
		≥12		Ï	ĺ							Ì
		≥14										
	<piii(m5)< td=""><td>>= Ratio1</td><td>XX</td><td>ХХ</td><td>XX.X</td><td>XX.X</td><td>XX.X</td><td>XX</td><td>XX</td><td>XX.X</td><td>XX.X</td><td>XX.X</td></piii(m5)<>	>= Ratio1	XX	ХХ	XX.X	XX.X	XX.X	XX	XX	XX.X	XX.X	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with available results

n/% = number/percentage of subjects with concentration within the specified range

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PII(M3) = Post-vaccination dose 2 at Month 3 for Co-Ad group

PIII(M5) = Post-vaccination dose 3 at Month 5 for Control group (considered as post dose 2 for HZ/su in Control group)
Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to
PI(M2) for Control group has to be considered

55

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 35 Listing of potential Immune Mediated Diseases (pIMDs) reported as identified by predefined list of preferred terms and/or by investigator assessment up to end of study <u>by age subgroup</u> <Exposed Set>

Group	Sub.No.	Country	<u>Age</u> strata	Age at onset (Y)	Gender	Race	Primary System Organ Class	Preferred term	Dose	Day of onset	Causality	Serious pIMD based on Investigator?	SAE (Y/N)	Outcome	pIMD Source

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

50-59YOA = subjects aged 50-59 years; 60-69YOA = subjects aged 60-69 years; ≥70YOA = subjects aged 70 years and over

Template 36 Listing of all SAEs up to end of study by age subgroup < Exposed Set>

Group	Sub. Gender No.	Country	Race	 Age at onset (Year)	Verbatim	term	Primary System Organ Class	MED type	Dose	Day of onset	Duration	Intensity	Causality	Outcome

Co-Ad = Dose 1: Prevenar 13+ HZ/su. Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

50-59YOA = subjects aged 50-59 years; 60-69YOA = subjects aged 60-69 years; ≥70YOA = subjects aged 70 years and over

Template 37 Listing of suspected HZ cases from first administered dose up to end of study by age subgroup < Exposed Set >

Group	Sub.	Age strata	Previous dose	Day on-set	Duration	Preferred	AE description	Medical advice	Medically attended visit	Intensity	Causality	Outcome
	No.					term						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

50-59YOA = subjects aged 50-59 years; 60-69YOA = subjects aged 60-69 years; ≥70YOA = subjects aged 70 years and over

20-NOV-2019 56

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 38 Listing of (S)AEs and solicited adverse events leading to study or treatment discontinuation <up to month 5><up to end of study> <u>by</u> age subgroup <Exposed Set>

Type of discontinuation: <study/treatment

Group	Subject number	<u>Age</u> strata	Country	AE Description	SAE (Y/N)	Causality	Vaccination and visit
							Vaccination: x at visit x

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

50-59YOA = subjects aged 50-59 years; 60-69YOA = subjects aged 60-69 years; ≥70YOA = subjects aged 70 years and over

Template 39 Maximum intensity of solicited <local, general> adverse event ongoing beyond the 7-day (Days 1-7) post-vaccination period following each dose and overall <Exposed Set>

			Time to resolution	<each group> Value or</each 	<each group> Value or</each
Dose	Adverse event	Туре	(days)	n	n
<each dose=""></each>	<each adverse<="" td=""><td>All</td><td>N</td><td>XX</td><td>XX</td></each>	All	N	XX	XX
	event>		n	xx	XX
			q1	XX.X	XX.X
			median	XX.X	XX.X
			q3	XX.X	XX.X
		Grade 3	N	XX	XX
			n	XX	XX
			q1	XX.X	XX.X
			median	XX.X	XX.X
			q3	XX.X	XX.X
		Grade 3*Related	N	XX	XX
			n	xx	xx
			q1	XX.X	XX.X
DVERALL/DOSE			median	xx.x	XX.X
			q3	XX.X	XX.X
OVERALL/DOSE	<each adverse="" event<="" td=""><td>><each type=""></each></td><td>N</td><td>XX</td><td>XX</td></each>	> <each type=""></each>	N	XX	XX
			n	XX	XX
			q1	XX.X	XX.X
			median	XX.X	XX.X
OVERALL/DOSE			q3	XX.X	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Time to resolution: number of days beyond the end of the follow-up period N = number of adverse events that were ongoing after the follow-up period

n = number of adverse events that were ongoing after the follow-up period with a complete end date

q1 = 25th percentile; q3= 75th percentile

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 40 Number and percentage of doses reporting the occurrence of <grade 3> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination> within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

			ach I =	gr	oup
					5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL
At least one adverse event					
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)				
, ,	Teething (10043183)				
	Vomiting (10047700)				
General disorders and administration site conditions (10018065)	Pyrexia (10037660)				
Immune system disorders (10021428)	Seasonal allergy (10048908)				
Infections and infestations (10021881)	Conjunctivitis (10010741)				
, ,	Otitis media (10033078)				
	Paronychia (10034016)				
	Tonsillitis (10044008)				
	Tonsillitis streptococcal (10044013)				
	Viral upper respiratory tract infection				
	(10047482)				
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)				
,	Face injury (10050392)				
	Head injury (10019196)				
Skin and subcutaneous tissue disorders (10040785)	Miliaria (10027627)				

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term) N = number of administered doses

n/% = number/percentage of doses followed by the adverse event

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 41 Number and percentage of subjects reporting the occurrence of <serious adverse events, potential Immune Mediated Disease> classified by MedDRA Primary System Organ Class and Preferred Term from <first vaccination up to 30 days post last vaccination, from 30 days post last vaccination dose up to end of study, from first vaccination up to study end> <,including number of events><Exposed Set>

			(-Ad =			(trol =
				95% CI					95% CI	
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%	LL	UL	n*	n ^c	% L	L UL
At least one adverse event										
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)									
Cardiac disorders (10007541)	Acute myocardial infarction (10000891)									
	Atrial fibrillation (10003658)									
	Cardiac failure congestive									
	(10007559)									
	Tachycardia (10043071)									
	Ventricular tachycardia (10047302)									

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

n* = **n**umber of events reported

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Please note that n* will be used to present pIMD for CTRS posting.

Template 42 Global Summary of <serious adverse events, potential Immune
Mediated Disease> <with causal relationship with vaccination>
reported from <first vaccination up to 30 days post last vaccination,
from 30 days post last vaccination dose up to end of study, from
first vaccination up to study end> <Exposed Set>

	Co-Ad	Control	Total
Number of subjects with at least one <sae, pimd=""> reported</sae,>			
Number of doses followed by at least one <sae, pimd=""></sae,>			
Number of <sae, pimd=""> classified by MedDRA Preferred Term*</sae,>			
Number of <sae, pimd=""> reported**</sae,>			

Co-Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects included in the considered cohort in each group

^{*} Adverse events reported by a subject after a given dose and classified by the same Preferred Term are counted once
** Adverse events reported by a subject after a given dose and classified by the same Preferred Term and the same
start date of the event, are counted once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 43 Vaccine response rates for anti-gE antibody concentrations at one month post dose 2 of HZ/su vaccine <PPS for immunogenicity, Exposed Set>

			•	<each gro<="" th=""><th>up></th><th></th></each>	up>	
					95	5% CI
A (2) . 1	Pre-vaccination	N.		0/		
Antibody	status	N	n	%	LL	UL
<each antibody=""></each>	S-	XXXX	XXXX	XX.X	XXX.X	XXX.X
•	S+	XXXX	XXXX	XX.X	XXX.X	XXX.X
	Total	XXXX	XXXX	XX.X	XXX.X	XXX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

<u>S</u>-= seronegative subjects (antibody <concentration> < <cut off> <unit>) at pre-vaccination; S+ = seropositive subjects (antibody <concentration>≥ <cut off> <unit>) at pre-vaccination

Total = subjects either seropositive or seronegative at pre-vaccination

Vaccine response defined as:

For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml)

For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

N = number of subjects with both pre- and post-vaccination results available


n/% = number/percentage of responders

<95>% CI = exact <95>% confidence interval, LL = Lower Limit, UL = Upper Limit

Please note – To calculate the vaccine response, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to PI(M2) for Control group has to be considered

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 44 Reverse cumulative distribution curves for <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> in each group at baseline and <post dose 2 of HZ/su vaccine, post dose of Prevenar 13> <PPS for immunogenicity, Exposed Set>



Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Note: This graph is provided as an example. The same graph will be provided in colour for each time point and each assay comparing the values of the groups

Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3) for Co-Ad and PI(M2) and PIII(M5) for Control group.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 45 Number and percentage of subjects <with><experiencing> fatal SAEs classified by MedDRA Primary System Organ Class and Preferred Term <who died><with onset of fatal SAE> <during the period starting> <from first vaccination up to 30 days post last vaccination dose> <after 30 days post last vaccination dose up to study end><from first vaccination until the study end><during the entire study period> <Exposed Set>

			_	o-A N =				ontr N =	trol =		
				95% CI				ć	95% CI		
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL		
At least one adverse event											
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)										
Cardiac disorders (10007541)	Acute myocardial infarction (10000891)										
	Atrial fibrillation (10003658)										
	Cardiac failure congestive										
	(10007559)										
	Tachycardia (10043071)										
	Ventricular tachycardia (10047302)										

Co-Ad = Dose 1: Prevenar 13+ HZ/su. Dose 2: HZ/su

Control = Dose 1: Prevenar 13. Dose 2: HZ/su. Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Template 46 Summary of subject disposition from Enrolled Set to Randomized Set

	Total N=XXX n %
Number of subjects who signed an informed consent	
Withdrawals prior to randomization	XXX XX.X
<withdrawal 1="" reason=""></withdrawal>	xxx xx.x
<withdrawal 2="" reason=""></withdrawal>	xxx xx.x
	xxx xx.x
	xxx xx.x
Number of subjects included in Randomized Set	

N = **n**umber of subjects

n% = number / percentage of subjects in a given category

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 47 Summary of subject disposition from Randomized Set to Per Protocol Set

	<group 1=""></group>	<group 2=""></group>	Total
	N=XXX	N=XXX	N=XXX
	n %	n %	n %
Number of subjects			
included in Randomized Set			
Withdrawals	XXX XX.X	XXX XX.X	XXX XX.X
<withdrawal 1="" reason=""></withdrawal>	XXX XX.X	xxx xx.x	xxx xx.x
<withdrawal 2="" reason=""></withdrawal>	XXX XX.X	xxx xx.x	xxx xx.x
Eliminations	xxx xx.x	xxx xx.x	xxx xx.x
<elimination 1<="" reason="" td=""><td>xxx xx.x</td><td>xxx xx.x</td><td>xxx xx.x</td></elimination>	xxx xx.x	xxx xx.x	xxx xx.x
(code)>	xxx xx.x	xxx xx.x	xxx xx.x
<elimination 2<="" reason="" td=""><td></td><td></td><td></td></elimination>			
(code)>			
	xxx xx.x	xxx xx.x	xxx xx.x
Number of subjects			
included in Exposed Set			
Elimination 1			
Number of subjects			
included in PPS for			
immunogenicity			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects

n% = number / percentage of subjects in a given category

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 48 Listing of subjects who died during the entire study period and their fatal SAEs by age subgroup < Enrolled Set>

	No.	Sex	Country	strata	Age at Onset (Year)	Verbatim	Preferred term	,	type	prior to onset of fatal SAE	between onset of	prior to death	,	SAE Duration	SAE Causality
No Group	PPD									0	-	0	-		
										0	-	0	-		
										1	XX	1	XX		
										1	XX	2	XX		
										1	XX	1	XX		
										1	XX	1	XX		

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

No Group= Enrolled not vaccinated

50-59YOA = subjects aged 50-59 years; 60-69YOA = subjects aged 60-69 years; ≥70YOA = subjects aged 70 years and over

MED = Medical Advice type (HO: hospitalisation, ER: emergency room visit, MD: medical practice visit)

20-NOV-2019 64

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 3

Template 49 Summary of subjects by unsolicited adverse event category, with onset within 30 days of each vaccination

		<gro N=X</gro 	up 1> XXX			iroup 2 =XXXX		
	•		95%	6 CI			95%	% CI
	n	%	LL	UL	n	%	LL	UL
At least one unsolicited adverse event	XXX	XX.X	XX.X	XX.X	XXX	XX.X	XX.X	XX.X
At least one grade 3 unsolicited adverse event	xxx	xx.x	xx.x	xx.x	XXX	XX.X	xx.x	xx.x
At least one related unsolicited adverse event	ххх	XX.X	XX.X	XX.X	XXX	XX.X	XX.X	XX.X
At least one grade 3 related unsolicited adverse event	ххх	XX.X	XX.X	XX.X	XXX	XX.X	XX.X	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once 95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Template 50 Summary of subjects by serious adverse event and potential Immune Mediated Disease categories, with onset <from first vaccination to 30 days post last vaccination, after 30 days post last vaccination until study end>

			•		iroup 2		>	
	N=X	XXX		N=XXXX				
		95%	6 CI			95% CI		
n	%	LL	UL	n	%	LL	UL	
XXX	xx.x	XX.X	XX.X	XXX	XX.X	XX.X	XX.X	
XXX	xx.x	xx.x	xx.x	XXX	XX.X	xx.x	xx.x	
XXX	XX.X	XX.X	XX.X	XXX	XX.X	XX.X	XX.X	
XXX	XX.X	XX.X	XX.X	XXX	xx.x	XX.X	XX.X	
	XXX XXX	n % xxx xx.x xxx xx.x xxx xx.x	n % LL xxx xx.x xx.x xx.x xxx xx.x xx.x x	95% CI	95% CI n % LL UL n xxx xx.x xx.x xx.x xx.x xxx xxx xx.x xx.x xx.x xx.x xxx xxx xx.x xx.x xx.x xx.x xxx	95% CI n % LL UL n % xxx xx.x xx.x xx.x xx.x xx.x xx.x xx	95% CI 95% n % LL UL n % LL xxx xx.x xx.x xx.x xx.x xx.x xx.x x	

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

	Statistical Analysis Flatt Americanent 2
GlaxoSmithKline	Statistical Analysis Plan
Detailed Title:	A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with <i>Prevenar13</i> in adults aged 50 years and older.
eTrack study number and Abbreviated Title	204487 (ZOSTER-059 PRI)
Scope:	All analyses planned per protocol.
Date of Statistical Analysis Plan	Amendment 2 Final: 20 November 2019

APP 9000058193 Statistical Analysis Plan Template V4 (Effective date: 3 June 2019)

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

TABLE OF CONTENTS

				PAGE
LIS	T OF A	BBREVIA	ΓΙΟΝS	10
1.	DOCU	JMENT HIS	STORY	12
2.	STUD	Y DESIGN	l	13
3.	OR IE	CTIVES		15
٥.	3.1.		ıry objectives	
	3.2.		ry objective	
4.	ENDF	OINTS		16
	4.1.		endpoints	
	4.2.	Secondar	ry endpoints	16
5.	ANAL	YSIS SETS	3	17
	5.1.			
		5.1.1.	Enrolled Set	
			Randomized Set	
		5.1.3.	Exposed Set (ES)*	
	5.2.	5.1.4.	Per-protocol set (PPS)* for immunogenicityor eliminating data from Analysis Sets	
	5.2.	5.2.1.	Eliminating data from Analysis Sets	
		5.2.2.	Elimination from Randomized Set	
		5.2.3.	Elimination from Exposed Set (ES)	
		5.2.4.	Elimination from Per-protocol analysis Set (PPS)	
	5.3.		t protocol deviation not leading to elimination from per- analysis set	21
6.			NALYSES	
	6.1.		phy	21
		6.1.1.	Analysis of demographics/baseline characteristics planned	0.4
		640	in the protocol	21
	6.2.		Additional considerations	
	0.2.	6.2.1.	Analysis of exposure planned in the protocol	
		6.2.2.	Additional considerations	
	6.3.		enicity	
		6.3.1.	Analysis of immunogenicity planned in the protocol	
			6.3.1.1. Within group assessment	
			6.3.1.2. Between group assessment	
		6.3.2.	Additional considerations	23
			6.3.2.1. Statistical considerations for confirmatory	24
	6.4.	Analysis	objectivesof safety	
	0.4.		Analysis of safety planned in the protocol	
			Additional considerations	
		J. 1.2.	6.4.2.1. Combined Solicited and Unsolicited Adverse	
			Events	28

	204487 (20\$1EF Statistical Analysis Plan Am	
7.	ANALYSIS INTERPRETATION	
8.	CONDUCT OF ANALYSES	28
	8.1. Sequence of analyses	<mark>28</mark>
	8.2. Statistical considerations for interim analyses	29
9.	CHANGES FROM PLANNED ANALYSES	29
10.	LIST OF FINAL REPORT TABLES, LISTINGS AND FIGURES	30
11.	ANNEX 1 STANDARD DATA DERIVATION RULE AND STATISTICAL	
	METHODS	30
	11.1. Standard data derivation	30
	11.1.1. Dose number	
	11.1.2. Immunogenicity	
	11.1.3. Safety	
	11.2. Statistical Method References	
	11.3. Number of decimals displayed:	
12.	ANNEX 2: STUDY SPECIFIC MOCK TFL	34
	12.1. List of individual data listing	
	12.2. Template of Tables and Figures	

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

LIST OF TABLES

		PAGE
Table 1	Study groups and epochs foreseen in the study	14
Table 2	Study groups and treatment foreseen in the study	14
Table 3	Blinding of study epochs	14
Table 4	Power to demonstrate VRR objective and non-inferiority of the immunogenicity of HZ/su and <i>Prevenar13</i> co-administered compared to Control group	24
Table 5	Analysis and disclosure plan for the planned analysis	29
Table 6	Group Definitions to be used for the sub-group analysis by age (Analysis will be included in the clinical report)	30

204487 Statistical Analysis Plan Amendment 2 20 Nov 2019 TMF-1632694 2.	204	4487 I	Statistical	Analysis Plan	Amendment 2 20 No	ov 2019	LTMF-1632694 L	2.0
---	-----	--------	-------------	---------------	-------------------	---------	----------------	-----

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

LIST OF FIGURES

		PAGE
Figure 1	Overview of Study Design	13

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

LIST OF TEMPLATES

		PAGE
Template 1	Number of subjects by country and center <exposed set=""></exposed>	35
Template 2	Number of enrolled subjects by country	36
Template 3	Number of enrolled subjects by age category	36
Template 4	Number of subjects by country and age category <exposed set=""></exposed>	36
Template 5	Number of subjects vaccinated, completed and withdrawn with reason for withdrawal – <end active="" end="" of="" phase,="" study=""> <exposed set=""></exposed></end>	37
Template 6	Visit attendance <exposed set=""></exposed>	37
Template 7	Summary of important protocol deviations leading to elimination from any analyses	38
Template 8	Percentage of subjects with serological results who were eliminated from PPS for immunogenicity	38
Template 9	Deviations from specifications for age and intervals between study visits for Co-Ad group <exposed set=""></exposed>	38
Template 10	Deviations from specifications for age and intervals between study visits - for Control group <exposed set=""></exposed>	39
Template 11	Summary of demographic characteristics <exposed for="" immunogenicity="" pps="" set,=""></exposed>	39
Template 12	Minimum and maximum activity dates <exposed set=""></exposed>	40
Template 13	Study Population <exposed set=""></exposed>	40
Template 14	Exposure to study vaccines <exposed set=""></exposed>	41
Template 15	Compliance in completing solicited adverse events information <exposed set=""></exposed>	41
Template 16	Incidence and nature of <grade 3="" 3,="" grade="" related,=""> adverse events (<unsolicited and="" only="" solicited="" solicited,="">) reported <during (days="" 1-7)="" 1-7),="" 7-day="" beyond="" the=""> post-vaccination period following each dose and overall</during></unsolicited></grade>	42
Template 17	Incidence of solicited local adverse events reported during the 7-day (Days 1-7) post-vaccination period by study vaccine following each dose and overall <exposed set=""></exposed>	43

	204487 (ZOSTER-059 F Statistical Analysis Plan Amendme	
Template 18	Incidence of solicited general adverse events reported during the 7-day (Days 1-7) post-vaccination period following each dose and overall <exposed set=""></exposed>	.44
Template 19	Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose <exposed set=""></exposed>	.45
Template 20	Number and percentage of subjects reporting the occurrence of <grade 3=""> <non-serious> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with attended="" causal="" medically="" relationship="" to="" vaccination,="" visit="" with="">, within the 30-day (Days 1-30) post-vaccination period <,including numbers of events><exposed set=""></exposed></with></non-serious></grade>	.46
Template 21	Global Summary of <grade 3=""> <non-serious>unsolicited signs and adverse events reported <with attended="" causal="" medically="" relationship="" vaccination,="" visit="" with=""> within the 30-day (Days 1-30) post-vaccination period <exposed set=""></exposed></with></non-serious></grade>	.47
Template 22	Number and percentage of subjects starting a concomitant medication during the 30- day (Days 1-30) post vaccination period by dose and overall <exposed set=""></exposed>	.47
Template 23	Number of days with solicited <local, general=""> adverse events <during (days="" 1-7)="" 7="" days="" following<br="" period="" post="" the="" vaccination="">each dose and overall> <- Prevenar 13 vaccine, - HZ/su vaccine> <exposed set=""></exposed></during></local,>	.48
Template 24	Solicited and unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term within the 30-day (Days 1-30) post-vaccination period including number of events - SAE excluded <exposed set=""></exposed>	.48
Template 25	Number (%) of subjects with serious adverse events from <first 30="" <database="" date(ddmmmyyyy)="" days="" dose="" end,="" first="" freeze="" last="" post="" study="" to="" up="" vaccination="" vaccination,=""><study end="">, including number of events reported <exposed set=""></exposed></study></first>	.49
Template 26	Number (%) of subjects reported solicited local adverse events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <exposed set=""></exposed>	.50
Template 27	Number (%) of subjects reported solicited general adverse events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <exposed set=""></exposed>	.51
Template 28	Number and percentage of subjects with <anti-ge <x="" anti-pneumococcal="" antibody="" concentration,=""> antibody titres> equal to or above <cut-off> and <gmcs, gmt=""> <pps exposed="" for="" immunogenicity,="" set=""></pps></gmcs,></cut-off></anti-ge>	52
	minanogomony, Exposod Oele	. 52

	204487 (ZOSTER- Statistical Analysis Plan Amer	
Template 29	Vaccine response rates for anti-gE antibody ELISA concentrations in Co-Ad group at one month post dose 2 of HZ/su vaccine – primary objective <pps exposed="" for="" immunogenicity,="" set=""></pps>	
Template 30	Adjusted ratios of GMCs between groups (Control group divided by Co-Ad group) for anti-gE antibody ELISA concentrations at one month post dose 2 of HZ/su vaccine <pps exposed="" for="" immunogenicity,="" set=""></pps>	53
Template 31	Adjusted ratios of GMTs between groups (Control group divided by Co-Ad group) for anti-pneumococcal <x> antibody titres at one month post Prevenar 13 vaccine <pps exposed="" for="" immunogenicity,="" set=""></pps></x>	53
Template 32	Mean Geometric Increase (MGI) of anti-gE antibody ELISA concentrations from baseline to one month post dose 2 of HZ/su vaccine < <i>PPS for immunogenicity</i> , Exposed Set>	53
Template 33	Descriptive statistics of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentration < PPS for immunogenicity, Exposed Set>	54
Template 34	Distribution of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentrations < PPS for immunogenicity, Exposed Set>	54
Template 35	Listing of potential Immune Mediated Diseases (pIMDs) reported as identified by predefined list of preferred terms and/or by investigator assessment up to end of study <exposed set=""></exposed>	55
Template 36	Listing of all SAEs up to end of study <exposed set=""></exposed>	55
Template 37	Listing of suspected HZ cases from first administered dose up to end of study <exposed set=""></exposed>	55
Template 38	Listing of (S)AEs and solicited adverse events leading to study or treatment discontinuation <up 5="" month="" to=""><up end="" of="" study="" to=""> <exposed set=""></exposed></up></up>	56
Template 39	Maximum intensity of solicited <local, general=""> adverse event ongoing beyond the 7-day (Days 1-7) post-vaccination period following each dose and overall <exposed set=""></exposed></local,>	56
Template 40	Number and percentage of doses reporting the occurrence of <grade 3=""> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal="" relationship="" to="" vaccination=""> within the 30-day (Days 1-30) post-vaccination period <exposed set=""></exposed></with></grade>	57
Template 41	Number and percentage of subjects reporting the occurrence of <serious adverse="" disease="" events,="" immune="" mediated="" potential=""> classified by MedDRA Primary System Organ Class and</serious>	

	204487 (ZOSTER-0 Statistical Analysis Plan Ameno	
	Preferred Term from <first 30="" days="" dose="" end="" first="" from="" last="" of="" post="" study="" study,="" to="" up="" vaccination="" vaccination,=""> <,including number of events><exposed set=""></exposed></first>	58
Template 42	Global Summary of <serious adverse="" disease="" events,="" immune="" mediated="" potential=""> <with causal="" relationship="" vaccination="" with=""> reported from <first 30="" days="" dose="" end="" first="" from="" last="" of="" post="" study="" study,="" to="" up="" vaccination="" vaccination,=""> <exposed set=""></exposed></first></with></serious>	58
Template 43	Vaccine response rates for anti-gE antibody concentrations at one month post dose 2 of HZ/su vaccine < <i>PPS for immunogenicity</i> , Exposed Set>	59
Template 44	Reverse cumulative distribution curves for <anti-ge <x="" anti-pneumococcal="" antibody="" concentration,=""> antibody titres> in each group at baseline and <post 13="" 2="" dose="" hz="" of="" post="" prevenar="" su="" vaccine,=""> <pps exposed="" for="" immunogenicity,="" set=""></pps></post></anti-ge>	60
Template 45	Number and percentage of subjects <with><experiencing> fatal SAEs classified by MedDRA Primary System Organ Class and Preferred Term <who died=""><with fatal="" of="" onset="" sae=""> <during period="" starting="" the=""> <from 30="" days="" dose="" first="" last="" post="" to="" up="" vaccination=""> <after 30="" days="" dose="" end="" last="" post="" study="" to="" up="" vaccination=""><from end="" first="" study="" the="" until="" vaccination=""><during entire="" period="" study="" the=""> <exposed set=""></exposed></during></from></after></from></during></with></who></experiencing></with>	61
Template 46	Summary of subject disposition from Enrolled Set to Randomized Set	61
Template 47	Summary of subject disposition from Randomized Set to Per Protocol Set	62
Template 48	Listing of subjects who died during the entire study period and their fatal SAEs <enrolled set=""></enrolled>	63
Template 49	Summary of subjects by unsolicited adverse event category, with onset within 30 days of each vaccination	64
Template 50	Summary of subjects by serious adverse event and potential Immune Mediated Disease categories, with onset <from 30="" after="" days="" end="" first="" last="" post="" study="" to="" until="" vaccination="" vaccination,=""></from>	64

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

LIST OF ABBREVIATIONS

AE Adverse event

AES Adverse Event Screen

ANCOVA Analysis of Covariance

AS01_B: MPL, QS21, liposome based Adjuvant System (50 µg MPL and 50

μg QS21)

BS Blood Sampling

CDR Clinical Data Reviewer

CI Confidence Interval

Co-Ad Co-administration

CRDL Clinical Research and Development Lead

CRF Case Report Form

CSR Clinical Study Report

CTRS Clinical Trial Registry Summary

ELISA Enzyme-linked immunosorbent assay

Eli Type Internal GSK database code for type of elimination code

EL.U/ml ELISA unit per milliliter

EoS End of Study

ES Exposed Set (formally called 'Total Vaccinated Cohort')

GMC Geometric mean antibody concentration

GMT Geometric mean antibody titre

GSK GlaxoSmithKline

IU/ml International units per milliliter

LL Lower Limit of the confidence interval

LLOQ Lower Limit of Quantification

MedDRA Medical Dictionary for Regulatory Activities

MGI Mean Geometric Increase

MOPA Multiplex Opsonophagocytosis Assay

PCD Primary Completion Date

PD Protocol Deviation

PDMP Protocol Deviation Management Plan

PPS Per-Protocol Set (formally called 'According to Protocol')

PT Preferred Term

204487 | Statistical Analysis Plan Amendment 2 20 Nov 2019 | TMF-1632694 | 2.0

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

SAE Serious adverse event
SAP Statistical Analysis Plan

SBIR GSK Internet Randomization System

SD Standard Deviation

SHS Study Headline Summary

SOC System Organ Class

SUSAR Suspected Unexpected Serious Adverse Reactions

TFL Tables Figures and Listings

TOC Table of Content

UL Upper Limit of the confidence interval

ULOQ Upper Limit of Quantification

VRR Vaccine response rate

YOA Years of Age

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2


1. DOCUMENT HISTORY

Date	Description	Protocol
		Version
13 APR 2018	First Version	Amendment 2:
		30 JAN 2018
11 JUN 2019	Amendment 1	Amendment 2:
	Summary of changes as below:	30 JAN 2018
	- As per new process applicable, the front page has been	
	modified to remove the names of all the contributing	
	author and reviewers. Also, sign-off is only required to be	
	done by Lead Statistician	
	- Updated LLOQ and newly calculated ULOQ for the 13	
	pneumococcal serotypes tested by MOPA have been	
	added and accordingly analysis of immunogenicity section	
	has been updated.	
	- Consort table have been added for subject disposition.	
	- Additional tables for fatal serious adverse events (SAEs)	
	and grade 3 non-serious unsolicited adverse events (AEs)	
	have been added.	
	- The term "symptom" has been changed to "adverse event	
	(AE)" in endpoints, table titles and content for solicited	
	AEs, unsolicited AEs, SAEs, and potential immune	
	mediated diseases (pIMDs).	
	- Table 'Summary of temperature value by half degree	
	increment reported during the 7-day (Days 1-7) post-	
	vaccination following each dose' has been removed	
	- Sequence of analysis has been updated	
	- Inclusion of Enrolled and Randomized Set definition	
	- Code 1500 in elimination codes has been removed and	
	added under code 1070. Also, mandatory columns have	
	been added in the elimination table under 'Elimination	
	from PPS section.	
20-NOV-2019	Amendment 2	Amendment
	Summary of changes as below:	2: 30 JAN
	- The active phase analysis has been removed as a	2018
	request for a CTRS posting extension has been	
	submitted to NIH; complete CTRS posting will be done	
	at Last Subject Last Visit (LSLV) + 12 months rather	
	than Primary Completion Date (PCD) +12 months as	
	previously planned	
	- Titles and Footnotes of selected templates have been	
	updated following the Dry run kick-off meeting	
	- Two new safety templates have been added	
	(Templates 49 and 50)	

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

2. STUDY DESIGN

Figure 1 Overview of Study Design



Vacc: vaccination; BS: blood sample; Pre-Vacc: pre-vaccination; FU: follow-up

Experimental design: Phase IIIB, open-label, randomized, controlled, multi-centric, and multi-country, with two parallel groups.

Duration of the study: The intended duration of the study per subject is approximately 14 months for subjects from the Co-Ad group and approximately 16 months for subjects from the Control group.

• Epoch 001: Primary starting at Visit Day 1 and ending with the phone contact at Month 16.

Primary completion date (PCD): Visit Month 5.

End of Study (EoS): Last testing results released of samples collected at Visit Month 3 (Co-Ad group) or at Visit Month 5 (Control group).

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Study groups:

Table 1 Study groups and epochs foreseen in the study

Study groups	Number of subjects	Age	Epochs Epoch 001
Co-Ad	456	≥ 50 years	Х
Control	456	≥ 50 years	Х

Table 2 Study groups and treatment foreseen in the study

Treatment name	Vaccine/Product name	Study	Groups
		Co-Ad	Control
HZ/su	VZV gE	Х	х
	AS01B	Х	х
Prevenar13	Prevenar 13	Х	х

Control: active control.

Vaccination schedule(s):

- Co-Ad Group:
 - at Visit Day 1: first dose of HZ/su and one dose of Prevenar13,
 - at Visit Month 2: second dose of HZ/su.
- Control Group:
 - at Visit Day 1: one dose of Prevenar13,
 - at Visit Month 2: first dose of HZ/su,
 - at Visit Month 4: second dose of HZ/su.

Treatment allocation: Subjects to be randomized in a 1:1 ratio at Visit Day 1 to either Co-Ad or Control group. Subjects in each group will be stratified by age with the following approximate distribution (not less than 25% in each age strata):

- 171 subjects in the 50-59 Years of Age (YOA) stratum,
- 171 subjects in the 60-69 YOA stratum, and
- 114 subjects in the \geq 70 YOA stratum.

Blinding: open-label.

Table 3 Blinding of study epochs

Study Epochs	Blinding
Epoch 001	open

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

3. OBJECTIVES

3.1. Co-Primary objectives

To determine the vaccine response rate (VRR) to HZ/su (based on humoral immune response) one month after the second vaccine dose, when the first dose of HZ/su is co-administered with *Prevenar13* (Co-Ad group).

Criterion to be used:

The objective is met if the lower limit (LL) of the 95% CI of the VRR for anti-gE antibody concentrations in the Co-Ad group one month after the second vaccine dose is >60%.

If the above objective is met in the Co-Ad group, then the following objective will be evaluated:

To demonstrate non-inferiority of the humoral immune response to two doses of HZ/su at one month after the last vaccine dose, when the first dose of HZ/su is co-administered with *Prevenar13* (Co-Ad group) compared to when two doses of HZ/su are administered subsequent to *Prevenar13* (Control Group).

Criterion for non-inferiority:

One month after the last vaccine dose in each study group, the upper limit (UL) of the 95% confidence interval (CI) for the anti-gE antibodies Geometric Mean Concentration (GMC) ratio between the Control group and the Co-Ad group is <1.5.

If the above non-inferiority objective is met, then the following objective will be evaluated:

To demonstrate non-inferiority of the humoral immune response to *Prevenar13* at one month after the vaccine dose, when *Prevenar13* is co-administered with the first HZ/su dose (Co-Ad group) compared to when *Prevenar13* is administered separately from HZ/su (Control group), for the 13 serotypes included in *Prevenar13* analyzed sequentially.

Criterion for non-inferiority:

One month after the Prevenar13 vaccine dose in each study group, the UL of the 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group is <2.

For the co-primary objectives, fixed sequence testing which allows for full alpha propagation in pre-ordered hypotheses families will be used (see section 6.3.2.1).

3.2. Secondary objective

To evaluate the safety and reactogenicity following administration of HZ/su and *Prevenar13* vaccines, up to one month post last vaccination and during the whole follow-up period, in the Control group and the Co-Ad group.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

4. ENDPOINTS

4.1. Primary endpoints

HZ/su immunogenicity:

- Vaccine response for anti-gE humoral immunogenicity, as determined by ELISA, in subjects from the Co-Ad group at one month post-dose 2, at Visit Month 3.
- Anti-gE antibody concentrations as determined by ELISA at one month post-dose 2, at Visit Month 3 for the Co-Ad group and Visit Month 5 for the Control group.

Pneumococcal vaccine immunogenicity:

• Anti-pneumococcal antibody titers for the 13 following serotypes as determined by MOPA at one month post-dose at Visit Month 1: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

The criteria used to define the VRR is given in Section 11.1.2.

4.2. Secondary endpoints

Occurrence of solicited local and general adverse events:

- Occurrence, duration and intensity of each solicited local adverse event within 7 days (Days 1 7) after each vaccination,
- Occurrence, duration, intensity and relationship to vaccination of each solicited general adverse event within 7 days (Days 1 7) after each vaccination.

Occurrence of unsolicited AEs:

Occurrence, intensity and relationship to vaccination of unsolicited AEs within 30 days (Days 1 - 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.

Occurrence of SAEs:

- Occurrence and relationship to vaccination of all SAEs from first vaccination at Day 1 up to 30 days post last vaccination.
- Occurrence and relationship to vaccination of all SAEs during the period starting after 30 days post last vaccination up to study end.

Occurrence of pIMDs:

- Occurrence and relationship to vaccination of any pIMDs from first vaccination at Day 1 up to 30 days post last vaccination.
- Occurrence of any pIMDs during the period starting after 30 days post last vaccination up to study end.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

5. ANALYSIS SETS

5.1. Definition

5.1.1. Enrolled Set

The Enrolled Set will include all the subjects for whom valid signed informed consent form is available.

5.1.2. Randomized Set

The Randomized Set will include all the subjects for whom valid signed informed consent form is available and treatment is allocated.

5.1.3. Exposed Set (ES)*

The Exposed set (ES) will include all subjects with at least one vaccine administration documented:

- The ES for analysis of solicited adverse events will include all subjects with at least one documented administered vaccine.
- The ES for analysis of unsolicited AEs, SAEs and pIMDs will include all subjects with at least one vaccine administered.
- The ES for analysis of immunogenicity will include vaccinated subjects for whom immunogenicity data are available.

The ES analysis will be performed per treatment actually administered (at Dose 1).

5.1.4. Per-protocol set (PPS)* for immunogenicity

The Per-protocol set for immunogenicity will include all evaluable subjects:

- who meet all eligibility criteria,
- who comply with the procedures and intervals allowed for the analysis,
- who do not meet any of the criteria for elimination during the study,
- for whom data concerning immunogenicity endpoint measures are available.

^{*} Note that in order to align to ICH and cDISC terminology the Total Vaccinated Cohort and the Per- Protocol cohort have been renamed Exposed Set (ES) and Per-Protocol Set (PPS) respectively.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

The intervals allowed for the inclusion in the *PPS for immunogenicity* are defined as follows:

	Group	Interval	Allowed interval for PPS analysis of immunogenicity
Interval between	Co-Ad	HZ/su (Dose 1) – HZ/su (Dose 2)	49-83 Days
vaccinations	Control	Prevenar13 (Dose 1) – HZ/su (Dose 2)	>= 60 days*
	Control	HZ/su (Dose 2) – HZ/su (Dose 3)	49-83 Days
Interval between vaccination and blood sample	Co-Ad	Prevenar13 (Dose 1) – Visit Month 1 for BS	28-48 Days*
taken	Co-Ad	HZ/su (Dose 2) – Visit Month 3 for BS	28-48 days*
	Control	Prevenar13 (Dose 1) – Visit Month 1 for BS	28-48 Days*
	Control	HZ/su (Dose 3)– Visit Month 5 for BS	28-48 days*

BS= blood sampling taken; *please note these intervals differ from protocol amendment 2 Table 8 and 9 to increase the number of evaluable subjects while not compromising the interpretation of immunogenicity data

5.2. Criteria for eliminating data from Analysis Sets

Elimination codes are used to identify subjects to be eliminated from analysis. Detail is provided below for each set.

5.2.1. Elimination from Enrolled Set

Code 900 (invalid informed consent or fraud data) will be used for identifying subjects eliminated from Enrolled Set.

5.2.2. Elimination from Randomized Set

Code 900 (invalid informed consent or fraud data) and code 1010 (vaccine number not allocated) will be used for identifying subjects eliminated from Randomized Set.

5.2.3. Elimination from Exposed Set (ES)

Code 1030 (Study vaccine not administered at all), code 1010 (vaccine number not allocated) and code 900 (invalid informed consent or fraud data) will be used for identifying subjects eliminated from ES.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

5.2.4. Elimination from Per-protocol analysis Set (PPS)

A subject will be excluded from the PPS analysis under the following conditions:

Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set
900	Invalid informed consent or fraudulent data. Subjects excluded from all stat analysis Note: Subjects receiving a code 900 should not receive any other elimination codes.	All	All
1010	Vaccine number not allocated Note: Subjects receiving a code 1010 should not receive any other elimination codes	Day 1	Randomized Set, ES, PPS
1030	Study vaccine not administered AT ALL but subject number allocated Note: Subjects receiving a code 1030 should not receive any other elimination codes	Day 1	ES, PPS
1040*	Administration of concomitant vaccine(s) forbidden in the protocol Comment: Co-Ad group: From 30 days before 1st vaccination up to Month 3 blood sampling Control group: From 30 days before 1st vaccination up to Month 5 blood sampling	Co-Ad group: Day -30 to Month 3 Control group : Day -30 to Month 5	PPS
1050	Randomization failure (subject not randomized in the correct group) Comment: To check for manual randomisation, treatment not compatible with one assigned by SBIR	Day 1	PPS
1070	 Side, site or route of study vaccine administration wrong or unknown Administration not according to protocol for reason specified by the investigator, other than side, site and route Wrong replacement or study vaccine administered (not compatible with the vaccine regimen associated to the treatment number) Administered study vaccine reported as being the correct one but is not compatible with the vaccine regimen associated to the treatment number. 	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
1080	Vaccine has been administered (effective treatment number) despite a temperature deviation qualified by Status QA GMP NON Use	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
1090	Expired vaccine administered	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
2010	Protocol violation (inclusion/exclusion criteria)	Day 1	PPS
2040*	Administration of any medication forbidden by the protocol Co-Ad group: From 1st vaccination up to Month 3 blood sampling Control group: From 1st vaccination up to Month 5 blood sampling	Co-Ad group – Day 1 up to Month 3 Control group – Day 1 up to Month 5	PPS

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

	Statistical Analysis Plan Amendment 2			
Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set	
2050*	Underlying medical condition forbidden by the protocol Co-Ad group: From 1st vaccination up to Month 3 blood sampling	Co-Ad group – Day 1 up to Month 3	PPS	
	Control group: From 1st vaccination up to Month 5 blood sampling	Control group – Day 1 up to Month 5		
2060*	Concomitant infection related to the vaccine which may influence immune response Co-Ad group: From 1st vaccination up to Month 3 blood sampling	Co-Ad group – Day 1 up to Month 3 Control group – Day 1 up	PPS	
	Control group: From 1st vaccination up to Month 5 blood sampling	to Month 5		
2070*	Concomitant infection not related to the vaccine which may influence immune response Comment:	Co-Ad group – Day 1 up to Month 3	PPS	
	Co-Ad group: From 1st vaccination up to Month 3 blood sampling Control group: From 1st vaccination up to Month 5 blood sampling	Control group – Day 1 up to Month 5		
2080	Subjects did not comply with vaccination schedule (dates of vaccination not corresponding to adapted protocol intervals provided in SAP or unknown	Co-Ad group: Day 1, Month 2	PPS	
	vaccination dates) Comment: Co-Ad group: DOSE 1 – DOSE 2 Control group: DOSE 1 – DOSE 2 DOSE 2 – DOSE 3	Control group: Day 1, Month 2, Month 4		
2090	Subjects did not comply with blood sample schedule (dates of BS not corresponding to adapted protocol intervals provided in SAP or unknown BS/vaccination	Co-Ad group: Month 1, Month 3	PPS	
	dates) Comment: Co-Ad group: DOSE 1 – MONTH 1 BS	Control group: Month 1, Month 5		
	DOSE 2 – MONTH 3 BS Control group: DOSE 1 – MONTH 1 BS DOSE 3 – MONTH 5 BS			
2100	Serological results not available post-vaccination (including lost samples, blood sample not done, unable to test, absence of parallelism). Please specify the applicable rule: elimination code if ALL are missing for a subject Comment:	Co-Ad – Month 1, Month 3 Control – Month 1, Month 5	PPS	
	Co-Ad group: Check for availability of anti-gE serological result at Month 3 and for pneumococcal serological results at Month 1 Control group: Check for availability of anti-gE serological result at Month 5 and for pneumococcal serological results at Month 1			
2120	Obvious incoherence or abnormality or error in data (incoherence between CRF and results, wrong labelling) Comment: Co-Ad group: Check for above condition on anti-gE	Co-Ad – Month 1, Month 3 Control – Month 1, Month 5	PPS	
	serological result at Month 3 and on pneumococcal serological results at Month 1			

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set
	Control group: Check for above condition on anti-gE serological result at Month 5 and on pneumococcal serological results at Month 1		
2500	Incomplete vaccination course. Comment: The subject should receive one dose of Prevenar 13 vaccine and 2 doses of Hz/su vaccine	Co-Ad – Day 1, Month 2 Control – Day 1, Month 2, Month 4	PPS

BS = Blood sample

5.3. Important protocol deviation not leading to elimination from per-protocol analysis set

For information on important protocol deviation not leading to elimination from the PPS set, refer to the study protocol deviation and management plan (PDMP).

6. STATISTICAL ANALYSES

Note that standard data derivation rule and stat methods are described in Section 11 and will not be repeated below. All analyses will be presented by study phase when there are data for both active and follow up phases.

6.1. Demography

6.1.1. Analysis of demographics/baseline characteristics planned in the protocol

Demographic characteristics (age at first vaccination, sex, race and ethnicity) will be tabulated per treatment group.

The mean age (plus range and standard deviation [SD]) of the subjects, as a whole, and per treatment group will be calculated for ES and PPS. The distribution of subjects enrolled among the study sites will be tabulated, as a whole, and per treatment group.

The same tabulations might be performed by age strata (50-59, 60-69 and \geq 70 YOA) if deemed necessary.

6.1.2. Additional considerations

- The following additional tables will be generated:
 - The number of subjects enrolled into the study as well as the number of subjects excluded from PPS analyses will be presented through two consort tables:
 - Consort table 1 Showing the subjects disposition from Enrolled Set to Randomized Set
 - Consort table 2 Showing the subjects disposition from Randomised Set to *Per Protocol Set for immunogenicity*
 - Withdrawal status will be summarized by group. The numbers of withdrawn subjects will be tabulated according to the reason for withdrawal

^{*} Attribution of these elimination codes are responsibility of CRDL following review of individual data listings

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

- The following table will be generated for CTRS:
 - Percentage of Enrolled subjects by country will be tabulated by group,
 - Percentage of Enrolled subjects in the following age categories ≤64, 65-84, ≥85 will be tabulated by group.
- For computation of age, following rule need to be considered:
 - Age will be calculated as the number of years between the date of birth and the date of first vaccination.
 - To ensure that the collection of date of birth will not jeopardise the privacy of Personally Identifiable Information (PII), only a partial date of birth (MMYYYY) will be collected.
 - Therefore, the 15th of the month will be used to replace the missing date.
 - In case the month is missing, the date will be replaced by the June 30th of the year.
- Summary of important protocol deviations leading to elimination will be presented.

6.2. Exposure

6.2.1. Analysis of exposure planned in the protocol

None

6.2.2. Additional considerations

The number of doses administered will be tabulated. The number of doses administered will be tabulated by age sub-group.

6.3. Immunogenicity

6.3.1. Analysis of immunogenicity planned in the protocol

The primary analysis will be based on the *Per-protocol set (PPS) for immunogenicity*. A second analysis based on the Exposed set will be performed to complement the per-protocol analysis (see section 9 for changes in the planned analysis).

Immunogenicity analyses for confirmatory objectives will be performed by age stratum (50-59, 60-69 and \geq 70 YOA) on PPS, if the number of subjects enrolled is sufficient in each stratum.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

6.3.1.1. Within group assessment

The following parameters will be tabulated by vaccine group at each time point when a blood sample result is available:

- Seropositivity with exact 95% CI for all antigens
- GMC/GMT with 95% CI for all antigens
- VRR with exact 95% CI for anti-gE
- Mean Geometric Increase (MGI) with exact 95% CI for anti-gE
- Descriptive statistics (N, mean, SD, min, Q1, median, Q3, max) of Mean Geometric Increase (MGI) for anti-gE
- Distribution of the fold increase i.e. Percentage of subjects with a more than X-fold (e.g. >2, >4, >6, -fold) increase will be tabulated for anti-gE per group with 95% CI.
- Antibody titre/concentration will be displayed using reverse cumulative curves.

6.3.1.2. Between group assessment

The following between group comparison will be performed:

- For the second co-primary objective for non-inferiority of the anti-gE humoral response, at one-month post-dose 2 of HZ/su vaccine:
 - The 95% CI of the group GMCs ratio (Control divided by Co-Ad) will be computed using an ANCOVA model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.
- For the third co-primary objective for non-inferiority of the humoral response to each vaccine pneumococcal serotype (according to the pre-specified order in the protocol), one month post-dose of *Prevenar13*:
 - The 95% CI of the group MOPA GMT ratios (Control divided by Co-Ad) will be computed using an ANCOVA model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

6.3.2. Additional considerations

The following additional points need to be considered for immunogenicity analysis:

- Percentage of subjects above the pneumococcal serotype specific LLOQ will be calculated for each serotype with exact 95% Cis.
- Immunogenicity descriptive analyses will be performed by age stratum (50-59, 60-69 and \geq 70 YOA), if the number of subjects enrolled is sufficient in each stratum.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

- Two-sided 95% CIs for Seropositivity and VRR will be computed by Clopper-Pearson method [Clopper, 1934]. The differences in percentages and the associated two-sided 95% between the groups CIs for the difference will be constructed using the method of Miettinen and Nurminen [Robert, 1998].
- The two-sided 95% CI for the mean of log-transformed titre/concentration will be first obtained assuming that log-transformed values were normally distributed with unknown variance. The 95% CI for the GMTs/GMCs/MGIs will be then obtained by exponential-transformation of the 95% CI for the mean of log-transformed titre/concentration.

6.3.2.1. Statistical considerations for confirmatory objectives

For the multiplicity adjustment, all hypotheses have been ranked into three families and one sub-family according to the following power of test:

Table 4 Power to demonstrate VRR objective and non-inferiority of the immunogenicity of HZ/su and *Prevenar13* co-administered compared to Control group

Family 1: HZ/su: VVR*(1-s	ided test with alpha = 2.5	%)		
Endpoint	Threshold	VR assumed	Total β	Power
VRR in Co-Ad group	0.60	95%	0.001%	99.99%
Family 2: HZ/su: non-infer	iority* (1-sided test with a	alpha = 2.5%) N=41	0	
Endpoint	Standard deviation	δ	Total β	Power
Anti-gE GMC ratio	0.35	1.5	0.001 %	99.99 %
Family 3: Prevenar13: Nor	n-inferiority* (1-sided test	with alpha = 2.5%)	N=410	
Endpoint (13 vaccine pneumococcal serotypes)	Standard deviation	δ	Total β	Power
3 GMT ratio	0.660	2	0.001%	99.99%
19A GMT ratio	0.644	2	0.001%	99.99%
1 GMT ratio	0.798	2	0.029%	99.97%
18C GMT ratio	0.891	2	0.203%	99.80%
4 GMT ratio	0.906	2	0.260%	99.74%
6A GMT ratio	0.919	2	0.320%	99.68%
5 GMT ratio	0.931	2	0.383%	99.62%
19F GMT ratio	0.971	2	0.664%	99.33%
6B GMT ratio	0.995	2	0.891%	99.11%
7F GMT ratio	1.014	2	1.107%	98.89%
9V GMT ratio	1.021	2	1.194%	98.81%
14 GMT ratio	1.045	2	1.530%	98.47%
23F GMT ratio	1.094	2	2.398%	97.60%
Global β to show non-inferiority ~				
Global power				~91%

VRR: vaccine response rate; gE: Varicella Zoster Virus glycoprotein E; GMT: geometric mean titer; GMC: geometric mean concentration.

For gE: non-inferiority limit = 0.176 (=log10(1.5)), power under equal GMC

For each pneumococcal serotype: non-inferiority limit = 0.301 (=log10(2)), variability for each of the 13 vaccine pneumococcal serotype taken from the EMA assessment report for *Prevenar13* and multiplied by 1.1, power under equal GMT.

^{*} Pass 12, alpha = 2.5%, for VRR: Exact test, for non-inferiority one-sided equivalence of means.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Fixed sequence testing which allows for full alpha propagation in pre-ordered hypotheses families will be applied in the following manner:

Family 1:

In the Co-Ad group, for anti-gE, at one month post-dose 2 of HZ/su vaccine:

• The VRR and 95% CI will be computed.

The objective is met if the LL of the 95% CI is \geq 60%.

Family 2:

For anti-gE, at one month post-dose 2 of HZ/su vaccine:

• The 95% CI of the group GMCs ratio will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

In terms of concentrations, the Co-Ad group will be considered non-inferior to the Control group if the UL of the 95% CI for the GMC ratio of the Control group to the Co-Ad group is <1.5.

Family 3:

For each vaccine pneumococcal serotype (according to the pre-specified order), one month post-dose of *Prevenar13*:

 The 95% CI of the group MOPA GMT ratios will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations.
 The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

In terms of MOPA GMTs, the Co-Ad group will be considered non-inferior to the Control group if the UL of the 95% CI for the MOPA GMTs ratio of the Control group to the Co-Ad group is <2 for each of the 13 vaccine serotypes.

In the ANCOVA models Adjusted Least Squares (LS) means and difference of LS means between the groups will be calculated together with the 2-sided 95% CIs and backtransformed to the original units to provide GMCs and GM ratios.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

6.4. Analysis of safety

6.4.1. Analysis of safety planned in the protocol

The analysis for safety will be based on the Exposed set. All safety analyses may also be performed by age strata (50-59, 60-69 and \geq 70 YOA), if deemed necessary.

When appropriate, tabulations will be presented overall and by time of occurrence relative to last vaccination (e.g. using windows such as Days 1 to 7, Days 1 to 30 and more than 30 days post-vaccination).

The results for the analysis of safety will be tabulated as follows:

- The number and percentage of subjects with at least one local solicited AE, with at least one general solicited AE, and with any solicited AE during the 7-day follow-up period with exact 95% CIs after each vaccine dose and overall by vaccination group will be provided;
- The percentage of subjects reporting each individual solicited local and general AE during the solicited 7-day follow-up period will be tabulated with exact 95% CI;
- For all solicited adverse events, the same tabulation will be performed for grade 3 solicited AEs and for solicited general AEs with relationship to vaccination;
- Number of days with each individual solicited local and general AE during the solicited 7-day follow-up period;
- The proportion of subjects with at least one report of unsolicited AE (containing both serious and non-serious unsolicited AEs) classified by the MedDRA Primary System Organ Class (SOC) and Preferred Terms (PTs) and reported up to 30 days after each vaccination will be tabulated with exact 95% CI;
- The same tabulation will be performed for grade 3 unsolicited AEs and for unsolicited AEs with a relationship to vaccination reported up to 30 days after each vaccination with exact 95% CI. The proportion of AEs resulting in a medically attended visit will also be tabulated;
- Total number/percentages of doses (per dose and overall) followed by AEs will be tabulated:
- Number of subjects with pIMDs will be tabulated;
- SAEs, including fatalities and withdrawal due to AE(s) will be described in detail.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

6.4.2. Additional considerations

- The following additional tables will be generated:
 - The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE (solicited and unsolicited) during the 7-day follow-up period will be tabulated with exact 95% CI after each vaccine dose and overall. The same computations will be done for Grade 3 AEs, for any AEs considered related to vaccination and for any Grade 3 AEs considered related to vaccination.
 - The percentage of subjects with at least one local solicited AE, with at least one general solicited AE and with any solicited AE will also be done for Grade 3 solicited AEs, for any solicited AEs considered related to vaccination and for any Grade 3 solicited AEs considered related to vaccination.
 - The percentage of subjects reporting each individual solicited local AE during the solicited 7-day follow-up period will be tabulated by study vaccine with exact 95% CI.
 - Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose.
 - For fever, the number and percentage of subjects reporting fever by half degree (°C) cumulative increments during the 7-day follow-up period (Day 1-7) will be tabulated for each group after each vaccine dose and overall. Similar tabulations will be performed for Grade 3 (> 39.0°C) causally related fever.
 - List of suspected HZ cases identified during the study will be presented.
 - The number and percentage of subjects starting a concomitant medication during the 30-day post-vaccination period by dose and overall will be presented.
 - The duration of solicited local adverse events (in days), not limited to the 7-day post-vaccination period, following each dose and overall/dose. The same tabulations after Prevenar13 and HZ/su vaccinations.
 - The duration of solicited general adverse events (in days), not limited to the 7day post-vaccination period, following each dose and overall/dose.
 - Solicited local adverse events ongoing beyond the 7-day (Days 1-7) post-vaccination period, following each dose and overall/dose. The same tabulations after Prevenar13 and HZ/su vaccinations.
 - Solicited general adverse events ongoing beyond the 7-day (Days 1-7) post-vaccination period, following each dose and overall/dose.
 - Number and percentage of subjects with at least one report of a grade 3 non-serious unsolicited AE during the 30-day (Days 0–29) follow-up period after each vaccination classified according to the MedDRA Primary SOC and PTs will be tabulated, with exact 95% CI. The same will be generated for grade 3 non-serious unsolicited AE considered related to vaccination.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

- Number and percentage of subjects with fatal SAEs, classified by MedDRA
 Primary SOC and PTs will be presented with exact 95% CI in two ways:
- With onset of fatal SAE during the period starting from first vaccination to 30 days post last vaccination dose, after 30 days post last vaccination dose to study end and from first vaccination to study end.
- Who died during the period starting from first vaccination to 30 days post last vaccination dose, after 30 days post last vaccination dose to study end and entire study period.
- The listing of all subjects who died during the entire study period and their fatal SAEs in the Enrolled Set

6.4.2.1. Combined Solicited and Unsolicited Adverse Events

A summary of subjects with all combined solicited (regardless of their duration) and unsolicited adverse events will be provided. Solicited adverse events will be coded by MedDRA as per the following codes:

Solicited adverse event	Lower level term name	Corresponding Lower level term code
Pain	Injection site pain	10022086
Redness	Redness at injection site	10022098
Swelling	Swelling at injection site	10053425
Fatigue	Fatigue	10016256
Gastrointestinal symptoms	Gastrointestinal disorder	10017944
Headache	Headache	10019211
Myalgia	Myalgia	10028411
Shivering	Shivering	10040558
Temperature	Fever	10016558

For clintrial.gov and EudraCT posting purposes, a summary of combined solicited and unsolicited non-serious adverse events will be produced by SOC and PTs and according to occurrence of each event.

7. ANALYSIS INTERPRETATION

All co-primary objectives will be evaluated using a one-sided Type I error of 2.5% (as already justified by fixed sequential testing procedure, no alpha adjustment needed). The trial will be considered conclusive if all co-primary objectives criteria are met.

8. CONDUCT OF ANALYSES

8.1. Sequence of analyses

The analysis will be performed in the following steps:

• The final analysis on immunogenicity, reactogenicity and safety data will be performed when all data up to study end (i.e., phone contact at Month 14 for Co-Ad group and phone contact at Month 16 for Control group) will be available and cleaned. Individual data listings will also be provided.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

An integrated clinical study report containing all data will be written and made available to the investigators following the final analysis.

Table 5 Analysis and disclosure plan for the planned analysis

Description	Analysis ID	Disclosure Purpose (CTRS=public posting, CSR=clinical study report, internal)	Dry run review needed (Y/N)	Reference for TFL
Final analysis	E1_01	CTRS CSR	Y	All tables from Section 12 of the SAP Amendment 2 140CT2019

8.2. Statistical considerations for interim analyses

Not applicable

9. CHANGES FROM PLANNED ANALYSES

- In Protocol Amendment 2 Final (30 Jan 2018), it was specified that a second analysis for immunogenicity of the ES would be performed only if, in any study group, the percentage of enrolled subjects with serological results excluded from the PPS for immunogenicity is 5% or more. At the request of Paul Ehrlich Institute, Germany (PEI), an analysis of the ES will be performed to complement the per-protocol analysis regardless of the percentage of enrolled subjects excluded from the PPS for immunogenicity.
- Updated LLOQ values (i.e. assay cut-off values) for the pneumococcal serotypes are provided in this version of SAP (section 11.1.2). The cut-off values presented in this SAP will be used to determine seropositivity rather than those presented in Protocol Amendment 2 Final (30 Jan 2018). Analysis of immunogenicity section has been updated accordingly.
- Additional tables on presentation of grade 3 non-serious unsolicited adverse events and fatal SAEs has been added based on CBER request.
- The sequence of analysis was updated from SAP amendment 1 to accommodate a delay in the availability of immunogenicity results. The active phase analysis has been removed as a request for a CTRS posting extension has been submitted to NIH; complete CTRS posting will be done at Last Subject Last Visit (LSLV) + 12 months rather than Primary Completion Date (PCD) +12 months as previously planned
- Two new cohorts Enrolled Set and Randomized Set has been defined as required for web disclosure and SAE tables presentation.
- Analysis of demography section has been updated to add consort table and summary of important protocol deviations.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

10. LIST OF FINAL REPORT TABLES, LISTINGS AND FIGURES

The TFL TOC provides the list of tables/listings and figures to be included in the study report.

The following group names will be used in the TFLs, in line with the T-domains:

Group order in tables	Group label in tables	Group definition for footnote
1	Co-Ad	Dose 1 : Prevenar 13 + HZ/su, Dose 2: HZ/su
2	Control	Dose 1 : Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

The following sub-groups will be used in the TFL, in line with the T-domains:

Table 6 Group Definitions to be used for the sub-group analysis by age (Analysis will be included in the clinical report)

Sub-group order in tables	Sub-group label in tables	Sub-group definition for footnote
1	50-59YOA	Subjects aged 50-59 years
2	60-69YOA	Subjects aged 60-69 years
3	≥70YOA	Subjects aged 70 years and over

YOA = Year of age

Please note that for table presentation in the sub-group analysis, the sequence maintained has to be each treatment group within each age sub-group.

11. ANNEX 1 STANDARD DATA DERIVATION RULE AND STATISTICAL METHODS

11.1. Standard data derivation

11.1.1. Dose number

The study dose number is defined in reference to the number of study visits at which vaccination occurred. More specifically dose 1 refers to all vaccines administered at the first vaccination visit while dose 2 corresponds to all vaccinations administered at the second vaccination visit even if this is the first time a product is administered to the subject.

Associated dose: the associated dose for an event (AE, medication, vaccination) is the most recent study dose given before an event. In case the event takes place on the day a study dose is given, the associated dose will be that of the study dose, even if the event actually took place before vaccination. For instance, if an adverse event begins on the day of the study vaccination but prior to administration of the vaccine, it will be assigned to this dose. In case a study dose is not administered and an event occurs after the subsequent study dose (e.g. 2nd study dose), the associated dose of the event will be study dose associated to the subsequent study dose (e.g. dose 2).

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

The number of doses for a product is the number of times the product was administered to a subject.

The incidence per dose is the number of visits with vaccine administered at which an event was reported among all visits with vaccine administered.

11.1.2. Immunogenicity

- For a given subject and given immunogenicity measurement, missing or nonevaluable measurements will not be replaced. Therefore, an analysis will exclude subjects with missing or non-evaluable measurements.
- A seronegative subject is a subject whose antibodies concentration/titer is below the cut-off value (cut-off value is defined by the laboratory prior to the analysis).
- A seropositive subject is a subject whose antibodies concentration/titer is greater than or equal to the assay cut-off value.
- The seropositivity rate is defined as the percentage of seropositive subjects.
- The VRR for anti-gE is defined as the percentage of subjects who have at least:
 - a 4-fold increase in the anti-gE antibodies concentration as compared to the prevaccination anti-gE antibodies concentration, for subjects who are seropositive at baseline, or,
 - a 4-fold increase in the anti-gE antibodies concentration as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who are seronegative at baseline.
- The GMC calculations for anti-gE antibody concentration are performed by taking the anti-log of the mean of the log base 10 concentration transformations. Antibody concentrations below the cut-off of the assay will be given an arbitrary value equal to half the cut-off for the purpose of GMC/GMT calculation.
- All CI computed will be two-sided 95% CI.
- Updated LLOQ and ULOQ values for the MOPA assay are described below for each of the 13 pneumococcal serotypes:

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Pneumococcal serotype	Method	Unit	LLOQ1	ULOQ	Laboratory	
Streptococcus pneumoniae Serotype 01/37 Brugmann Hospital Ab			14	3504		
Streptococcus pneumoniae Serotype 03/1 Statens Serum Institut Ab			11	2822		
Streptococcus pneumoniae Serotype 04/2656 Brugmann Hospital Ab			40	18042		
Streptococcus pneumoniae Serotype 05 Ambrose- Statens Serum Institut Ab			15	13304		
Streptococcus pneumoniae Serotype 06A Centers for Disease Control Ab			45	15305		
Streptococcus pneumoniae Serotype 06B/DS2212/94 Centers for Disease Control Ab			29	20806	University of	
Streptococcus pneumoniae Serotype 07F/46 Brugmann Hospital Ab	MOPA	1/ dilution	28	59809	University of Alabama at Birmingham	
Streptococcus pneumoniae Serotype 09V/112 161/95 Statens Serum Institut Ab			39	28095	Diffilligitatif	
Streptococcus pneumoniae Serotype 14/58 Brugmann Hospital Ab			16	47856		
Streptococcus pneumoniae Serotype 18C/4593/40 Statens Serum Institut Ab			40	13318		
Streptococcus pneumoniae Serotype 19A/DB18 Kansanterveyslaitos Folkhalsoinstitutet Ab				13	34881	
Streptococcus pneumoniae Serotype 19F/2737 Brugmann Hospital Ab			33	29352		
Streptococcus pneumoniae Serotype 23F Mac- Statens Serum Institut Ab			40	10662		

¹LLOQ corresponds to serotype-specific assay cut-off value.

• The Geometric Mean Titres (GMTs) calculations for pneumococcal serotypes are performed by taking the anti-log of the mean of the log base 10 titre transformations. For GMT calculation for pneumococcal serotypes, antibody titres below the LLOQ of the assay will be given an arbitrary value of half the cut-off for GMT calculation. Antibody titres above the ULOQ of the assay will be given the value of ULOQ for GMT calculation.

11.1.3. Safety

For a given subject and the analysis of solicited adverse event during the 7 day follow-up period after vaccination, missing or non-evaluable measurements will not be replaced. Therefore, the analysis of the solicited adverse events based on the ES will include only vaccinated subjects with documented safety data (i.e., symptom screen completed). More specifically the following rules will be used:

- Subjects who documented the absence of a solicited adverse event after one dose will be considered not having that adverse event after that dose.
- Subjects who documented the presence of a solicited adverse event and fully or partially recorded daily measurement over the solicited period will be included in the summaries at that dose and classified according to their maximum observed daily recording over the solicited period.
- Subjects who documented the presence of a solicited adverse event after one dose without having recorded any daily measurement will be assigned to the lowest

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

intensity category at that dose (i.e., 38°C for fever or grade 1 for other adverse events). The subject will only be presented in the subject with adverse event experienced and not in specific grade information.

Doses without adverse event sheets documented will be excluded.

For analysis of unsolicited AEs, such as SAEs or adverse events by MedDRA Primary SOC and PTs term, and for the analysis of concomitant medications, all vaccinated subjects will be considered. Subjects who did not report the event or the concomitant medication will be considered as subjects without the event or the concomitant medication respectively.

Associated dose: The associated dose for an event (e.g., AE, medication, vaccination,...) is the study dose given before an event. In case the event takes place on a day a study dose is given, the associated dose will be that of the study dose even if the event actually took place before. For instance, for a conc. medication started on the day of study dose 2 but before dose 2 administrations, the associated dose will be dose 2

The way the percentage of subjects will be derived will depend on the event analysed (see the following table for details). As a result, the denominator (N) will differ from one table to another.

Event	N used for deriving %	Terminology used in the tables for N
Concomitant	All vaccinated subjects	Number of subjects with at least one
medication		administered dose
Solicited local	All vaccinated subjects with at least one	For each dose and overall/subject:
adverse event	solicited local adverse event	N= number of subjects with at least one
	documented as either present or absent	documented dose
		For overall/dose:
		N= number of documented doses
Solicited general	All vaccinated subjects with at least one	For each dose and overall/subject:
adverse event	solicited general adverse event	N= number of subjects with at least one
	documented as either present or absent	documented dose
		For overall/dose:
		N= number of documented doses
Unsolicited adverse	All vaccinated subjects	Number of subjects with at least one
event from day 0 to		administered dose
day X		
SAE	All vaccinated subjects	Number of subjects with at least one
		administered dose

- The maximum intensity of local injection site redness and swelling will be scored at GSK Biologicals as follows:
 - − 0 : <20 mm
 - $-1: \ge 20 \text{ mm to} \le 50 \text{ mm diameter}$
 - 2: > 50 mm to \leq 100 mm diameter
 - 3 : > 100 mm diameter

Fever is defined as temperature \geq 38.0 C / 100.4 F for oral, axillary, tympanic or rectal route. The preferred route for recording temperature in this study will be oral. For the analysis, temperatures will be coded as follows:

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Grade	Temperature (oral, axillary, tympanic or rectal route)
0	< 38°C
1	≥ 38°C - ≤ 38.5°C
2	> 38.5°C - ≤ 39°C
3	> 39°C

• Conversion of temperature to °C -

The following conversion rule is used for the conversion of temperature to °C

- Temperature in °Celsius = ((Temperature in °Fahrenheit -32) *5)/9

The result is rounded to 1 decimal digit.

11.2. Statistical Method References

Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. *Biometrika*. 1934; 26:404-413.

Robert G. Newcombe, interval estimation for the difference between independent proportions: comparison of eleven methods, *Statist Med.* 1998; 17, 873-890.

11.3. Number of decimals displayed:

The following decimal description from the decision rules will be used for the demography, immunogenicity and safety/reactogenicity.

Display Table	Parameters	Number of decimal digits
Demographic characteristics	Mean, median age	1
Demographic characteristics	SD (age)	1
Immunogenicity	Ratio of GMT/C	2
All summaries	% of count, including LL & UL of CI	1
All summaries	% of difference, including LL & UL of CI	2

12. ANNEX 2: STUDY SPECIFIC MOCK TFL

The study specific mocks are annexed to this SAP in a separate document.

The data display, title and footnote are for illustration purpose and will be adapted to the study specificity as indicated in the TFL TOC. Note that there may be few changes between the study specific SAP mock TFL and the final TFLs as editorial/minor changes do not require a SAP amendment

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

12.1. List of individual data listing

Following individual data listing will be generated. *Please refer to TFL TOC for the numbering of these Appendices*.

- Elimination codes
- Demography
- Physical examination/vital signs
- Dates of birth, Informed consent, Vaccination and blood sampling, Contact
- Reason for visit not done
- General medical history Physical examination
- Study Conclusion
- Notes (this appendix is provided for info only and should not be used for the clinical report)
- Vaccination procedure
- Reason for not administration of vaccine
- Reason for non-eligibility
- Previous history of vaccination
- Previous history of disease
- Solicited local adverse events
- Solicited general adverse events
- Unsolicited adverse events within (30) days post-vaccination
- Unsolicited adverse events after (30) days post-vaccination
- Concomitant medications
- Concomitant vaccinations
- Immunogenicity

12.2. Template of Tables and Figures

Template 1 Number of subjects by country and center < Exposed Set>

			<each group=""> N=XXXX</each>		• .		Total N=XXXX	
Country	Center	n	%	n	%	n	%	
<each country=""></each>	<each center=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X	
	All	XXX	XX.X	XXX	XX.X	XXX	XX.X	

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

Center = GSK Biologicals assigned center number

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 2 Number of enrolled subjects by country

		<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>		otal XXXX
Country	n	%	n	%	n	%
<each country=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

n = number of subjects in a given country

N = total number of subjects

 $% = n/N \times 100$

Template 3 Number of enrolled subjects by age category

	<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>		Total N=XXXX	
Age category	n	%	n	%	n	%
Adults [18-64 years]	XXX	XX.X	XXX	XX.X	XXX	XX.X
From 65-84 years						
85 years and over						

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of enrolled subjects

n = number of enrolled subjects included in each group or in total for a given age category or for all age categories $\% = n/N \times 100$

Template 4 Number of subjects by country and age category <Exposed Set>

			<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>		Total N=XXXX	
Country	Age category	n	%	n	%	n	%	
<each country=""></each>	50-59YOA	XXX	XX.X	XXX	XX.X	XXX	XX.X	
•	60-69YOA							
	≥70YOA							
	All	XXX	XX.X	XXX	XX.X	XXX	XX.X	

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

50-59YOA = Subjects aged 50-59 years

60-69YOA = Subjects aged 60-69 years

≥70YOA = Subjects aged 70 years and over

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 5 Number of subjects vaccinated, completed and withdrawn with reason for withdrawal – <end of active phase, study end> <Exposed set>

	<each group=""> N=XXXX</each>	<each group=""> N=XXXX</each>	Total N=XXXX
	n	n	n
Number of subjects vaccinated	XXX	XXX	XXX
End of study status			
[EACH CATEGORY]	XXX	XXX	XXX
Reasons for withdrawal:			
[REASONS]	XXX	XXX	XXX

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Vaccinated = number of subjects who were vaccinated in the study

Completed = number of subjects who completed <end of active phase visit, last study visit>
Withdrawn = number of subjects who did not come for the <end of active phase visit, last study visit>
Unknown = number/percentage of subjects who have not come for the <end of active phase visit, last study visit> yet

Template 6 Visit attendance <Exposed set>

		<each group=""> N=XXX</each>				
Visit	Status	n	%			
INFORMED CONSENT	Completed					
RANDOMIZATION	Completed					
<each visit=""></each>	Attended					
	Not attended yet					
	Permanent discontinuation prior to this visit					
	Not attended					
CONCLUSION	Completed					

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Number of subjects in each group or in total

Conclusion = date of last visit or withdrawal

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 7 Summary of important protocol deviations leading to elimination from any analyses

Category Sub-category	<	Each group)>		otal I=XXXX			
	осс	n	%	осс	n	%		
At least one important protocol deviation	XXX	XXX	XX.X	XXX	XXX	XX.X		
.0.1	XXX	XXX	XX.X	XXX	XXX	XX.X		
<category 1=""></category>	XXX	XXX	XX.X	XXX	XXX	XX.X		
<sub-category 1=""> <sub-category 2=""></sub-category></sub-category>	XXX	XXX	XX.X	XXX	XXX	XX.X		
	xxx	XXX	XX.X	XXX	XXX	XX.X		
<category 2=""></category>								

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Total number of subjects

Occ = number of occurrences = number of important protocol deviations

n/% = number / percentage of subjects with important protocol deviations

Template 8 Percentage of subjects with serological results who were eliminated from PPS for immunogenicity

	[each gr	oup]
Number of subjects in Exposed Set with serological results available		
Number of subjects with serological results eliminated from PPS for immunogenicity		
Percentage of subjects with serological results eliminated from PPS for immunogenicity		

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 9 Deviations from specifications for age and intervals between study visits for Co-Ad group <Exposed Set>

Age			Dose:1-PI ((M1)	Dose:1- Dose:2	Dose:2-PII	Dose:2- PHC (M14)		
Group		Protocol	col Protocol Adapted		Protocol	Protocol Adapted		Protocol	
		from ≥ 50 years	from 30 to 42 days	from 28 to 48 days	from 49 to 83 days	from 30 to 48 days	from 28 to 48 days	from 335 to 395 days	
Co-Ad	N								
	n %								
	% range								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Adapted = interval used for defining PPS for immunogenicity

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PI (M1) = Blood sample at Month 1, post-vaccination Dose 1

PII (M3) = Blood sample at Month 3, post-vaccination Dose 2

PHC (M14) = Phone Contact MONTH 14

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 10 Deviations from specifications for age and intervals between study visits - for Control group <Exposed Set>

		Age	Dose:1-PI(M1)			Dose:3- Dose:3		` ,	Dose:3- PHONE CONT M16
Group		Protocol	Protocol	Adapted	Protocol	Adapted	Protocol	Protocol	Adapted	Protocol
		from ≥ 50	from 30 to	from 28 to	from 60 to	≥ 60	from 49 to	from 30 to	from 28 to	from 335 to
		years	42 days	48 days	83 days	days	83 days	48 days	48 days	395 days
Control	N									
	n									
	%									
	range									

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adapted = interval used for defining the **PPS for immunogenicity**

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PI(M1) = Blood sample at Month 1, post-vaccination Dose 1

PIII(M5) = Blood sample at Month 5, post-vaccination Dose 3

PHC (M16) = Phone Contact Month 16

Template 11 Summary of demographic characteristics <Exposed Set, PPS for immunogenicity>

		group>		group>	Total N=XXXX		
	Value or n	%	Value or n	%	Value or n	%	
Age in Years at <timepoint></timepoint>							
N with data	XXX		XXX		XXX		
Mean	XXX.X		XXX.X		XXX.X		
SD	XXX.X		XXX.X		XXX.X		
Median	XXX.X		XXX.X		XXX.X		
Minimum	XXX		xxx		xxx		
Maximum	xxx		xxx		XXX		
Gender							
<each gender=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X	
	XXX	XX.X	xxx	XX.X	xxx	XX.X	
Ethnicity							
<each ethnicity=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X	
	XXX	XX.X	xxx	XX.X	xxx	XX.X	
Geographic Ancestry							
<each ancestry="" geographic=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X	
	XXX	XX.X	xxx	XX.X	xxx	XX.X	
Age category							
<each age="" category=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X	
Country							
<each country=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X	
	xxx	XX.X	XXX	XX.X	XXX	XX.X	

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = total number of subjects

n/% = number / percentage of subjects in a given category

Value = value of the considered parameter

N with data = number of subjects with documentation of the corresponding data

SD = standard deviation

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 12 Minimum and maximum activity dates <Exposed Set>

Group	Activity number	Activity Description	Minimum date	Maximum date
Co-Ad	10	VISIT DAY 1		
	20	VISIT MONTH 1		
	30	VISIT MONTH 2		
	40	VISIT MONTH 3		
	70	PHONE CONTACT MONTH 14		
Control	10	VISIT DAY 1		
	20	VISIT MONTH 1		
	30	VISIT MONTH 2		
	50	VISIT MONTH 4		
	60	VISIT MONTH 5		
	80	PHONE CONTACT MONTH 16		

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 13 Study Population < Exposed Set>

	<each group=""> N=XXXX</each>	<each group=""> N=XXXX</each>	Total N=XXXX
Number of subjects			
Planned, N	XXX	XXX	XXX
Randomised, N <cohort name=""></cohort>	XXX	XXX	XXX
Completed to visit Month 3, n (%)*	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
Completed to visit Month 5, n (%)**	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
Completed to Phone contact Month 14, n (%)*	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
Completed to Phone contact Month 16, n (%)**	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<unknown></unknown>	XXX	XXX	XXX
Demographics			
N <cohort name=""></cohort>	XXX	XXX	XXX
Females:Males	XXX:XXX	XXX:XXX	XXX:XXX
Mean Age, <unit> (SD)</unit>	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median Age, <unit> (minimum, maximum)</unit>	xxx (xxx,xxx)	xxx (xxx,xxx)	xxx (xxx,xxx)
<most category="" frequent="" of="" race=""></most>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<second category="" frequent="" most="" of="" race=""></second>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<third category="" frequent="" most="" of="" race=""></third>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Total number of subjects SD = Standard deviation

*applicable for Co-Ad group and ** applicable for Control group

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 14 Exposure to study vaccines <Exposed Set>

		group>	<eac< th=""><th>h group></th><th>Total N=XXX</th><th>X</th></eac<>	h group>	Total N=XXX	X
Number of subjects receiving	n	%	n	%	n	%
Exactly 1 Dose						
Exactly 2 Doses						
Exactly 3 Doses						
At least 1 Dose						
Total number of doses administered during the study						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects in each group or in total included in the considered cohort

n = number of subjects/doses in the given category

% = percentage of subjects in the given category

Template 15 Compliance in completing solicited adverse events information <Exposed Set>

			<each gro<="" th=""><th>oup></th><th colspan="5"><each group=""></each></th></each>	oup>	<each group=""></each>				
DOSE	Adverse event information			Compliance (%)	N	n	Compliance (%)		
DOSE <each dose="" number=""></each>	General AES								
	Local AES								
TOTAL	General AES								
	Local AES								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N=Number of administered doses

n = number of doses with AES returned

General AES = Adverse event screens used for the collection of general solicited AEs

Local AES = Adverse event screens used for the collection of local solicited AEs

Compliance (%) = $(n / N) \times 100$

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 16 Incidence and nature of <grade 3, related, grade 3 related, > adverse events (<unsolicited and solicited, solicited only>) reported <during the 7-day (Days 1-7), beyond the 7-day (Days 1-7)> post-vaccination period following each dose and overall

		<e< th=""><th>ach</th><th>gro</th><th>up></th><th></th><th><e< th=""><th>ach</th><th>gro</th><th>up></th><th></th></e<></th></e<>	ach	gro	up>		<e< th=""><th>ach</th><th>gro</th><th>up></th><th></th></e<>	ach	gro	up>	
				•	95% CI				•	95%	CI
Dose	Adverse event	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Any adverse event										
	General adverse events										
	Local adverse events										
Dose 2	Any adverse event										
	General adverse events										
	Local adverse events										
Dose 3	Any adverse event										
	General adverse events										
	Local adverse events										
Overall/dose	Any adverse event										
	General adverse events										
	Local adverse events										
Overall/subject	Any adverse event										
•	General adverse events										
	Local adverse events										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects presenting at least one type of adverse event For overall/dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of adverse event

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 17 Incidence of solicited local adverse events reported during the 7-day (Days 1-7) post-vaccination period by study vaccine following each dose and overall <Exposed Set>

						Co-A	١d			(Conti	ol	
							95%	6 CI				95%	6 CI
Dose	Adverse event	Product	Type	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Pain	HZ/su	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
ı		Prevenar13	All										
			Grade 2 or 3										
			Grade 3										
ı			Medical advice										
	Redness (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar 13	All										
			>50										
			>100										
			Medical advice										
	Swelling (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar 13	All										
			>50										
			>100										
			Medical advice										
Dose 2													
Dose 3													
Overall/Dose													
Overall/Subject													
20 Ad - Doco 1: I	Prevenar 13+ H7/	cu Doco 2: UZ	leu	_									

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the type of adverse event at least once following the corresponding dose

For Overall/dose:

N = number of documented dose

n/% = number/percentage of doses followed by at least one type of adverse event For Overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the type of adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 18 Incidence of solicited general adverse events reported during the 7day (Days 1-7) post-vaccination period following each dose and overall <Exposed Set>

					<each gr<="" th=""><th></th><th></th></each>		
							5 % CI
Dose	Adverse event	Type	N	n	%	LL	UL
Oose 1	Fatigue	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Gastrointestinal symptoms	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Headache	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Myalgia	All					
	, ,	Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Shivering	All					
	3	Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Fever (Oral) (°C)	All (≥38.0)					
	. 575. (514.) (5)	>38.0					
		>38.5					
		>39.0					
		>39.5					
		>40.0					
		Related					
		>39.0*Related					
		Medical advice					
Pose 2							
Dose 3		•••					
Overall/Dose							
Overall/Subject	yanar 13+ H7/su. Dosa 2: H7/su						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the adverse event at least once following the corresponding dose For Overall/dose:

N = number of documented dose

n/% = number/percentage of doses followed by at least one type of adverse event

For Overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the type of adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 19 Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose <Exposed Set>

						C	o-Ad				Co	ontrol	
							95	% CI				95	% CI
Dose	Symptom	Route	Type	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Temperature (°C)	Oral	≥35.0										
	, ,		>35.5										
			>36.0										
			>36.5										
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
		Axillary	≥35.0										
			>35.5										
			>36.0										
			>36.5										
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
Dose 2	Temperature (°C)	Oral	≥35.0										
			>35.5										
			>36.0										
			>36.5										
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
Dose 3			10.0				1			\vdash		1	

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the temperature at least once

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 20 Number and percentage of subjects reporting the occurrence of <grade 3> <non-serious> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination, with medically attended visit>, within the 30-day (Days 1-30) post-vaccination period <,including numbers of events><Exposed Set>

		Ea N		gro	oup	
						5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%	L	UL
	At least one adverse event					
Gastrointestinal disorders (10017947)	At least one PT related to the corresponding SOC					
	Diarrhoea (10012735)					
	Teething (10043183)					
	Vomiting (10047700)					
General disorders and administration site conditions (10018065)	At least one PT related to the corresponding SOC					
(10010000)	Pyrexia (10037660)					
Immune system disorders (10021428)	Seasonal allergy (10048908)					
Infections and infestations (10021881)	Conjunctivitis (10010741)					
(Otitis media (10033078)					
	Paronychia (10034016)					
	Tonsillitis (10044008)					
	Tonsillitis streptococcal (10044013)					
	Viral upper respiratory tract infection (10047482)					
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)					
,	Face injury (10050392)					
	Head injury (10019196)					
Skin and subcutaneous tissue disorders (10040785)	Miliaria (10027627)					

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

n* = number of events reported

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Please note the n* will only be presented for the CTRS posting with the time interval as per the secondary endpoint

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 21 Global Summary of <grade 3> <non-serious>unsolicited signs and adverse events reported <with causal relationship with vaccination, with medically attended visit> within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

·	Co-Ad	Control	Total
Number of subjects with at least one unsolicited adverse event reported			
Number of doses followed by at least one unsolicited adverse event			
Number of unsolicited adverse events classified by MedDRA Preferred Term*			
Number of unsolicited adverse events reported**			

Co-Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

Template 22 Number and percentage of subjects starting a concomitant medication during the 30- day (Days 1-30) post vaccination period by dose and overall <Exposed Set>

				<each g<="" th=""><th>group></th><th></th></each>	group>	
						5% CI
Dose	Туре	N	n	%	LL	UL
Dose 1	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Dose 2	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Dose 3	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Overall/Dose	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Overall/Subject	Any					
·	Any in anticipation of study vaccine reaction					
	Any chronic use					

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = total number of subjects with the corresponding administered dose

n/% = number/percentage of subjects **who** took the specified type of concomitant medication at least once during the considered period

For Overall/dose:

N = number of administered doses

n/% = number/percentage of doses after which the specified type of concomitant medication was taken at least once during the considered period

For Overall/subject:

N = total number of subjects with at least one administered dose

n/% = number/percentage of subjects who took the specified type of concomitant medication at least once during the considered period

^{*} Adverse events reported by a subject after a given dose and classified by the same Preferred Term are counted once

^{**} Adverse events reported by a subject after a given dose and classified by the same Preferred Term and the same start date of the event, are counted once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 23 Number of days with solicited <local, general> adverse events <during the 7 days (Days 1-7) post vaccination period following each dose and overall> <- Prevenar 13 vaccine, - HZ/su vaccine> <Exposed Set>

			<co-ad group=""></co-ad>	<control group=""></control>
Dose	Adverse event	Statistic	value	value
<each dose=""></each>	<each adverse="" event=""></each>	n	XXXX	XXXX
		Mean	XX.X	XX.X
		Minimum	XX.X	XX.X
		Q1	XX.X	XX.X
		Median	XX.X	XX.X
		Q3	XX.X	XX.X
		Maximum	XX.X	XX.X
Overall/Dose	<each adverse="" event=""></each>	n	xxxx	XXXX
		Mean	XX.X	XX.X
		Minimum	XX.X	XX.X
		Q1	XX.X	XX.X
		Median	XX.X	XX.X
		Q3	XX.X	XX.X
		Maximum	XX.X	XX.X

Co-Ad group = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control group = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

n= number of doses with adverse event

Q1= 25th percentile

Q3= 75th percentile

Please note the table by vaccine type will only be done for local solicited adverse events.

Template 24 Solicited and unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term within the 30-day (Days 1-30) post-vaccination period including number of events - SAE excluded <Exposed Set>

			oup>	
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%
	At least one adverse event			
<each soc=""></each>	<each pt="" term=""></each>			

<each group>:

Co-Ad group = Dose 1: Prevenar+ HZ/su, Dose 2: HZ/su

Control group = Dose 1: Prevenar, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n* = number of events reported

n/% = number/percentage of subjects reporting the adverse event at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 25 Number (%) of subjects with serious adverse events from <first vaccination dose up to 30 days post last vaccination, 30 days post last vaccination up to study end, first vaccination dose up to <database freeze date(DDMMMYYYY)><study end>, including number of events reported <Exposed Set>

			<ea< th=""><th>ch gro N =</th><th>up></th></ea<>	ch gro N =	up>
Type of Event	Primary System Organ Class	Preferred Term (CODE)	n*	n	%
SAE	At least one adverse event				
	<each soc=""></each>	<each pt="" term=""></each>			
Related SAE	At least one adverse event				
	<each soc=""></each>	<each pt="" term=""></each>			
Fatal SAE	At least one adverse event				
	<each soc=""></each>	<each pt="" term=""></each>			
Related fatal SAE	At least one adverse event				
	<each soc=""></each>	<each pt="" term=""></each>			

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with the administered dose

n* = number of events reported

n/% = number/percentage of subjects reporting the adverse event at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 26 Number (%) of subjects reported solicited local adverse events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <Exposed Set>

					Co-A	٧d			(Contr	ol 💮	
						95%	6 CI				95%	6 CI
Adverse event	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL
Pain	HZ/su	All										
		Grade 2 or 3										
		Grade 3										
		Medical advice										
	Prevenar	All										
		Grade 2 or 3										
		Grade 3										
		Medical advice										
Redness (mm)	HZ/su	All										
, ,		>50										
		>100										
		Medical advice										
	Prevenar	All										
		>50										
		>100										
		Medical advice										
Swelling (mm)	HZ/su	All										
		>50										
		Medical advice										
	Prevenar	All										
		>50										
	Pain	Prevenar Redness (mm) HZ/su Prevenar Swelling (mm) HZ/su	Pain HZ/su All Grade 2 or 3 Grade 3 Medical advice Prevenar All Grade 2 or 3 Grade 3 Medical advice Redness (mm) HZ/su All S50 S100 Medical advice Prevenar All S50 S100 Medical advice Swelling (mm) HZ/su All S50 S100 Medical advice Prevenar All S100 Medical advice Prevenar All All S100 Medical advice Prevenar All All All S100 Medical advice	Pain	Adverse event Product Type N n	Adverse event Product Type N n %	Adverse event Product Type N n % LL	Adverse event Product Type N n % LL UL	Adverse event Product Type N n % LL UL N	Adverse event Product Type N n % LL UL N n	Adverse event Product Type N n % LL UL N n % M M M M M M M M M	Adverse event Product Type N n % LL UL N n % LL

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the type of adverse event at least once following the corresponding dose

For Across dose:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 27 Number (%) of subjects reported solicited general adverse events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <Exposed Set>

					<each gr<="" th=""><th>oup></th><th></th></each>	oup>	
							5 % CI
Dose	Adverse event	Туре	N	n	%	LL	UL
Dose 1	Fatigue	All					
		Grade 3					
		Related					
	Gastrointestinal symptoms	All					
		Grade 3					
		Related					
	Headache	All					
		Grade 3					
		Related					
	Myalgia	All					
		Grade 3					
		Related					
		All					
	_	Grade 3					
		Related					
	Fever (Oral) (°C)	All (≥38.0)					
		>39.0					
		Related					
Dose 2	Fatigue						
	Gastrointestinal symptoms						
	Headache						
	Myalgia						
	Shivering						
	Fever (Oral) (°C)						
Across Dose							

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the adverse event at least once following the corresponding dose For Across dose:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 28 Number and percentage of subjects with <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> equal to or above <cut-off> and <GMCs, GMT> <PPS for immunogenicity, Exposed Set>

				1	<≥cut-off unit, each serotype LLOQ>		<	GMC, G				
						95	% CI		9	95% CI		
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL	Min	Max
<anti-ge antibody, anti- pneumococcal <x> antibody></x></anti-ge 	Co-Ad	PRE										
		PI(M1) or PII(M3)										
	Control	PRE or PI(M2)										
		PI(M1) or PIII(M5)										

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

GM<C,T> = geometric mean antibody <concentration, titre> calculated on all subjects

N = Number of subjects with available results

95% CI = 95% confidence interval; LL = lower limit, UL = upper limit

n/% = number/percentage of subjects with <concentration, titre> equal to or above specified value

MIN/MAX = Minimum/Maximum

PRE= Pre-vaccination at Day 1

PII(M3) = Post-vaccination dose 2 at Month 3

PI(M1) = Post-vaccination dose 1 at Month 1

PI(M2) = Post-vaccination dose 1 at Month 2

PIII(M5) = Post-vaccination dose 3 at Month 5

Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3) for Co-Ad and PI(M2) and PIII(M5) for Control group.

Template 29 Vaccine response rates for anti-gE antibody ELISA concentrations in Co-Ad group at one month post dose 2 of HZ/su vaccine – primary objective <PPS for immunogenicity, Exposed Set>

			Co-Ad		
				95	% CI
Antibody	N	n	%	LL	UL
Anti-gE antibody	XXXX	XXXX	XX.X	XXX.X	XXX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Vaccine response defined as :

For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mI)

For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

N = number of subjects (subjects either seropositive or seronegative at pre-vaccination) with both pre- and post-vaccination results available

n/% = number/percentage of responders

<95>% CI = exact <95>% confidence interval, LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 30 Adjusted ratios of GMCs between groups (Control group divided by Co-Ad group) for anti-gE antibody ELISA concentrations at one month post dose 2 of HZ/su vaccine <PPS for immunogenicity, Exposed Set>

	Contro	I			Co-Ad			Adjusted GMC ratio (Control / Co-Ad)					
	95% CI*					95%	CI*		95	5% CI			
N	Adjusted GMC	LL	UL	N	Adjusted GMC	LL	UL	Value	LL	UL			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adjusted GMC = geometric mean antibody concentration adjusted for vaccine group, age and baseline concentration N = Number of subjects with both pre- and post-vaccination results available

95% CI* = 95% confidence interval for the adjusted GMC (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

95% CI = 95% confidence interval for the adjusted GMC ratio (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

Template 31 Adjusted ratios of GMTs between groups (Control group divided by Co-Ad group) for anti-pneumococcal <X> antibody titres at one month post Prevenar 13 vaccine <PPS for immunogenicity, Exposed Set>

	Contro		Co-Ad			Adjuste (Contr	d GMT rol / Co			
		959	% CI*			95%	CI*		95	% CI
N	Adjusted GMT	LL	UL	N	Adjusted GMT	LL	UL	Value	LL	UL

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adjusted GMT = geometric mean antibody titre adjusted for vaccine group, age and baseline concentration N = Number of subjects with both pre- and post-vaccination results available

95% CI* = 95% confidence interval for the adjusted GMT (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

95% CI = 95% confidence interval for the adjusted GMT ratio (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

Template 32 Mean Geometric Increase (MGI) of anti-gE antibody ELISA concentrations from baseline to one month post dose 2 of HZ/su vaccine <PPS for immunogenicity, Exposed Set>

								MGI		
									9	5% CI
Antibody	Group	N	Time point description	GMC	Time point description	GMC	Ratio order	Value	LL	UL
<antibody></antibody>	Co-Ad		PII(M3)		PRE		PII(M3)/PRE			
	Control		PIII(M5)		PI(M2)		PIII(M5)/PI(M2)			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Number of subjects with available results at the two considered time points

GMC = geometric mean antibody concentration

95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit

PRE= Pre-vaccination at Day 1

PII(M3) = Post-vaccination dose 2 at Month 3 for Co-Ad group

PI(M2) = Post-vaccination dose 1 at Month 2 for Control group (considered as pre-vaccination for HZ/su in Control group)

PIII(M5) = Post-vaccination dose 3 at Month 5 for Control group (considered as post dose 2 for HZ/su in Control group)

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 33 Descriptive statistics of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentration < PPS for immunogenicity, Exposed Set>

		Each Group N=							
				95% CI					
Antibody	Parameter	Value	LL	UL					
Anti-gE antibody	n								
	Nmiss								
	Mean								
	SD								
	Min								
	Q1								
	Median								
	Q3								
	Max								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = total number of subjects

n = number of subjects with available results

Nmiss = number of subjects with missing results

SD = Standard Deviation

Q1, Q3 = First and third quartiles

Min/Max = Minimum/Maximum

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to PI(M2) for Control group has to be considered

Template 34 Distribution of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentrations <PPS for immunogenicity, Exposed Set>

				<ea< th=""><th>ch gro</th><th>up></th><th></th><th></th><th><ea< th=""><th>ch gro</th><th>up></th><th></th></ea<></th></ea<>	ch gro	up>			<ea< th=""><th>ch gro</th><th>up></th><th></th></ea<>	ch gro	up>	
			•				% CI					% CI
Antibody	Timing	Fold change	N	n	%	LL	UL	N	n	%	LL	UL
<each antibody=""></each>	<pii(m3)></pii(m3)>	≥2	XX	XX	XX.X	XX.X	XX.X	XX	XX	XX.X	XX.X	XX.X
		≥4										
		≥6										
		≥8				İ						
		≥10				İ						
		≥12										
		≥14										
	<piii(m5)< td=""><td>>= Ratio1</td><td>хх</td><td>XX</td><td>XX.X</td><td>xx.x</td><td>xx.x</td><td>хх</td><td>XX</td><td>XX.X</td><td>xx.x</td><td>xx.x</td></piii(m5)<>	>= Ratio1	хх	XX	XX.X	xx.x	xx.x	хх	XX	XX.X	xx.x	xx.x

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with available results

n/% = number/percentage of subjects with concentration within the specified range

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PII(M3) = Post-vaccination dose 2 at Month 3 for Co-Ad group

PIII(M5) = Post-vaccination dose 3 at Month 5 for Control group (considered as post dose 2 for HZ/su in Control group)

Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to

PI(M2) for Control group has to be considered

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 35 Listing of potential Immune Mediated Diseases (pIMDs) reported as identified by predefined list of preferred terms and/or by investigator assessment up to end of study <Exposed Set>

Group	Patient ID	Country	Age at onset (Y)	Gender	Race	 Preferred term	Dose	Day of onset	Serious pIMD based on Investigator?	SAE (Y/N)	Outcome	pIMD Source

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 36 Listing of all SAEs up to end of study <Exposed Set>

Group	Sub. No.	Sex	Country	Race	Age at onset (Year)	Verbatim	Preferred term	Primary System Organ Class	MED type	Dose	Day of onset	Duration	Intensity	Causality	Outcome

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 37 Listing of suspected HZ cases from first administered dose up to end of study <Exposed Set>

Group	Sub.	Previous dose	Day on-set	Duration	Preferred	AE description	Medical advice	Medically attended visit	Intensity	Causality	Outcome
	No.				term						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

20-NOV-2019 Page 55 of 64

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 38 Listing of (S)AEs and solicited adverse events leading to study or treatment discontinuation <up to month 5><up to end of study> <Exposed Set>

Type of discontinuation: <study/treatment

Group	Subject number	Gender	Country	Race	AE Description	SAE (Y/N)	Causality	Outcome	Vaccination and visit
									Vaccination: x at visit x

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 39 Maximum intensity of solicited <local, general> adverse event ongoing beyond the 7-day (Days 1-7) post-vaccination period following each dose and overall <Exposed Set>

				<each group=""></each>	<each group></each
			Time to resolution	Value or	
Dose	Adverse event	Туре	(days)	n	n
<each dose=""></each>	<each adverse<="" td=""><td>All</td><td>N</td><td>XX</td><td>XX</td></each>	All	N	XX	XX
	event>		n	xx	xx
			q1	XX.X	XX.X
			median	XX.X	XX.X
			q3	XX.X	XX.X
		Grade 3	N	ХХ	XX
			n	xx	xx
			q1	XX.X	XX.X
			median	xx.x	xx.x
			q3	XX.X	XX.X
		Grade 3*Related	N	ХХ	XX
			n	xx	xx
			q1	XX.X	XX.X
OVERALL/DOSE			median	xx.x	xx.x
			q3	XX.X	XX.X
	<each adverse="" eve<="" td=""><td>nt><each type=""></each></td><td>N</td><td>XX</td><td>XX</td></each>	nt> <each type=""></each>	N	XX	XX
			n	XX	XX
			q1	XX.X	XX.X
			median	XX.X	XX.X
			q3	XX.X	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Time to resolution: number of days beyond the end of the follow-up period

N = number of adverse events that were ongoing after the follow-up period

n = number of adverse events that were ongoing after the follow-up period with a complete end date

q1 = 25th percentile q3= 75th percentile

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 40 Number and percentage of doses reporting the occurrence of <grade 3> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination> within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

			acl	n gr	oup
					5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL
At least one adverse event					
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)				
,	Teething (10043183)				
	Vomiting (10047700)				
General disorders and administration site conditions (10018065)	Pyrexia (10037660)				
Immune system disorders (10021428)	Seasonal allergy (10048908)				
Infections and infestations (10021881)	Conjunctivitis (10010741)				
,	Otitis media (10033078)				
	Paronychia (10034016)				
	Tonsillitis (10044008)				
	Tonsillitis streptococcal (10044013)				
	Viral upper respiratory tract infection				1
	(10047482)				
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)				1
, , , , , , , , , , , , , , , , , , , ,	Face injury (10050392)				1
	Head injury (10019196)				1
Skin and subcutaneous tissue disorders (10040785)	Miliaria (10027627)				1
20 Ad - Dogg 4: Drawager 42: 117/2: Dogg 9: 117/2:	Ivillialia (1002/02/)				

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term) N = number of administered doses

n/% = number/percentage of doses followed by the adverse event

11//0 - Humber/percentage of doses followed by the adverse event

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 41 Number and percentage of subjects reporting the occurrence of <serious adverse events, potential Immune Mediated Disease> classified by MedDRA Primary System Organ Class and Preferred Term from <first vaccination up to 30 days post last vaccination, from 30 days post last vaccination dose up to end of study, from first vaccination up to study end> <,including number of events><Exposed Set>

			(-Ad =		Cor N				ol
						5% Cl				9	5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%	LL	UL	n*	'n	% L	L l	UL
At least one adverse event											
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)										
Cardiac disorders (10007541)	Acute myocardial infarction (10000891)										
	Atrial fibrillation (10003658)										
	Cardiac failure congestive (10007559)										
	Tachycardia (10043071)										
	Ventricular tachycardia (10047302)										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

n* = Number of events reported

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Please note that n* will be used to present pIMD for CTRS posting.

Template 42 Global Summary of <serious adverse events, potential Immune
Mediated Disease> <with causal relationship with vaccination>
reported from <first vaccination up to 30 days post last vaccination,
from 30 days post last vaccination dose up to end of study, from
first vaccination up to study end> <Exposed Set>

	Co-Ad	Control	Total
Number of subjects with at least one <sae, pimd=""> reported</sae,>			
Number of doses followed by at least one <sae, pimd=""></sae,>			
Number of <sae, pimd=""> classified by MedDRA Preferred Term*</sae,>			
Number of <sae, pimd=""> reported**</sae,>			

Co-Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

^{*} Adverse events reported by a subject after a given dose and classified by the same Preferred Term are counted once ** Adverse events reported by a subject after a given dose and classified by the same Preferred Term and the same

start date of the event, are counted once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 43 Vaccine response rates for anti-gE antibody concentrations at one month post dose 2 of HZ/su vaccine <PPS for immunogenicity, Exposed Set>

		<each group=""></each>						
				95	5% CI			
	Pre-vaccination							
Antibody	status	N	n	%	LL	UL		
<each antibody=""></each>	S-	XXXX	XXXX	XX.X	XXX.X	XXX.X		
	S+	XXXX	XXXX	XX.X	XXX.X	XXX.X		
	Total	XXXX	XXXX	XX.X	XXX.X	XXX.X		

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

S- = seronegative subjects (antibody <concentration> < <cut off> <unit>) at pre-vaccination

S+ = seropositive subjects (antibody <concentration>≥ <cut off> <unit>) at pre-vaccination

Total = subjects either seropositive or seronegative at pre-vaccination

Vaccine response defined as:

For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml)

For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

N = number of subjects with both pre- and post-vaccination results available


n/% = number/percentage of responders

<95>% CI = exact <95>% confidence interval, LL = Lower Limit, UL = Upper Limit

Please note – To calculate the vaccine response, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to PI(M2) for Control group has to be considered

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 44 Reverse cumulative distribution curves for <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> in each group at baseline and <post dose 2 of HZ/su vaccine, post dose of Prevenar 13> <PPS for immunogenicity, Exposed Set>



Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Note: This graph is provided as an example. The same graph will be provided in colour for each time point and each assay comparing the values of the groups

Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3) for Co-Ad and PI(M2) and PIII(M5) for Control group.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 45 Number and percentage of subjects <with><experiencing> fatal SAEs classified by MedDRA Primary System Organ Class and Preferred Term <who died><with onset of fatal SAE> <during the period starting> <from first vaccination up to 30 days post last vaccination dose > <after 30 days post last vaccination dose up to study end><from first vaccination until the study end><during the entire study period> <Exposed Set>

		Co-Ad N =				Control N =			
					5% CI			;	95% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	n % L		UL	n	n % l		UL
At least one adverse event									
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)								
Cardiac disorders (10007541)	Acute myocardial infarction (10000891)								
	Atrial fibrillation (10003658)								
	Cardiac failure congestive								
	(10007559) Tachycardia (10043071)								
	Ventricular tachycardia (10047302)								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Template 46 Summary of subject disposition from Enrolled Set to Randomized Set

	Total N=XXX n %
Number of subjects who signed an informed consent	
Withdrawals prior to randomization	XXX XX.X
<withdrawal 1="" reason=""></withdrawal>	xxx xx.x
<withdrawal 2="" reason=""></withdrawal>	xxx xx.x
	xxx xx.x
	xxx xx.x
Number of subjects included in Randomized Set	

N = Number of subjects

n% = Number / Percentage of subjects in a given category

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 47 Summary of subject disposition from Randomized Set to Per Protocol Set

	<group 1=""></group>	<group 2=""></group>	Total
	N=XXX	N=XXX	N=XXX
	n %	n %	n %
Number of subjects			
included in Randomized Set			
Withdrawals	XXX XX.X	XXX XX.X	XXX XX.X
<withdrawal 1="" reason=""></withdrawal>	xxx xx.x	xxx xx.x	xxx xx.x
<withdrawal 2="" reason=""></withdrawal>	xxx xx.x	xxx xx.x	xxx xx.x
Eliminations	xxx xx.x	xxx xx.x	xxx xx.x
<elimination 1<="" reason="" td=""><td>xxx xx.x</td><td>xxx xx.x</td><td>xxx xx.x</td></elimination>	xxx xx.x	xxx xx.x	xxx xx.x
(code)>	xxx xx.x	xxx xx.x	xxx xx.x
<elimination 2<="" reason="" td=""><td></td><td></td><td></td></elimination>			
(code)>			
	xxx xx.x	xxx xx.x	xxx xx.x
Number of subjects			
included in Exposed Set			
Elimination 1			
Number of subjects			
included in PPS for			
immunogenicity			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Number of subjects

n% = Number / Percentage of subjects in a given category

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 48 Listing of subjects who died during the entire study period and their fatal SAEs <Enrolled Set>

Group	Sub. No.	Sex	Country	Race	Age at Onset (Year)	Verbatim	Preferred term	Primary System Organ Class	MED type	prior to onset of fatal SAE	between	prior to death	Days between death and previous dose	SAE Duration	SAE Causality
No Group	PPD									0	-	0	-		
										0	-	0	-		
										1	XX	1	XX		
										1	xx	2	XX		
										1	XX	1	XX		
										1	XX	1	XX		

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

No Group= Enrolled not vaccinated

MED = Medical Advice type (HO: hospitalisation, ER: emergency room visit, MD: medical practice visit)

20-NOV-2019 Page 63 of 64

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 2

Template 49 Summary of subjects by unsolicited adverse event category, with onset within 30 days of each vaccination

		<gro N=X</gro 	up 1> XXX	•		Froup 2 STOUP 2		
	95% CI					95%	% CI	
	n	%	LL	UL	n	%	LL	UL
At least one unsolicited adverse event	XXX	XX.X	XX.X	XX.X	XXX	XX.X	XX.X	XX.X
At least one grade 3 unsolicited adverse event	xxx	xx.x	XX.X	xx.x	XXX	XX.X	XX.X	xx.x
At least one related unsolicited adverse event	XXX	XX.X	XX.X	XX.X	XXX	XX.X	XX.X	XX.X
At least one grade 3 related unsolicited adverse event		XX.X	XX.X	XX.X	XXX	XX.X	XX.X	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Template 50 Summary of subjects by serious adverse event and potential Immune Mediated Disease categories, with onset <from first vaccination to 30 days post last vaccination, after 30 days post last vaccination until study end>

		<gro< th=""><th>up 1></th><th>•</th><th><g< th=""><th></th></g<></th></gro<>	up 1>	•	<g< th=""><th></th></g<>			
		N=X	XXX		N=	XXXX	(
		95% CI					95%	6 CI
	n	%	LL	UL	n	%	LL	UL
At least one serious adverse event	XXX	XX.X	XX.X	XX.X	XXX	XX.X	XX.X	XX.X
At least one causally related serious adverse event	ххх	xx.x	xx.x	xx.x	XXX	xx.x	XX.X	xx.x
At least one potential Immune Mediated Disease	XXX	XX.X	XX.X	xx.x	XXX	XX.X	XX.X	XX.X
At least one causally related potential Immune Mediated Disease		хх.х	хх.х	xx.x	XXX	хх.х	хх.х	хх.х

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the adverse event at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

	Statistical Arialysis Flan American entit
GlaxoSmithKline	Statistical Analysis Plan
Detailed Title:	A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with <i>Prevenar13</i> in adults aged 50 years and older.
eTrack study number and Abbreviated Title	204487 (ZOSTER-059 PRI)
Scope:	All analyses planned per protocol.
Date of Statistical Analysis Plan	Amendment 1 Final : 11 June 2019

APP 9000058193 Statistical Analysis Plan Template V4 (Effective date: 3 June 2019)

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

TABLE OF CONTENTS

				Р	AGE
LIS	T OF AI	BBREVIA	TIONS		10
1.	DOCU	MENT HI	STORY		12
2.	STUD	Y DESIGN	١		13
3.	OBJE0 3.1. 3.2.	Co-Prima	ary objectiv	es	15
4.	ENDP(4.1. 4.2.	Primary 6	endpoints	ts	16
5.	ANALY 5.1. 5.2.	Definition 5.1.1. 5.1.2. 5.1.3. 5.1.4. Criteria for 5.2.1. 5.2.2. 5.2.3. 5.2.4.	Enrolled S Randomiz Exposed S Per-protoc or elimination Elimination Elimination Elimination	Set	17 17 17 17 18 18
	5.3.			leviation not leading to elimination from per- t	21
6.	STATI 6.1.		aphy Analysis o in the prot	f demographics/baseline characteristics planned ocol	21
	6.2.	Exposure 6.2.1. 6.2.2.	Analysis o	f exposure planned in the protocol	22
	6.3.	Immunog 6.3.1.	Analysis o 6.3.1.1. 6.3.1.2.	f immunogenicity planned in the protocol	22 23
		0.0.2.	6.3.2.1.	Statistical considerations for confirmatory objectives	
	6.4.	Analysis 6.4.1. 6.4.2.	Analysis o	f safety planned in the protocol	26 26 27

				Statistical	Analysis Plan Ame	,
7.	ANAL'	YSIS INTERPF	RETATION			
8.	CONE	UCT OF ANAL	_YSES			29
	8.1.		analyses			
	8.2.	Statistical cor	nsiderations for inter	im analyses		30
9.	CHAN	GES FROM PI	LANNED ANALYSE	S		30
10.	LIST (F FINAL REP	ORT TABLES, LIST	ΓINGS AND FIGU	RES	31
11.			D DATA DERIVATI			
	11.1.		a derivation			
			e number			
		11.1.2. Imm	nunogenicity			32
		11.1.3. Safe	ety			33
	11.2.		thod References			
	11.3.	Number of de	cimals displayed:			35
12.	ANNE	X 2: STUDY S	PECIFIC MOCK TF	ጌ		36
			ual data listing			
			ables and Figures .			

204487 | Statistical Analysis Plan Amendment 1 11 Jun 2019 | TMF-561649 | 2.0

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

LIST OF TABLES

		PAGE
Table 1	Study groups and epochs foreseen in the study	14
Table 2	Study groups and treatment foreseen in the study	14
Table 3	Blinding of study epochs	14
Table 4	Power to demonstrate VRR objective and non-inferiority of the immunogenicity of HZ/su and <i>Prevenar13</i> co-administered compared to Control group	25
Table 5	Analysis and disclosure plan for the planned analysis	30
Table 6	Group Definitions to be used for the sub-group analysis by age (Analysis will be included in the clinical report)	31

204487 Statistical Analysis Plan	Amendment 1 11 Ju	un 2019 TMF-561649 2.0
------------------------------------	-------------------	----------------------------

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

LIST OF FIGURES

	PA	GE
Figure 1	Overview of Study Design	.13

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

LIST OF TEMPLATES

		PAGE
Template 1	Number of subjects by country and center <exposed set=""></exposed>	37
Template 2	Number of enrolled subjects by country	37
Template 3	Number of enrolled subjects by age category	37
Template 4	Number of subjects by country and age category <exposed set=""></exposed>	38
Template 5	Number of subjects vaccinated, completed and withdrawn with reason for withdrawal – <end active="" end="" of="" phase,="" study=""> <exposed set=""></exposed></end>	38
Template 6	Visit attendance <exposed set=""></exposed>	38
Template 7	Summary of important protocol deviations leading to elimination from any analyses	39
Template 8	Percentage of subjects with serological results who were eliminated from PPS for immunogenicity	39
Template 9	Deviations from specifications for age and intervals between study visits for Co-Ad group <exposed for="" immunogenicity="" pps="" set,=""></exposed>	39
Template 10	Deviations from specifications for age and intervals between study visits - for Control group <exposed for="" immunogenicity="" pps="" set,=""></exposed>	40
Template 11	Summary of demographic characteristics <exposed for="" immunogenicity="" pps="" set,=""></exposed>	40
Template 12	Minimum and maximum activity dates <exposed set=""></exposed>	41
Template 13	Study Population <exposed set=""></exposed>	41
Template 14	Exposure to study vaccines <exposed set=""></exposed>	42
Template 15	Compliance in completing solicited adverse events information <exposed set=""></exposed>	42
Template 16	Incidence and nature of <grade 3="" 3,="" grade="" related,=""> adverse events (<unsolicited and="" only="" solicited="" solicited,="">) reported <during (days="" 1-7)="" 1-7),="" 7-day="" beyond="" the=""> post-vaccination period following each dose and overall</during></unsolicited></grade>	43
Template 17	Incidence of solicited local <i>adverse events</i> reported during the 7-day (Days 1-7) post-vaccination period by study vaccine following each dose and overall <exposed set=""></exposed>	44

	204487 (ZOSTER-059 Statistical Analysis Plan Amendm	
Template 18	Incidence of solicited general <i>adverse events</i> reported during the 7-day (Days 1-7) post-vaccination period following each dose and overall <exposed set=""></exposed>	45
	and overall \Exposed Set>	45
Template 19	Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose <exposed set=""></exposed>	46
Template 20	Number and percentage of subjects reporting the occurrence of <grade 3=""> <non-serious> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with attended="" causal="" medically="" relationship="" to="" vaccination,="" visit="" with="">, within the 30-day (Days 1-30) post-vaccination period <,including numbers of events><exposed set=""></exposed></with></non-serious></grade>	47
Template 21	Global Summary of <grade 3=""> <non-serious>unsolicited signs and adverse events reported <with attended="" causal="" medically="" relationship="" vaccination,="" visit="" with=""> within the 30-day (Days 1-30) post-vaccination period <exposed set=""></exposed></with></non-serious></grade>	48
Template 22	Number and percentage of subjects starting a concomitant medication during the 30- day (Days 1-30) post vaccination period by dose and overall <exposed set=""></exposed>	48
Template 23	Number of days with <local, general=""> solicited adverse events <during (days="" 1-7)="" 1-7),="" 7="" 7-days="" beyond="" days="" of="" the=""> post vaccination period following each dose and overall <- Prevenar 13 vaccine, - HZ/su vaccine> <exposed set=""></exposed></during></local,>	49
Template 24	Solicited and unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term within the 30-day (Days 1-30) post-vaccination period including number of events - SAE excluded <exposed set=""></exposed>	49
Template 25	Number (%) of subjects with serious adverse events from <first 30="" <database="" date(ddmmmyyyy)="" days="" dose="" end,="" first="" freeze="" last="" post="" study="" to="" up="" vaccination="" vaccination,=""><study end="">, including number of events reported <exposed set=""></exposed></study></first>	50
Template 26	Number (%) of subjects reported solicited local <i>adverse events</i> during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <exposed set=""></exposed>	51
Template 27	Number (%) of subjects reported solicited general <i>adverse</i> events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <exposed set=""></exposed>	52
Template 28	Number and percentage of subjects with <anti-ge <x="" anti-pneumococcal="" antibody="" concentration,=""> antibody titres> equal to or above <cut-off> and <gmcs, gmt=""> <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps></gmcs,></cut-off></anti-ge>	53

	204487 (ZOSTER-0: Statistical Analysis Plan Amend	
Template 29	Vaccine response rates for anti-gE antibody ELISA concentrations in Co-Ad group at one month post dose 2 of HZ/su vaccine – primary objective <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps>	53
Template 30	Adjusted ratios of GMCs between groups (Control group divided by Co-Ad group) for anti-gE antibody ELISA concentrations at one month post dose 2 of HZ/su vaccine <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps>	54
Template 31	Adjusted ratios of GMTs between groups (Control group divided by Co-Ad group) for anti-pneumococcal <x> antibody titres at one month post Prevenar 13 vaccine <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps></x>	54
Template 32	Mean Geometric Increase (MGI) of anti-gE antibody ELISA concentrations from baseline to one month post dose 2 of HZ/su vaccine <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps>	54
Template 33	Descriptive statistics of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentration <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps>	55
Template 34	Distribution of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentrations <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps>	56
Template 35	Listing of potential Immune Mediated Diseases (pIMDs) reported as identified by predefined list of preferred terms and/or by investigator assessment up to end of study <exposed set=""></exposed>	
Template 36	Listing of all SAEs up to end of study <exposed set=""></exposed>	57
Template 37	Listing of suspected HZ cases from first administered dose up to end of study <exposed set=""></exposed>	57
Template 38	Listing of (S)AEs and solicited adverse events leading to study or treatment discontinuation <up 5="" month="" to=""><up end="" of="" study="" to=""> <exposed set=""></exposed></up></up>	58
Template 39	Maximum intensity of solicited <local, general=""> adverse event ongoing beyond the 7-day (Days 1-7) post-vaccination period following each dose and overall <exposed set=""></exposed></local,>	58
Template 40	Number and percentage of doses reporting the occurrence of <grade 3=""> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal="" relationship="" to="" vaccination=""> within the 30-day (Days 1-30) post-vaccination period <exposed set=""></exposed></with></grade>	59

Page 8 of 65

	204487 (ZOSTER-05 Statistical Analysis Plan Amend	
Template 41	Number and percentage of subjects reporting the occurrence of <serious adverse="" disease="" events,="" immune="" mediated="" potential=""> classified by MedDRA Primary System Organ Class and Preferred Term from <first 30="" days="" dose="" end="" first="" from="" last="" of="" post="" study="" study,="" to="" up="" vaccination="" vaccination,=""> <,including number of events><exposed set=""></exposed></first></serious>	60
Template 42	Global Summary of <serious adverse="" disease="" events,="" immune="" mediated="" potential=""> <with causal="" relationship="" vaccination="" with=""> reported from <first 30="" days="" dose="" end="" first="" from="" last="" of="" post="" study="" study,="" to="" up="" vaccination="" vaccination,=""> <exposed set=""></exposed></first></with></serious>	60
Template 43	Vaccine response rates for anti-gE antibody concentrations at one month post dose 2 of HZ/su vaccine <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps>	61
Template 44	Reverse cumulative distribution curves for <anti-ge <x="" anti-pneumococcal="" antibody="" concentration,=""> antibody titres> in each group at baseline and <post 13="" 2="" dose="" hz="" of="" post="" prevenar="" su="" vaccine,=""> <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps></post></anti-ge>	62
Template 45	Number and percentage of subjects <with><experiencing> fatal SAEs classified by MedDRA Primary System Organ Class and Preferred Term <who died=""><with fatal="" of="" onset="" sae=""> <during period="" starting="" the=""> <from 30="" days="" dose="" first="" last="" post="" to="" up="" vaccination=""> <after 30="" days="" dose="" end="" last="" post="" study="" to="" up="" vaccination=""><from end="" first="" study="" the="" until="" vaccination=""><during entire="" period="" study="" the=""> <exposed set=""></exposed></during></from></after></from></during></with></who></experiencing></with>	63
Template 46	Summary of subject disposition from enrolled set to randomized set	63
Template 47	Summary of subject disposition from Randomised Set to Per Protocol Set	64
Template 48	Listing of subjects who died during the entire study period and their fatal SAEs <enrolled set=""></enrolled>	65

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

LIST OF ABBREVIATIONS

AE Adverse event

AES Adverse Event Screen

ANCOVA Analysis of Covariance

AS01_B: MPL, QS21, liposome based Adjuvant System (50 µg MPL and 50

μg QS21)

BS Blood Sampling

CDR Clinical Data Reviewer

CI Confidence Interval

Co-Ad Co-administration

CRDL Clinical Research and Development Lead

CRF Case Report Form

CSR Clinical Study Report

CTRS Clinical Trial Registry Summary

ELISA Enzyme-linked immunosorbent assay

Eli Type Internal GSK database code for type of elimination code

EL.U/ml ELISA unit per milliliter

EoS End of Study

ES Exposed Set (formally called 'Total Vaccinated Cohort')

GMC Geometric mean antibody concentration

GMT Geometric mean antibody titre

GSK GlaxoSmithKline

IU/ml International units per milliliter

LL Lower Limit of the confidence interval

LLOQ Lower Limit of Quantification

MedDRA Medical Dictionary for Regulatory Activities

MGI Mean Geometric Increase

MOPA Multiplex Opsonophagocytosis Assay

PCD Primary Completion Date

PD Protocol Deviation

PDMP Protocol Deviation Management Plan

PPS Per-Protocol Set (formally called 'According to Protocol')

PT Preferred Term

204487 | Statistical Analysis Plan Amendment 1 11 Jun 2019 | TMF-561649 | 2.0

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

SAE Serious adverse event
SAP Statistical Analysis Plan

SBIR GSK Internet Randomization System

SD Standard Deviation

SHS Study Headline Summary

SOC System Organ Class

SUSAR Suspected Unexpected Serious Adverse Reactions

TFL Tables Figures and Listings

TOC Table of Content

UL Upper Limit of the confidence interval

ULOQ Upper Limit of Quantification

VRR Vaccine response rate

YOA Years of Age

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1


1. DOCUMENT HISTORY

Date	Description	Protocol
		Version
13 APR 2018	First Version	Amendment 2:
		30 JAN 2018
11 JUN 2019	Amendment 1	Amendment
	Summary of changes as below:	2: 30 JAN
	- As per new process applicable, the front page has	2018
	been modified to remove the names of all the	
	contributing author and reviewers. Also, sign-off is	
	only required to be done by Lead Statistician	
	- Updated LLOQ and newly calculated ULOQ for the 13	
	pneumococcal serotypes tested by MOPA have been	
	added and accordingly analysis of immunogenicity	
	section has been updated.	
	- Consort table have been added for subject	
	disposition.	
	- Additional tables for fatal serious adverse events	
	(SAEs) and grade 3 non-serious unsolicited adverse	
	events (AEs) have been added.	
	- The term "symptom" has been changed to "adverse	
	event (AE)" in endpoints, table titles and content for	
	solicited AEs, unsolicited AEs, SAEs, and potential	
	immune mediated diseases (pIMDs).	
	- Table 'Summary of temperature value by half degree	
	increment reported during the 7-day (Days 1-7) post-	
	vaccination following each dose' has been removed	
	- Sequence of analysis has been updated	
	- Inclusion of Enrolled and Randomized Set definition	
	- Code 1500 in elimination codes has been removed	
	and added under code 1070. Also, mandatory columns	
	have been added in the elimination table under	
	'Elimination from PPS section.	

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

2. STUDY DESIGN

Figure 1 Overview of Study Design



Vacc: vaccination; BS: blood sample; Pre-Vacc: pre-vaccination; FU: follow-up

Experimental design: Phase IIIB, open-label, randomized, controlled, multi-centric, and multi-country, with two parallel groups.

Duration of the study: The intended duration of the study per subject is approximately 14 months for subjects from the Co-Ad group and approximately 16 months for subjects from the Control group.

• Epoch 001: Primary starting at Visit Day 1 and ending with the phone contact at Month 16.

Primary completion date (PCD): Visit Month 5.

End of Study (EoS): Last testing results released of samples collected at Visit Month 3 (Co-Ad group) or at Visit Month 5 (Control group).

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Study groups:

Table 1 Study groups and epochs foreseen in the study

Study groups	Number of subjects	Age	Epochs Epoch 001
Co-Ad	456	≥ 50 years	Х
Control	456	≥ 50 years	Х

Table 2 Study groups and treatment foreseen in the study

Treatment name	Vaccine/Product name	Study Groups	
		Co-Ad	Control
HZ/su	VZV gE	Х	X
	AS01B	Х	X
Prevenar13	Prevenar 13	Х	X

Control: active control.

Vaccination schedule(s):

- Co-Ad Group:
 - at Visit Day 1: first dose of HZ/su and one dose of Prevenar13,
 - at Visit Month 2: second dose of HZ/su.
- Control Group:
 - at Visit Day 1: one dose of *Prevenar13*,
 - at Visit Month 2: first dose of HZ/su,
 - at Visit Month 4: second dose of HZ/su.

Treatment allocation: Subjects to be randomized in a 1:1 ratio at Visit Day 1 to either Co-Ad or Control group. Subjects in each group will be stratified by age with the following approximate distribution (not less than 25% in each age strata):

- 171 subjects in the 50-59 Years of Age (YOA) stratum,
- 171 subjects in the 60-69 YOA stratum, and
- 114 subjects in the \geq 70 YOA stratum.

Blinding: open-label.

Table 3 Blinding of study epochs

Study Epochs	Blinding
Epoch 001	open

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

3. OBJECTIVES

3.1. Co-Primary objectives

To determine the vaccine response rate (VRR) to HZ/su (based on humoral immune response) one month after the second vaccine dose, when the first dose of HZ/su is co-administered with *Prevenar13* (Co-Ad group).

Criterion to be used:

The objective is met if the lower limit (LL) of the 95% CI of the VRR for anti-gE antibody concentrations in the Co-Ad group one month after the second vaccine dose is >60%.

If the above objective is met in the Co-Ad group, then the following objective will be evaluated:

To demonstrate non-inferiority of the humoral immune response to two doses of HZ/su at one month after the last vaccine dose, when the first dose of HZ/su is co-administered with *Prevenar13* (Co-Ad group) compared to when two doses of HZ/su are administered subsequent to *Prevenar13* (Control Group).

Criterion for non-inferiority:

One month after the last vaccine dose in each study group, the upper limit (UL) of the 95% confidence interval (CI) for the anti-gE antibodies Geometric Mean Concentration (GMC) ratio between the Control group and the Co-Ad group is <1.5.

If the above non-inferiority objective is met, then the following objective will be evaluated:

To demonstrate non-inferiority of the humoral immune response to *Prevenar13* at one month after the vaccine dose, when *Prevenar13* is co-administered with the first HZ/su dose (Co-Ad group) compared to when *Prevenar13* is administered separately from HZ/su (Control group), for the 13 serotypes included in *Prevenar13* analyzed sequentially.

Criterion for non-inferiority:

One month after the Prevenar13 vaccine dose in each study group, the UL of the 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group is <2.

For the co-primary objectives, fixed sequence testing which allows for full alpha propagation in pre-ordered hypotheses families will be used (see section 6.3.2.1).

3.2. Secondary objective

To evaluate the safety and reactogenicity following administration of HZ/su and *Prevenar13* vaccines, up to one month post last vaccination and during the whole follow-up period, in the Control group and the Co-Ad group.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

4. ENDPOINTS

4.1. Primary endpoints

HZ/su immunogenicity:

- Vaccine response for anti-gE humoral immunogenicity, as determined by ELISA, in subjects from the Co-Ad group at one month post-dose 2, at Visit Month 3.
- Anti-gE antibody concentrations as determined by ELISA at one month post-dose 2, at Visit Month 3 for the Co-Ad group and Visit Month 5 for the Control group.

Pneumococcal vaccine immunogenicity:

• Anti-pneumococcal antibody titers for the 13 following serotypes as determined by MOPA at one month post-dose at Visit Month 1: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

The criteria used to define the VRR is given in Section 11.1.2.

4.2. Secondary endpoints

Occurrence of solicited local and general *adverse events*:

- Occurrence, duration and intensity of each solicited local *adverse event* within 7 days (Days 1 7) after each vaccination,
- Occurrence, duration, intensity and relationship to vaccination of each solicited general *adverse event* within 7 days (Days 1 7) after each vaccination.

Occurrence of unsolicited AEs:

Occurrence, intensity and relationship to vaccination of unsolicited AEs within 30 days (Days 1 - 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.

Occurrence of SAEs:

- Occurrence and relationship to vaccination of all SAEs from first vaccination at Day 1 up to 30 days post last vaccination.
- Occurrence and relationship to vaccination of all SAEs during the period starting after 30 days post last vaccination up to study end.

Occurrence of pIMDs:

- Occurrence and relationship to vaccination of any pIMDs from first vaccination at Day 1 up to 30 days post last vaccination.
- Occurrence of any pIMDs during the period starting after 30 days post last vaccination up to study end.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

5. ANALYSIS SETS

5.1. Definition

5.1.1. Enrolled Set

The enrolled set will include all the subjects for whom valid signed informed consent form is available.

5.1.2. Randomized Set

The randomized set will include all the subjects for whom valid signed informed consent form is available and treatment is allocated.

5.1.3. Exposed Set (ES)*

The Exposed set (ES) will include all subjects with at least one vaccine administration documented:

- The ES for analysis of solicited adverse events will include all subjects with at least one documented administered vaccine.
- The ES for analysis of unsolicited AEs, SAEs and pIMDs will include all subjects with at least one vaccine administered.
- The ES for analysis of immunogenicity will include vaccinated subjects for whom immunogenicity data are available.

The ES analysis will be performed per treatment actually administered (at Dose 1).

5.1.4. Per-protocol set (PPS)* for analysis of immunogenicity

The Per-protocol set for analysis of immunogenicity will include all evaluable subjects:

- who meet all eligibility criteria,
- who comply with the procedures and intervals allowed for the analysis,
- who do not meet any of the criteria for elimination during the study,
- for whom data concerning immunogenicity endpoint measures are available.

^{*} Note that in order to align to ICH and cDISC terminology the Total Vaccinated Cohort and the Per- Protocol cohort have been renamed Exposed Set (ES) and Per-Protocol Set (PPS) respectively.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

The intervals allowed for the inclusion in the PPS for analysis of immunogenicity are defined as follows:

	Group	Interval	Allowed interval for PPS analysis of immunogenicity
Interval between	Co-Ad	HZ/su (Dose 1) – HZ/su (Dose 2)	49-83 Days
vaccinations	Control	Prevenar13 (Dose 1) – HZ/su (Dose 2)	>= 60 days*
	Control	HZ/su (Dose 2) – HZ/su (Dose 3)	49-83 Days
Interval between vaccination and blood sample	Co-Ad	Prevenar13 (Dose 1) – Visit Month 1 for BS	28-48 Days*
taken	Co-Ad	HZ/su (Dose 2) – Visit Month 3 for BS	28-48 days*
	Control	Prevenar13 (Dose 1) – Visit Month 1 for BS	28-48 Days*
	Control	HZ/su (Dose 3)- Visit Month 5 for BS	28-48 days*

BS= blood sampling taken; *please note these intervals differ from protocol amendment 2 Table 8 and 9 to increase the number of evaluable subjects while not compromising the interpretation of immunogenicity data

5.2. Criteria for eliminating data from Analysis Sets

Elimination codes are used to identify subjects to be eliminated from analysis. Detail is provided below for each set.

5.2.1. Elimination from Enrolled Set

Code 900 (invalid informed consent or fraud data) will be used for identifying subjects eliminated from Enrolled Set.

5.2.2. Elimination from Randomized Set

Code 900 (invalid informed consent or fraud data) and code 1010 (vaccine number not allocated) will be used for identifying subjects eliminated from Randomized Set.

5.2.3. Elimination from Exposed Set (ES)

Code 1030 (Study vaccine not administered at all), *code 1010 (vaccine number not allocated)* and code 900 (invalid informed consent or fraud data) will be used for identifying subjects eliminated from ES.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

5.2.4. Elimination from Per-protocol analysis Set (PPS)

A subject will be excluded from the PPS analysis under the following conditions:

Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set
900	Invalid informed consent or fraudulent data. Subjects excluded from all stat analysis Note: Subjects receiving a code 900 should not receive any other elimination codes.	All	All
1010	Vaccine number not allocated Note: Subjects receiving a code 1010 should not receive any other elimination codes	Day 1	Randomized Set, ES, PPS
1030	Study vaccine not administered AT ALL but subject number allocated Note: Subjects receiving a code 1030 should not receive any other elimination codes	Day 1	ES, PPS
1040*	Administration of concomitant vaccine(s) forbidden in the protocol Comment: Co-Ad group: From 30 days before 1st vaccination up to Month 3 blood sampling Control group: From 30 days before 1st vaccination up to Month 5 blood sampling	Co-Ad group: Day -30 to Month 3 Control group : Day -30 to Month 5	PPS
1050	Randomization failure (subject not randomized in the correct group) Comment: To check for manual randomisation, treatment not compatible with one assigned by SBIR	Day 1	PPS
1070	 Side, site or route of study vaccine administration wrong or unknown Administration not according to protocol for reason specified by the investigator, other than side, site and route Wrong replacement or study vaccine administered (not compatible with the vaccine regimen associated to the treatment number) Administered study vaccine reported as being the correct one but is not compatible with the vaccine regimen associated to the treatment number. 	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
1080	Vaccine has been administered (effective treatment number) despite a temperature deviation qualified by Status QA GMP NON Use	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
1090	Expired vaccine administered	Co-Ad group – Day 1, Month 2 Control group – Day 1, Month 2, Month 4	PPS
2010	Protocol violation (inclusion/exclusion criteria)	Day 1	PPS
2040*	Administration of any medication forbidden by the protocol Co-Ad group: From 1st vaccination up to Month 3 blood sampling Control group: From 1st vaccination up to Month 5 blood sampling	Co-Ad group – Day 1 up to Month 3 Control group – Day 1 up to Month 5	PPS

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

		Statistical Analysis Pla	
Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set
2050*	Underlying medical condition forbidden by the protocol Co-Ad group: From 1st vaccination up to Month 3 blood sampling	Co-Ad group – Day 1 up to Month 3	PPS
	Control group: From 1 st vaccination up to Month 5 blood sampling	Control group – Day 1 up to Month 5	
2060*	Concomitant infection related to the vaccine which may influence immune response Co-Ad group: From 1st vaccination up to Month 3	Co-Ad group – Day 1 up to Month 3	PPS
	blood sampling Control group: From 1st vaccination up to Month 5	Control group – Day 1 up to Month 5	
2070*	blood sampling Concomitant infection not related to the vaccine which may influence immune response Comment:	Co-Ad group – Day 1 up to Month 3	PPS
	Co-Ad group: From 1st vaccination up to Month 3 blood sampling Control group: From 1st vaccination up to Month 5 blood sampling	Control group – Day 1 up to Month 5	
2080	Subjects did not comply with vaccination schedule (dates of vaccination not corresponding to adapted protocol intervals provided in SAP or unknown	Co-Ad group: Day 1, Month 2	PPS
	vaccination dates) Comment: Co-Ad group: DOSE 1 – DOSE 2 Control group: DOSE 1 – DOSE 2	Control group: Day 1, Month 2, Month 4	
2090	DOSE 2 – DOSE 3 Subjects did not comply with blood sample schedule (dates of BS not corresponding to adapted protocol	Co-Ad group: Month 1, Month 3	PPS
	intervals provided in SAP or unknown BS/vaccination dates) Comment: Co-Ad group: DOSE 1 – MONTH 1 BS DOSE 2 – MONTH 3 BS Control group: DOSE 1 – MONTH 1 BS DOSE 3 – MONTH 5 BS	Control group: Month 1, Month 5	
2100	Serological results not available post-vaccination (including lost samples, blood sample not done, unable to test, absence of parallelism). Please specify the applicable rule: elimination code if ALL are missing for a subject Comment: Co-Ad group: Check for availability of anti-gE serological result at Month 3 and for pneumococcal serological results at Month 1 Control group: Check for availability of anti-gE	Co-Ad – Month 1, Month 3 Control – Month 1, Month 5	PPS
2120	serological result at Month 5 and for pneumococcal serological results at Month 1 Obvious incoherence or abnormality or error in data	Co-Ad – Month 1, Month	PPS
	(incoherence between CRF and results, wrong labelling) Comment: Co-Ad group: Check for above condition on anti-gE serological result at Month 3 and on pneumococcal serological results at Month 1	3 Control – Month 1, Month 5	

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Code	Condition under which the code is used	Visit (timepoints) where the code is applicable	Applicable for analysis set
	Control group: Check for above condition on anti-gE serological result at Month 5 and on pneumococcal serological results at Month 1		
2500	Incomplete vaccination course. Comment: The subject should receive one dose of Prevenar 13 vaccine and 2 doses of Hz/su vaccine	Co-Ad – Day 1, Month 2 Control – Day 1, Month 2, Month 4	PPS

BS = Blood sample

5.3. Important protocol deviation not leading to elimination from per-protocol analysis set

For information on important protocol deviation not leading to elimination from the PPS set, refer to the study protocol deviation and management plan (PDMP).

6. STATISTICAL ANALYSES

Note that standard data derivation rule and stat methods are described in Section 11 and will not be repeated below. All analyses will be presented by study phase when there are data for both active and follow up phases.

6.1. Demography

6.1.1. Analysis of demographics/baseline characteristics planned in the protocol

Demographic characteristics (age *at first vaccination*, sex, race and ethnicity) will be tabulated per treatment group.

The mean age (plus range and standard deviation [SD]) of the subjects, as a whole, and per treatment group will be calculated for *ES and PPS*. The distribution of subjects enrolled among the study sites will be tabulated, as a whole, and per treatment group.

The same tabulations might be performed by age strata (50-59, 60-69 and \geq 70 YOA) if deemed necessary.

6.1.2. Additional considerations

- The following additional tables will be generated:
 - The number of subjects enrolled into the study as well as the number of subjects excluded from PPS analyses will be presented through two consort tables:
 - Consort table 1 Showing the subjects disposition from Enrolled Set to Randomized Set
 - Consort table 2 Showing the subjects disposition from Randomised Set to Per Protocol Set

^{*} Attribution of these elimination codes are responsibility of CRDL following review of individual data listings

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

- Withdrawal status will be summarized by group. The numbers of withdrawn subjects will be tabulated according to the reason for withdrawal
- The following table will be generated for CTRS:
 - Percentage of Enrolled subjects by country will be tabulated by group,
 - Percentage of Enrolled subjects in the following age categories ≤64, 65-84, ≥85 will be tabulated by group.
- For computation of age, following rule need to be considered:
 - Age will be calculated as the number of years between the date of birth and the date of first vaccination.
 - To ensure that the collection of date of birth will not jeopardise the privacy of Personally Identifiable Information (PII), only a partial date of birth (MMYYYY) will be collected.
 - Therefore, the 15th of the month will be used to replace the missing date.
 - In case the month is missing, the date will be replaced by the June 30th of the year.
- Summary of important protocol deviations leading to elimination will be presented.

6.2. Exposure

6.2.1. Analysis of exposure planned in the protocol

None

6.2.2. Additional considerations

The number of doses administered will be tabulated. The number of doses administered will be tabulated by age sub-group.

6.3. Immunogenicity

6.3.1. Analysis of immunogenicity planned in the protocol

The primary analysis will be based on the per-protocol set for analysis of immunogenicity. A second analysis based on the Exposed set will be performed to complement the per-protocol analysis (see section 9 for changes in the planned analysis).

Immunogenicity analyses for confirmatory objectives will be performed by age stratum (50-59, 60-69 and \geq 70 YOA) on PPS, if the number of subjects enrolled is sufficient in each stratum

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

6.3.1.1. Within group assessment

The following parameters will be tabulated by vaccine group at each time point when a blood sample result is available:

- Seropositivity with exact 95% CI for all antigens
- GMC/GMT with 95% CI for all antigens
- VRR with exact 95% CI for anti-gE
- Mean Geometric Increase (MGI) with exact 95% CI for anti-gE
- Descriptive statistics (N, mean, SD, min, Q1, median, Q3, max) of Mean Geometric Increase (MGI) for anti-gE
- Distribution of the fold increase i.e. Percentage of subjects with a more than X-fold (e.g. >2, >4, >6, -fold) increase will be tabulated for anti-gE per group with 95% CI.
- Antibody titre/concentration will be displayed using reverse cumulative curves.

6.3.1.2. Between group assessment

The following between group comparison will be performed:

- For the second co-primary objective for non-inferiority of the anti-gE humoral response, at one-month post-dose 2 of HZ/su vaccine:
 - The 95% CI of the group GMCs ratio (Control divided by Co-Ad) will be computed using an ANCOVA model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.
- For the third co-primary objective for non-inferiority of the humoral response to each vaccine pneumococcal serotype (according to the pre-specified order in the protocol), one month post-dose of *Prevenar13*:
 - The 95% CI of the group MOPA GMT ratios (Control divided by Co-Ad) will be computed using an ANCOVA model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

6.3.2. Additional considerations

The following additional points need to be considered for immunogenicity analysis:

- Percentage of subjects above the pneumococcal serotype specific LLOQ will be calculated for each serotype with exact 95% Cis.
- Immunogenicity descriptive analyses will be performed by age stratum (50-59, 60-69 and \geq 70 YOA), if the number of subjects enrolled is sufficient in each stratum.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

- Two-sided 95% CIs for Seropositivity and VRR will be computed by Clopper-Pearson method [Clopper, 1934]. The differences in percentages and the associated two-sided 95% between the groups CIs for the difference will be constructed using the method of Miettinen and Nurminen [Robert, 1998].
- The two-sided 95% CI for the mean of log-transformed titre/concentration will be first obtained assuming that log-transformed values were normally distributed with unknown variance. The 95% CI for the GMTs/GMCs/MGIs will be then obtained by exponential-transformation of the 95% CI for the mean of log-transformed titre/concentration.

6.3.2.1. Statistical considerations for confirmatory objectives

For the multiplicity adjustment, all hypotheses have been ranked into three families and one sub-family according to the following power of test:

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Table 4 Power to demonstrate VRR objective and non-inferiority of the immunogenicity of HZ/su and *Prevenar13* co-administered compared to Control group

Family 1: HZ/su: VVR*(1-s	ided test with alpha = 2.5	%)			
Endpoint	Threshold	VR assumed	Total β	Power	
VRR in Co-Ad group	0.60	95%	0.001%	99.99%	
Family 2: HZ/su: non-inferiority* (1-sided test with alpha = 2.5%) N=410					
Endpoint	Standard deviation	δ	Total β	Power	
Anti-gE GMC ratio	0.35	1.5	0.001 %	99.99 %	
Family 3: Prevenar13: Nor	n-inferiority* (1-sided test	with alpha = 2.5%)	N=410		
Endpoint (13 vaccine pneumococcal serotypes)	Standard deviation	δ	Total β	Power	
3 GMT ratio	0.660	2	0.001%	99.99%	
19A GMT ratio	0.644	2	0.001%	99.99%	
1 GMT ratio	0.798	2	0.029%	99.97%	
18C GMT ratio	0.891	2	0.203%	99.80%	
4 GMT ratio	0.906	2	0.260%	99.74%	
6A GMT ratio	0.919	2	0.320%	99.68%	
5 GMT ratio	0.931	2	0.383%	99.62%	
19F GMT ratio	0.971	2	0.664%	99.33%	
6B GMT ratio	0.995	2	0.891%	99.11%	
7F GMT ratio	1.014	2	1.107%	98.89%	
9V GMT ratio	1.021	2	1.194%	98.81%	
14 GMT ratio	1.045	2	1.530%	98.47%	
23F GMT ratio	1.094	2	2.398%	97.60%	
Global β to show non-inferior	ority		~9%		
Global power			·	~91%	

VRR: vaccine response rate; gE: Varicella Zoster Virus glycoprotein E; GMT: geometric mean titer; GMC: geometric mean concentration.

For gE: non-inferiority limit = 0.176 (=log10(1.5)), power under equal GMC

For each pneumococcal serotype: non-inferiority limit = 0.301 (=log10(2)), variability for each of the 13 vaccine pneumococcal serotype taken from the EMA assessment report for *Prevenar13* and multiplied by 1.1, power under equal GMT.

Fixed sequence testing which allows for full alpha propagation in pre-ordered hypotheses families will be applied in the following manner:

Family 1:

In the Co-Ad group, for anti-gE, at one month post-dose 2 of HZ/su vaccine:

• The VRR and 95% CI will be computed.

The objective is met if the LL of the 95% CI is \geq 60%.

^{*} Pass 12, alpha = 2.5%, for VRR: Exact test, for non-inferiority one-sided equivalence of means.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Family 2:

For anti-gE, at one month post-dose 2 of HZ/su vaccine:

• The 95% CI of the group GMCs ratio will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

In terms of concentrations, the Co-Ad group will be considered non-inferior to the Control group if the UL of the 95% CI for the GMC ratio of the Control group to the Co-Ad group is <1.5.

Family 3:

For each vaccine pneumococcal serotype (according to the pre-specified order), one month post-dose of *Prevenar13*:

The 95% CI of the group MOPA GMT ratios will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations.
 The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

In terms of MOPA GMTs, the Co-Ad group will be considered non-inferior to the Control group if the UL of the 95% CI for the MOPA GMTs ratio of the Control group to the Co-Ad group is <2 for each of the 13 vaccine serotypes.

In the ANCOVA models Adjusted Least Squares (LS) means and difference of LS means between the groups will be calculated together with the 2-sided 95% CIs and backtransformed to the original units to provide GMCs and GM ratios.

6.4. Analysis of safety

6.4.1. Analysis of safety planned in the protocol

The analysis for safety will be based on the Exposed set. All safety analyses may also be performed by age strata (50-59, 60-69 and \geq 70 YOA), if deemed necessary.

When appropriate, tabulations will be presented overall and by time of occurrence relative to last vaccination (e.g. using windows such as Days 1 to 7, Days 1 to 30 and more than 30 days post-vaccination).

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

The results for the analysis of safety will be tabulated as follows:

- The number and percentage of subjects with at least one local solicited AE, with at least one general solicited AE, and with any solicited AE during the 7-day follow-up period with exact 95% CIs after each vaccine dose and overall by vaccination group will be provided;
- The percentage of subjects reporting each individual solicited local and general AE during the solicited 7-day follow-up period will be tabulated with exact 95% CI;
- For all solicited adverse events, the same tabulation will be performed for grade 3 solicited AEs and for solicited general AEs with relationship to vaccination;
- Number of days with each individual solicited local and general AE during the solicited 7-day follow-up period;
- The proportion of subjects with at least one report of unsolicited AE (containing both serious and non-serious unsolicited AEs) classified by the MedDRA Primary System Organ Class (SOC) and Preferred Terms (PTs) and reported up to 30 days after each vaccination will be tabulated with exact 95% CI;
- The same tabulation will be performed for grade 3 unsolicited AEs and for unsolicited AEs with a relationship to vaccination *reported up to 30 days after each vaccination with exact 95% CI*. The proportion of AEs resulting in a medically attended visit will also be tabulated;
- Total number/percentages of doses (per dose and overall) followed by AEs will be tabulated;
- Number of subjects with pIMDs will be tabulated;
- SAEs, including fatalities and withdrawal due to AE(s) will be described in detail.

6.4.2. Additional considerations

- The following additional tables will be generated:
 - The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE (solicited and unsolicited) during the 7-day follow-up period will be tabulated with exact 95% CI after each vaccine dose and overall. The same computations will be done for Grade 3 AEs, for any AEs considered related to vaccination and for any Grade 3 AEs considered related to vaccination.
 - The percentage of subjects with at least one local solicited AE, with at least one general solicited AE and with any solicited AE will also be done for Grade 3 solicited AEs, for any solicited AEs considered related to vaccination and for any Grade 3 solicited AEs considered related to vaccination.
 - The percentage of subjects reporting each individual solicited local AE during the solicited 7-day follow-up period will be tabulated by study vaccine with exact 95% CI.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

- Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose.
- For fever, the number and percentage of subjects reporting fever by half degree (°C) cumulative increments during the 7-day follow-up period (Day 1-7) will be tabulated for each group after each vaccine dose and overall. Similar tabulations will be performed for Grade 3 (> 39.0°C) causally related fever.
- List of suspected HZ cases identified during the study will be presented.
- The number and percentage of subjects starting a concomitant medication during the 30-day post-vaccination period by dose and overall will be presented.
- The duration of solicited local adverse events (in days), not limited to the 7-day post-vaccination period, following each dose and overall/dose. The same tabulations after Prevenar13 and HZ/su vaccinations.
- The duration of solicited general adverse events (in days), not limited to the 7day post-vaccination period, following each dose and overall/dose.
- Solicited local adverse events ongoing beyond the 7-day (Days 1-7) post-vaccination period, following each dose and overall/dose. The same tabulations after Prevenar13 and HZ/su vaccinations.
- Solicited general adverse events ongoing beyond the 7-day (Days 1-7) post-vaccination period, following each dose and overall/dose.
- Number and percentage of subjects with at least one report of a grade 3 non-serious unsolicited AE during the 30-day (Days 0-29) follow-up period after each vaccination classified according to the MedDRA Primary SOC and PTs will be tabulated, with exact 95% CI. The same will be generated for grade 3 non-serious unsolicited AE considered related to vaccination.
- Number and percentage of subjects with fatal SAEs, classified by MedDRA
 Primary SOC and PTs will be presented with exact 95% CI in two ways:
- With onset of fatal SAE during the period starting from first vaccination to 30 days post last vaccination dose, after 30 days post last vaccination dose to study end and from first vaccination to study end.
- Who died during the period starting from first vaccination to 30 days post last vaccination dose, after 30 days post last vaccination dose to study end and entire study period.
- The listing of all subjects who died during the entire study period and their fatal SAEs in the Enrolled Set

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

6.4.2.1. Combined Solicited and Unsolicited Adverse Events

A summary of subjects with all combined solicited (regardless of their duration) and unsolicited adverse events will be provided. Solicited adverse events will be coded by MedDRA as per the following codes:

Solicited adverse event	Lower level term name	Corresponding Lower level term code
Pain	Injection site pain	10022086
Redness	Redness at injection site	10022098
Swelling	Swelling at injection site	10053425
Fatigue	Fatigue	10016256
Gastrointestinal symptoms	Gastrointestinal disorder	10017944
Headache	Headache	10019211
Myalgia	Myalgia	10028411
Shivering	Shivering	10040558
Temperature	Fever	10016558

For clintrial gov and EudraCT posting purposes, a summary of combined solicited and unsolicited non-serious adverse events will be produced by SOC and PTs and according to occurrence of each event.

7. ANALYSIS INTERPRETATION

All co-primary objectives will be evaluated using a one-sided Type I error of 2.5% (as already justified by fixed sequential testing procedure, no alpha adjustment needed). The trial will be considered conclusive if all co-primary objectives criteria are met.

8. CONDUCT OF ANALYSES

8.1. Sequence of analyses

The analysis will be performed in the following steps:

- An active phase analysis for public disclosure of demography and safety/reactogenicity result will be performed on available data as clean as possible at the end of active phase.
- The final analysis on immunogenicity, reactogenicity and safety data will be performed when all data up to study end (i.e., phone contact at Month 14 for Co-Ad group and phone contact at Month 16 for Control group) will be available and cleaned. Individual data listings will also be provided.

An integrated clinical study report containing all data will be written and made available to the investigators following the final analysis.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Table 5 Analysis and disclosure plan for the planned analysis

Description	Analysis ID	Disclosure Purpose (CTRS=public posting, CSR=clinical study report, internal)	Dry run review needed (Y/N)	Reference for TFL
End of Active phase – posting	E1_02	CTRS	Υ	See in TFL TOC where POSTING=YES
Final analysis	E1_01	CTRS CSR	Y	All tables from Section 12 of the SAP Amendment 1 03JUN2018

8.2. Statistical considerations for interim analyses

Not applicable

9. CHANGES FROM PLANNED ANALYSES

- In Protocol Amendment 2 Final (30 Jan 2018), it was specified that a second analysis for immunogenicity of the ES would be performed only if, in any study group, the percentage of enrolled subjects with serological results excluded from the PPS for immunogenicity is 5% or more. At the request of Paul Ehrlich Institute, Germany (PEI), an analysis of the ES will be performed to complement the per-protocol analysis regardless of the percentage of enrolled subjects excluded from the PPS for immunogenicity.
- Updated LLOQ values (i.e. assay cut-off values) for the pneumococcal serotypes are provided in this version of SAP (section 11.1.2). The cut-off values presented in this SAP will be used to determine seropositivity rather than those presented in Protocol Amendment 2 Final (30 Jan 2018). Analysis of immunogenicity section has been updated accordingly.
- Additional tables on presentation of grade 3 non-serious unsolicited adverse events and fatal SAEs has been added based on CBER request.
- The sequence of analysis was updated to accommodate a delay in the availability of immunogenicity results.
- Two new cohorts Enrolled Set and Randomized Set has been defined as required for web disclosure and SAE tables presentation.
- Analysis of demography section has been updated to add consort table and summary of important protocol deviations.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

10. LIST OF FINAL REPORT TABLES, LISTINGS AND FIGURES

The TFL TOC provides the list of tables/listings and figures to be included in the study report.

The following group names will be used in the TFLs, in line with the T-domains:

	Group order in tables	Group label in tables	Group definition for footnote
	1	Co-Ad	Dose 1 : Prevenar 13 + HZ/su, Dose 2: HZ/su
ſ	2	Control	Dose 1 : Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

The following sub-groups will be used in the TFL, in line with the T-domains:

Table 6 Group Definitions to be used for the sub-group analysis by age (Analysis will be included in the clinical report)

Sub-group order in tables	Sub-group label in tables	Sub-group definition for footnote
1	50-59YOA	Subjects aged 50-59 years
2	60-69YOA	Subjects aged 60-69 years
3	≥70YOA	Subjects aged 70 years and over

YOA = Year of age

Please note that for table presentation in the sub-group analysis, the sequence maintained has to be each treatment group within each age sub-group.

11. ANNEX 1 STANDARD DATA DERIVATION RULE AND STATISTICAL METHODS

11.1. Standard data derivation

11.1.1. **Dose number**

The study dose number is defined in reference to the number of study visits at which vaccination occurred. More specifically dose 1 refers to all vaccines administered at the first vaccination visit while dose 2 corresponds to all vaccinations administered at the second vaccination visit even if this is the first time a product is administered to the subject.

Associated dose: the associated dose for an event (AE, medication, vaccination) is the most recent study dose given before an event. In case the event takes place on the day a study dose is given, the associated dose will be that of the study dose, even if the event actually took place before vaccination. For instance, if an adverse event begins on the day of the study vaccination but prior to administration of the vaccine, it will be assigned to this dose. In case a study dose is not administered and an event occurs after the

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

subsequent study dose (e.g. 2nd study dose), the associated dose of the event will be study dose associated to the subsequent study dose (e.g. dose 2).

The number of doses for a product is the number of times the product was administered to a subject.

The incidence per dose is the number of visits with vaccine administered at which an event was reported among all visits with vaccine administered.

11.1.2. Immunogenicity

- For a given subject and given immunogenicity measurement, missing or nonevaluable measurements will not be replaced. Therefore, an analysis will exclude subjects with missing or non-evaluable measurements.
- A seronegative subject is a subject whose antibodies concentration/titer is below the cut-off value (cut-off value is defined by the laboratory prior to the analysis).
- A seropositive subject is a subject whose antibodies concentration/titer is greater than or equal to the assay cut-off value.
- The seropositivity rate is defined as the percentage of seropositive subjects.
- The VRR for anti-gE is defined as the percentage of subjects who have at least:
 - a 4-fold increase in the anti-gE antibodies concentration as compared to the prevaccination anti-gE antibodies concentration, for subjects who are seropositive at baseline, or,
 - a 4-fold increase in the anti-gE antibodies concentration as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who are seronegative at baseline.
- The GMC calculations for anti-gE antibody concentration are performed by taking the anti-log of the mean of the log base 10 concentration transformations. Antibody concentrations below the cut-off of the assay will be given an arbitrary value equal to half the cut-off for the purpose of GMC/GMT calculation.
- All CI computed will be two-sided 95% CI.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

• Updated LLOQ and ULOQ values for the MOPA assay are described below for each of the 13 pneumococcal serotypes:

Pneumococcal serotype	Method	Unit	LLOQ1	ULOQ	Laboratory
Streptococcus pneumoniae Serotype 01/37 Brugmann Hospital Ab			14	3504	
Streptococcus pneumoniae Serotype 03/1 Statens Serum Institut Ab			11	2822	
Streptococcus pneumoniae Serotype 04/2656 Brugmann Hospital Ab			40	18042	
Streptococcus pneumoniae Serotype 05 Ambrose- Statens Serum Institut Ab			15	13304	
Streptococcus pneumoniae Serotype 06A Centers for Disease Control Ab			45	15305	
Streptococcus pneumoniae Serotype 06B/DS2212/94 Centers for Disease Control Ab			29	20806	University of
Streptococcus pneumoniae Serotype 07F/46 Brugmann Hospital Ab	МОРА	1/ dilution	28	59809	Alabama at Birmingham
Streptococcus pneumoniae Serotype 09V/112 161/95 Statens Serum Institut Ab			39	28095	Dirillingnam
Streptococcus pneumoniae Serotype 14/58 Brugmann Hospital Ab			16	47856	
Streptococcus pneumoniae Serotype 18C/4593/40 Statens Serum Institut Ab			40	13318	
Streptococcus pneumoniae Serotype 19A/DB18 Kansanterveyslaitos Folkhalsoinstitutet Ab			13	34881	
Streptococcus pneumoniae Serotype 19F/2737 Brugmann Hospital Ab			33	29352	
Streptococcus pneumoniae Serotype 23F Mac- Statens Serum Institut Ab			40	10662	

¹LLOQ corresponds to serotype-specific assay cut-off value.

• The Geometric Mean Titres (GMTs) calculations for pneumococcal serotypes are performed by taking the anti-log of the mean of the log base 10 titre transformations. For GMT calculation for pneumococcal serotypes, antibody titres below the LLOQ of the assay will be given an arbitrary value of half the cut-off for GMT calculation. Antibody titres above the ULOQ of the assay will be given the value of ULOQ for GMT calculation.

11.1.3. Safety

For a given subject and the analysis of solicited *adverse event* during the 7 day follow-up period after vaccination, missing or non-evaluable measurements will not be replaced. Therefore, the analysis of the solicited *adverse events* based on the ES will include only vaccinated subjects with documented safety data (i.e., symptom screen completed). More specifically the following rules will be used:

- Subjects who documented the absence of a solicited *adverse event* after one dose will be considered not having that *adverse event* after that dose.
- Subjects who documented the presence of a solicited *adverse event* and fully or partially recorded daily measurement over the solicited period will be included in the

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

summaries at that dose and classified according to their maximum observed daily recording over the solicited period.

- Subjects who documented the presence of a solicited adverse event after one dose
 without having recorded any daily measurement will be assigned to the lowest
 intensity category at that dose (i.e., 38°C for fever or grade 1 for other adverse
 events). The subject will only be presented in the subject with adverse event
 experienced and not in specific grade information.
- Doses without *adverse event* sheets documented will be excluded.

For analysis of unsolicited AEs, such as SAEs or adverse events by MedDRA Primary SOC and PTs term, and for the analysis of concomitant medications, all vaccinated subjects will be considered. Subjects who did not report the event or the concomitant medication will be considered as subjects without the event or the concomitant medication respectively.

Associated dose: The associated dose for an event (e.g., AE, medication, vaccination,...) is the study dose given before an event. In case the event takes place on a day a study dose is given, the associated dose will be that of the study dose even if the event actually took place before. For instance, for a conc. medication started on the day of study dose 2 but before dose 2 administrations, the associated dose will be dose 2

The way the percentage of subjects will be derived will depend on the event analysed (see the following table for details). As a result, the denominator (N) will differ from one table to another.

Event	N used for deriving %	Terminology used in the tables for N
Concomitant	All vaccinated subjects	Number of subjects with at least one
medication		administered dose
Solicited local	All vaccinated subjects with at least one	For each dose and overall/subject:
adverse event	solicited local adverse event	N= number of subjects with at least one
	documented as either present or absent	documented dose
		For overall/dose:
		N= number of documented doses
Solicited general	All vaccinated subjects with at least one	For each dose and overall/subject:
adverse event	solicited general adverse event	N= number of subjects with at least one
	documented as either present or absent	documented dose
		For overall/dose:
		N= number of documented doses
Unsolicited adverse	All vaccinated subjects	Number of subjects with at least one
event from day 0 to		administered dose
day X		
SAE	All vaccinated subjects	Number of subjects with at least one
		administered dose

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

- The maximum intensity of local injection site redness and swelling will be scored at GSK Biologicals as follows:
 - 0: <20 mm
 - 1 : \geq 20 mm to \leq 50 mm diameter
 - 2: > 50 mm to \leq 100 mm diameter
 - -3:>100 mm diameter

Fever is defined as temperature $\geq 38.0 \text{ C} / 100.4 \text{ F}$ for oral, axillary, tympanic or rectal route. The preferred route for recording temperature in this study will be oral. For the analysis, temperatures will be coded as follows:

Grade	Temperature (oral, axillary, tympanic or rectal route)	
0	< 38°C	
1	≥ 38°C - ≤ 38.5°C	
2	> 38.5°C - ≤ 39°C	
3	> 39°C	

• Conversion of temperature to °C -

The following conversion rule is used for the conversion of temperature to °C

Temperature in °Celsius = ((Temperature in °Fahrenheit -32) *5)/9

The result is rounded to 1 decimal digit.

11.2. Statistical Method References

Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. *Biometrika*. 1934; 26:404-413.

Robert G. Newcombe, interval estimation for the difference between independent proportions: comparison of eleven methods, *Statist Med.* 1998; 17, 873-890.

11.3. Number of decimals displayed:

The following decimal description from the decision rules will be used for the demography, immunogenicity and safety/reactogenicity.

Display Table	Parameters	Number of decimal digits
Demographic characteristics	Mean, median age	1
Demographic characteristics	SD (age)	1
Immunogenicity	Ratio of GMT/C	2
All summaries	% of count, including LL & UL of CI	1
All summaries	% of difference, including LL & UL of CI	2

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

12. ANNEX 2: STUDY SPECIFIC MOCK TFL

The study specific mocks are annexed to this SAP in a separate document.

The data display, title and footnote are for illustration purpose and will be adapted to the study specificity as indicated in the TFL TOC. Note that there may be few changes between the study specific SAP mock TFL and the final TFLs as editorial/minor changes do not require a SAP amendment

12.1. List of individual data listing

Following individual data listing will be generated

Appendix Table I.A - Elimination codes

Appendix Table I.B – Demography

Appendix Table IBii - Physical examination/vital signs

Appendix Table I.Ci - Dates of birth, Informed consent, Vaccination and blood sampling, Contact

Appendix Table I.Cii - Reason for visit not done

Appendix Table I.D - General medical history - Physical examination

Appendix Table I.Ei – Study Conclusion

Appendix Table I.F – Notes (this appendix is provided for info only and should not be used for the clinical report)

Appendix Table I.G / I.H - Vaccination procedure

Appendix Table I.I - Reason for not administration of vaccine

Appendix Table I.J - Reason for non-eligibility

Appendix Table I.Ki – Previous history of vaccination

Appendix Table I.Kii – Previous history of disease

Appendix Table II.Ai - Solicited local adverse events

Appendix Table II.B - Solicited general adverse events

Appendix Table II.Ci - Unsolicited adverse events within (30) days post-vaccination

Appendix Table II.Cii - Unsolicited adverse events after (30) days post-vaccination

Appendix Table II.Di - Concomitant medications

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Appendix Table II.Dii - Concomitant vaccinations

Appendix Table III.A – Immunogenicity

12.2. Template of Tables and Figures

Template 1 Number of subjects by country and center < Exposed Set>

			nch group> N=XXXX		nch group> N=XXXX	Total N=XXXX	
Country	Center	n	%	n	%	n	%
<each country=""></each>	<each center=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X
	All	XXX	XX.X	XXX	XX.X	XXX	XX.X

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

Center = GSK Biologicals assigned center number

Template 2 Number of enrolled subjects by country

	<each group=""> N=XXXX</each>			ich group> N=XXXX	Total N=XXXX	
Country	n	%	n	%	n	%
<each country=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

n = number of subjects in a given country

N = total number of subjects

 $% = n/N \times 100$

Template 3 Number of enrolled subjects by age category

		<pre><each group=""> N=XXXX N=XXXX</each></pre>				Total N=XXXX	
Age category	n	%	n	%	n	n %	
Adults [18-64 years]	XXX	XX.X	XXX	XX.X	XXX	XX.X	
From 65-84 years							
85 years and over							

<each group>:

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of enrolled subjects

n = number of enrolled subjects included in each group or in total for a given age category or for all age categories $\% = n/N \times 100$

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 4 Number of subjects by country and age category <Exposed Set>

		<e:< th=""><th></th><th>ach group> N=XXXX</th><th colspan="2">Total N=XXXX</th></e:<>		ach group> N=XXXX	Total N=XXXX		
Country	Age category	n	%	n	%	n	%
<each country=""></each>	50-59YOA	XXX	XX.X	XXX	XX.X	XXX	XX.X
·	60-69YOA						
	≥70YOA						
	All	XXX	XX.X	XXX	XX.X	XXX	XX.X

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

50-59YOA = Subjects aged 50-59 years

60-69YOA = Subjects aged 60-69 years

≥70YOA = Subjects aged 70 years and over

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

Template 5 Number of subjects vaccinated, completed and withdrawn with reason for withdrawal – <end of active phase, study end> <Exposed set>

	<each group=""> N=XXXX</each>	<each group=""> N=XXXX</each>	Total N=XXXX
	n	n	n
Number of subjects vaccinated	XXX	XXX	XXX
End of study status			
[EACH CATEGORY]	XXX	XXX	XXX
Reasons for withdrawal:			
[REASONS]	XXX	XXX	XXX

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Vaccinated = number of subjects who were vaccinated in the study

Completed = number of subjects who completed <end of active phase visit, last study visit>
Withdrawn = number of subjects who did not come for the <end of active phase visit, last study visit>
Unknown = number/percentage of subjects who have not come for the <end of active phase visit, last study visit> yet

Template 6 Visit attendance <Exposed set>

		<e< th=""><th>ach group N=X)</th><th></th></e<>	ach group N=X)	
Visit	Status	n		%
INFORMED CONSENT	Completed			
RANDOMIZATION	Completed			
<each visit=""></each>	Attended			
	Not attended yet			
	Permanent discontinuation prior to this visit			
	Not attended			
CONCLUSION	Completed			

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Number of subjects in each group or in total Conclusion = date of last visit or withdrawal

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 7 Summary of important protocol deviations leading to elimination from any analyses

Category Sub-category		<each group=""> N=XXXX</each>				Total N=XXXX		
	-	осс	n	%	осс	n	%	
At least one important protocol deviation	xxx	xxx	XX.X		xxx	XXX	xx.x	
	XXX	xxx	XX.X		XXX	XXX	XX.X	
<category 1=""></category>	XXX	XXX	XX.X		XXX	XXX	XX.X	
<sub-category 1=""> <sub-category 2=""></sub-category></sub-category>	XXX	XXX	XX.X		XXX	XXX	XX.X	
	xxx	xxx	XX.X		xxx	XXX	xx.x	
<category 2=""></category>								

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Total number of subjects

Occ = number of occurrences = number of important protocol deviations

n/% = number / percentage of subjects with important protocol deviations

Template 8 Percentage of subjects with serological results who were eliminated from PPS for immunogenicity

	[each gro	oup]
Number of subjects in Exposed Set with serological results available		
Number of subjects with serological results eliminated from PPS for immunogenicity		
Percentage of subjects with serological results eliminated from PPS for immunogenicity		

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 9 Deviations from specifications for age and intervals between study visits for Co-Ad group <Exposed Set, PPS for immunogenicity>

		Age	/		Dose:1- Dose:2	Dose:2-PII (M3)		Dose:2- PHC (M14)	
Group		Protocol	Protocol	Adapted	Protocol	Protocol	Adapted	Protocol	
		from ≥ 50	from 30 to	from 28 to 48	from 49 to 83	from 30 to	from 28 to 48	from 335	
		years	42 days	days	days	48 days	days	to 395 days	
Co-Ad	N								
	n								
	%								
	range								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Adapted = interval used for defining PPS for immunogenicity

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PI (M1) = Blood sample at Month 1, post-vaccination Dose 1

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

PII (M3) = Blood sample at Month 3, post-vaccination Dose 2

PHC (M14) = Phone Contact MONTH 14

Note that the exact age is unknown since only the month and year of birthdate are recorded. Accordingly the age estimated using the middle of the month may be inexact by one month

Template 10 Deviations from specifications for age and intervals between study visits - for Control group <Exposed Set, PPS for immunogenicity>

	Age		Dose:1-PI(M1)		Dose:1-Do	Dose:1-Dose:2		,		Dose:3- PHONE CONT M16
Group		Protocol	Protocol	Adapted	Protocol	Adapted	Protocol	Protocol	Adapted	Protocol
		from ≥ 50	from 30 to	from 28 to	from 60 to	≥ 60	from 49 to	from 30 to	from 28 to	from 335 to
		years	42 days	48 days	83 days	days	83 days	48 days	48 days	395 days
Control	N									
	n									
	%									
	range									

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adapted = interval used for defining the ATP cohorts for immunogenicity

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PI(M1) = Blood sample at Month 1, post-vaccination Dose 1

PIII(M5) = Blood sample at Month 5, post-vaccination Dose 3

PHC (M16) = Phone Contact Month 16

Template 11 Summary of demographic characteristics <Exposed Set, PPS for immunogenicity>

		<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>		otal XXXX
	Value or n	%	Value or n	%	Value or n	%
Age in Years at <timepoint></timepoint>						
N with data	xxx		xxx		xxx	
Mean	XXX.X		xxx.x		XXX.X	
SD	XXX.X		xxx.x		XXX.X	
Median	XXX.X		xxx.x		XXX.X	
Minimum	xxx		xxx		xxx	
Maximum	xxx		xxx		xxx	
Gender						
<each gender=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X
	xxx	XX.X	xxx	XX.X	xxx	XX.X
Ethnicity						
<each ethnicity=""></each>	xxx	XX.X	xxx	XX.X	xxx	XX.X
	xxx	XX.X	xxx	XX.X	xxx	XX.X
Geographic Ancestry						
<each ancestry="" geographic=""></each>	xxx	XX.X	xxx	XX.X	xxx	XX.X
	XXX	XX.X	xxx	XX.X	xxx	XX.X
Age category						
<each age="" category=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X
Country						
<each country=""></each>	xxx	XX.X	xxx	XX.X	xxx	XX.X
	xxx	XX.X	xxx	XX.X	xxx	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = total number of subjects

n/% = number / percentage of subjects in a given category

Value = value of the considered parameter

N with data = number of subjects with documentation of the corresponding data

SD = standard deviation

Template 12 Minimum and maximum activity dates <Exposed Set>

Group	Activity number	Activity Description	Minimum date	Maximum date
Co-Ad	10	VISIT DAY 1		
	20	VISIT MONTH 1		
	30	VISIT MONTH 2		
	40	VISIT MONTH 3		
	70	PHONE CONTACT MONTH 14		
Control	10	VISIT DAY 1		
	20	VISIT MONTH 1		
	30	VISIT MONTH 2		
	50	VISIT MONTH 4		
	60	VISIT MONTH 5		
	80	PHONE CONTACT MONTH 16		

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 13 Study Population < Exposed Set>

	<each group=""> N=XXXX</each>	<each group=""> N=XXXX</each>	Total N=XXXX
Number of subjects			
Planned, N	XXX	XXX	XXX
Randomised, N <cohort name=""></cohort>	XXX	XXX	XXX
Completed, n (%)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<unknown></unknown>	XXX	XXX	XXX
Demographics			
N <cohort name=""></cohort>	XXX	XXX	XXX
Females:Males	xxx:xxx	XXX:XXX	xxx:xxx
Mean Age, <unit> (SD)</unit>	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median Age, <unit> (minimum, maximum)</unit>	xxx (xxx,xxx)	xxx (xxx,xxx)	xxx (xxx,xxx)
<most category="" frequent="" of="" race=""></most>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<second category="" frequent="" most="" of="" race=""></second>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<third category="" frequent="" most="" of="" race=""></third>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Total number of subjects

SD = Standard deviation

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 14 Exposure to study vaccines <Exposed Set>

	<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>		Total N=XXXX	
Number of subjects receiving	n	%	n	%	n	%
Exactly 1 Dose						
Exactly 2 Doses						
Exactly 3 Doses						
At least 1 Dose						
Total number of doses administered during the study						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects in each group or in total included in the considered cohort

n = number of subjects/doses in the given category

% = percentage of subjects in the given category

Template 15 Compliance in completing *solicited adverse events* information <Exposed Set>

			<each gro<="" th=""><th>oup></th><th>•</th><th>each grou</th><th>p></th></each>	oup>	•	each grou	p>
DOSE	Adverse event information	N	n	Compliance (%)	N	n	Compliance (%)
DOSE <each dose="" number=""></each>	General AES						
	Local AES						
TOTAL	General AES						
	Local AES						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N=Number of administered doses

n = number of doses with AES returned

General AES = Adverse event screens used for the collection of general solicited AEs

Local AES = Adverse event screens used for the collection of local solicited AEs

Compliance (%) = $(n / N) \times 100$

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 16 Incidence and nature of <grade 3, related, grade 3 related, > adverse events (<unsolicited and solicited, solicited only>) reported <during the 7-day (Days 1-7), beyond the 7-day (Days 1-7)> post-vaccination period following each dose and overall

		<e< th=""><th>ach</th><th>gro</th><th>up></th><th></th><th><e< th=""><th>ach</th><th>gro</th><th>up></th><th></th></e<></th></e<>	ach	gro	up>		<e< th=""><th>ach</th><th>gro</th><th>up></th><th></th></e<>	ach	gro	up>	
					95%	CI				95%	CI
Dose	Adverse event	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Any adverse event										
Daga 2	General adverse events										
	Local adverse events										
Dose 2	Any adverse event										
	General adverse events										
	Local adverse events										
Dose 3	Any adverse event										
	General adverse events										
	Local adverse events										
Overall/dose	Any adverse event										
	General adverse events										
	Local adverse events										
Overall/subject	Any adverse event										
•	General adverse events										
	Local adverse events										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects presenting at least one type of **adverse event**For overall/dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of *adverse event*

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 17 Incidence of solicited local *adverse events* reported during the 7-day (Days 1-7) post-vaccination period by study vaccine following each dose and overall <Exposed Set>

						Co-A	١d			(Conti	ol	
							95%	6 CI				95%	6 CI
Dose	Adverse event	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Pain	HZ/su	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
		Prevenar13	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
	Redness (mm)	HZ/su	All										
	, ,		>50										
			>100										
			Medical advice										
		Prevenar 13	All										
			>50										
			>100										
			Medical advice										
	Swelling (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar 13	All										
			>50										
			>100										
			Medical advice										
Dose 2													
Dose 3													
Overall/Dose													
Overall/Subject													
	Drovenar 13± H7/	Dogg 2: UZ	lou										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the type of **adverse event** at least once following the corresponding dose

For Overall/dose:

N = number of documented dose

n/% = number/percentage of doses followed by at least one type of **adverse event** For Overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the type of *adverse event* at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 18 Incidence of solicited general *adverse events* reported during the 7-day (Days 1-7) post-vaccination period following each dose and overall <Exposed Set>

					<each gr<="" th=""><th></th><th></th></each>		
							5 % CI
Dose	Adverse event	Type	N	n	%	LL	UL
Oose 1	Fatigue	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Gastrointestinal symptoms	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Headache	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Myalgia	All					
		Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Shivering	All					
	3	Grade 3					
		Related					
		Grade 3*Related					
		Medical advice					
	Fever (Oral) (°C)	All (≥38.0)					
	. 575. (514.) (5)	>38.0					
		>38.5					
		>39.0					
		>39.5					
		>40.0					
		Related					
		>39.0*Related					
		Medical advice					
Pose 2							
Dose 3		•••					
Overall/Dose							
Overall/Subject	yanar 13+ H7/su. Dosa 2: H7/su						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the **adverse event** at least once following the corresponding dose For Overall/dose:

N = number of documented dose

n/% = number/percentage of doses followed by at least one type of **adverse event**

For Overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the type of adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 19 Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose <Exposed Set>

						C	o-Ad				Co	ontrol	
							95	% CI				95	% CI
Dose	Symptom	Route	Type	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Temperature (°C)	Oral	≥35.0										
	, , ,		>35.5										
			>36.0										
			>36.5										
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
		Axillary	≥35.0										
			>35.5										
			>36.0										
			>36.5										
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
Dose 2	Temperature (°C)	Oral	≥35.0										
			>35.5										
			>36.0										
			>36.5										
			>37.0										
			>37.5										
			>38.0										
			>38.5										
			>39.0										
			>39.5										
			>40.0										
Dose 3				1	t								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the *adverse event* at least once

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

*=Temperature is defined on oral, axillary, tympanic or rectal

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 20 Number and percentage of subjects reporting the occurrence of <grade 3> <non-serious> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination, with medically attended visit>, within the 30-day (Days 1-30) post-vaccination period <,including numbers of events><Exposed Set>

		Ea N		gro	oup	
						5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%	LL	UL
	At least one adverse event					
Gastrointestinal disorders (10017947)	At least one PT related to the corresponding SOC					
	Diarrhoea (10012735)					
	Teething (10043183)					
	Vomiting (10047700)					
General disorders and administration site conditions	At least one PT related to the					
(10018065)	corresponding SOC					
	Pyrexia (10037660)					
Immune system disorders (10021428)	Seasonal allergy (10048908)					
Infections and infestations (10021881)	Conjunctivitis (10010741)					
	Otitis media (10033078)					
	Paronychia (10034016)					
	Tonsillitis (10044008)					
	Tonsillitis streptococcal (10044013)					
	Viral upper respiratory tract infection (10047482)					
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)					
,	Face injury (10050392)					
	Head injury (10019196)					
Skin and subcutaneous tissue disorders (10040785)	Miliaria (10027627)					

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the *adverse event* at least once

n* = number of events reported

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Please note the n* will only be presented for the CTRS posting with the time interval as per the secondary endpoint

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 21 Global Summary of <grade 3> <non-serious>unsolicited signs and adverse events reported <with causal relationship with vaccination, with medically attended visit> within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

	Co-Ad	Control	Total
Number of subjects with at least one unsolicited adverse event reported			
Number of doses followed by at least one unsolicited adverse event			
Number of unsolicited adverse events classified by MedDRA Preferred Term*			
Number of unsolicited adverse events reported**			

Co-Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

Template 22 Number and percentage of subjects starting a concomitant medication during the 30- day (Days 1-30) post vaccination period by dose and overall <Exposed Set>

				<each g<="" th=""><th>group></th><th></th></each>	group>	
						5% CI
Dose	Туре	N	n	%	LL	UL
Dose 1	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Dose 2	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Dose 3	Any					
	Any in anticipation of study					
	vaccine reaction					
	Any chronic use					
Overall/Dose	Any					
	Any in anticipation of study					
	vaccine reaction					
	Any chronic use					
Overall/Subject	Any					
	Any in anticipation of study					
	vaccine reaction					
	Any chronic use					

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = total number of subjects with the corresponding administered dose

n/% = number/percentage of subjects took the specified type of concomitant medication at least once during the considered period

For Overall/dose:

N = number of administered doses

n/% = number/percentage of doses after which the specified type of concomitant medication was taken at least once during the considered period

^{*} Adverse events reported by a subject after a given dose and classified by the same Preferred Term are counted once

^{**} **Adverse events** reported by a subject after a given dose and classified by the same Preferred Term and the same start date of the event, are counted once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

For Overall/subject:

N = total number of subjects with at least one administered dose

n/% = number/percentage of subjects who took the specified type of concomitant medication at least once during the considered period

Template 23 Number of days with <local, general> solicited adverse events <during the 7 days (Days 1-7), beyond the 7-days (Days 1-7) of> post vaccination period following each dose and overall <- Prevenar 13 vaccine, - HZ/su vaccine> <Exposed Set>

			<co-ad group=""></co-ad>	<control group=""></control>
Dose	Adverse event	Statistic	value	value
<each dose=""></each>	<each adverse="" event=""></each>	n	XXXX	XXXX
		Mean	XX.X	XX.X
		Minimum	XX.X	XX.X
		Q1	XX.X	XX.X
		Median	XX.X	XX.X
		Q3	XX.X	XX.X
		Maximum	XX.X	XX.X
Overall/Dose	<each adverse="" event=""></each>	n	XXXX	XXXX
		Mean	XX.X	XX.X
		Minimum	XX.X	XX.X
		Q1	XX.X	XX.X
		Median	XX.X	XX.X
		Q3	XX.X	XX.X
		Maximum	XX.X	XX.X

Co-Ad group = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control group = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of doses with adverse event

Q1= 25th percentile

Q3= 75th percentile

Please note the table by vaccine type will only be done for local solicited adverse events.

Template 24 Solicited and unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term within the 30-day (Days 1-30) post-vaccination period including number of events - SAE excluded <Exposed Set>

		<each group=""> N =</each>					
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%			
	At least one adverse event						
<each soc=""></each>	<each pt="" term=""></each>						

<each group>:

Co-Ad group = Dose 1: Prevenar+ HZ/su, Dose 2: HZ/su

Control group = Dose 1: Prevenar, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n* = number of events reported

n/% = number/percentage of subjects reporting the adverse event at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 25 Number (%) of subjects with serious adverse events from <first vaccination dose up to 30 days post last vaccination, 30 days post last vaccination up to study end, first vaccination dose up to <database freeze date(DDMMMYYYY)><study end>, including number of events reported <Exposed Set>

			<each group=""> N =</each>				
Type of Event	Primary System Organ Class	Preferred Term (CODE)	n*	n	%		
SAE	At least one adverse event						
	<each soc=""></each>	<each pt="" term=""></each>					
Related SAE	At least one adverse event						
	<each soc=""></each>	<each pt="" term=""></each>					
Fatal SAE	At least one adverse event						
	<each soc=""></each>	<each pt="" term=""></each>					
Related fatal SAE	At least one adverse event						
	<each soc=""></each>	<each pt="" term=""></each>					

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with the administered dose

n* = number of events reported

n/% = number/percentage of subjects reporting the *adverse event* at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 26 Number (%) of subjects reported solicited local *adverse* events during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <Exposed Set>

				Co-A			4d		Cont			rol	
							95%	6 CI				95%	6 CI
Dose	Adverse event	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Pain	HZ/su	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
		Prevenar	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
	Redness (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar	All										
			>50										
			>100										
			Medical advice										
	Swelling (mm)	n) HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar	All										
		>50											
			>100										
			Medical advice										
Dose 2													
Dose 3													
Across dose													

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the type of **adverse event** at least once following the corresponding dose

For Across dose:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 27 Number (%) of subjects reported solicited general *adverse events* during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <Exposed Set>

					<each gi<="" th=""><th>oup></th><th></th></each>	oup>	
							5 % CI
Dose	Adverse event	Туре	N	n	%	LL	UL
Dose 1	Fatigue	All					
	_	Grade 3					
		Related					
	Gastrointestinal symptoms	All					
		Grade 3					
		Related					
	Headache	All					
		Grade 3					
		Related					
	Myalgia	All					
		Grade 3					
		Related					
	Shivering	All					
		Grade 3					
		Related					
	Fever (Oral) (°C)	All (≥38.0)					
		>39.0					
		Related					
Dose 2	Fatigue						
	Gastrointestinal symptoms						
	Headache						
	Myalgia						
	Shivering						
	Fever (Oral) (°C)						
Across Dose							

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the **adverse event** at least once following the corresponding dose For Across dose:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the adverse event at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 28 Number and percentage of subjects with <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> equal to or above <cut-off> and <GMCs, GMT> <PPS for analysis of immunogenicity, Exposed Set>

					ut-off rotyp			•	GMC, G	MT>		
						95	% CI		9	5% CI		
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL	Min	Max
<anti-ge antibody, anti- pneumococcal <x> antibody titres></x></anti-ge 	Co-Ad	PRE										
		PI(M1) or PII(M3)										
	Control	PRE or PI(M2)										
		PI(M1) or PIII(M5)										

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

GM<C,T> = geometric mean antibody <concentration, titre> calculated on all subjects

N = Number of subjects with available results

95% CI = 95% confidence interval; LL = lower limit, UL = upper limit

n/% = number/percentage of subjects with <concentration, titre> equal to or above specified value

MIN/MAX = Minimum/Maximum

PRE= Pre-vaccination at Day 1

PII(M3) = Post-vaccination dose 2 at Month 3

PI(M1) = Post-vaccination dose 1 at Month 1

PI(M2) = Post-vaccination dose 1 at Month 2

PIII(M5) = Post-vaccination dose 3 at Month 5

Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3) for Co-Ad and PI(M2) and PIII(M5) for Control group.

Template 29 Vaccine response rates for anti-gE antibody ELISA concentrations in Co-Ad group at one month post dose 2 of HZ/su vaccine – primary objective <PPS for analysis of immunogenicity, Exposed Set>

				Co-Ad		
					95%	6 CI
Antibody		N	n	%	LL	UL
Anti-gE antibody	XXX	XX	XXXX	XX.X	XXX.X	XXX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Total = subjects either seropositive or seronegative at pre-vaccination

Vaccine response defined as:

Vaccine response defined as:

For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mI)

For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

N = number of subjects with both pre- and post-vaccination results available

n/% = number/percentage of responders

<95>% CI = exact <95>% confidence interval, LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 30 Adjusted ratios of GMCs between groups (Control group divided by Co-Ad group) for anti-gE antibody ELISA concentrations at one month post dose 2 of HZ/su vaccine <PPS for analysis of immunogenicity, Exposed Set>

	Control				Co-Ad			Adjusted GMC ratio (Control / Co-Ad)				
		95	% CI*			95%	CI*		95	% CI		
N	Adjusted GMC	LL	UL	N	Adjusted GMC	LL	UL	Value	LL	UL		
					-							

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adjusted GMC = geometric mean antibody concentration adjusted for vaccine group, age and baseline concentration N = Number of subjects with both pre- and post-vaccination results available

95% CI* = 95% confidence interval for the adjusted GMC (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

95% CI = 95% confidence interval for the adjusted GMC ratio (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

Template 31 Adjusted ratios of GMTs between groups (Control group divided by Co-Ad group) for anti-pneumococcal <X> antibody titres at one month post Prevenar 13 vaccine <PPS for analysis of immunogenicity, Exposed Set>

	Contro	ol			Co-A	d			ted GM ntrol / C	
		95	% CI*			959	% CI*		g	5% CI
N Adjusted LL UL GMT				N	Adjusted GMT	LL	UL	Value	LL	UL

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adjusted GMT = geometric mean antibody titre adjusted for vaccine group, age and baseline concentration N = Number of subjects with both pre- and post-vaccination results available

95% CI* = 95% confidence interval for the adjusted GMT (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

95% CI = 95% confidence interval for the adjusted GMT ratio (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

Template 32 Mean Geometric Increase (MGI) of anti-gE antibody ELISA concentrations from baseline to one month post dose 2 of HZ/su vaccine <PPS for analysis of immunogenicity, Exposed Set>

							MGI		
								9	5% CI
Antibody	Group	N	Time point description	GMC	Time point description	Ratio order	Value	LL	UL
<antibody></antibody>	Co-Ad		PII(M3)		PRE	PII(M3)/PRE			
	Control		PIII(M5)		PI(M2)	PIII(M5)/PI(M2)			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Number of subjects with available results at the two considered time points

MGI = Geometric mean of the within -subject ratios of the post-vaccination reciprocal anti-gE concentration to the Day 1 reciprocal anti-gE concentration

GMC = geometric mean antibody concentration

95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

PRE= Pre-vaccination at Day 1

PII(M3) = Post-vaccination dose 2 at Month 3 for Co-Ad group

PI(M2) = Post-vaccination dose 1 at Month 2 for Control group (considered as pre-vaccination for HZ/su in Control group)

PIII(M5) = Post-vaccination dose 3 at Month 5 for Control group (considered as post dose 2 for HZ/su in Control group)

Template 33 Descriptive statistics of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentration <PPS for analysis of immunogenicity, Exposed Set>

			Each Grou N=	p
				95% CI
Parameters	Parameter	Value	LL	UL
Anti-gE antibody	n			
	Nmiss			
	Mean			
	SD			
	Min			
	Q1			
	Median			
	Q3			
	Max			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with available results

Nmiss = number of subjects with missing results

SD = Standard Deviation

Q1, Q3 = First and third quartiles

Min/Max = Minimum/Maximum

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to PI(M2) for Control group has to be considered

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 34 Distribution of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentrations <PPS for analysis of immunogenicity, Exposed Set>

				< E	ach gr	oup>			<e< th=""><th>ach gr</th><th>oup></th><th></th></e<>	ach gr	oup>	
						95	% CI					% CI
Antibody	Timing	Fold change	N	n	%	LL	UL	N	n	%	LL	UL
<each antibody=""></each>	<pii(m3)></pii(m3)>	≥2	XX	XX	XX.X	XX.X	XX.X	XX	XX	XX.X	XX.X	XX.X
		≥4										
		≥6										
		≥8	İ			İ						
		≥10										
		≥12	İ					Ì				
		≥14	İ					Ì				
	<piii(m5)< td=""><td>>= Ratio1</td><td>XX</td><td>XX</td><td>XX.X</td><td>XX.X</td><td>XX.X</td><td>ХХ</td><td>XX</td><td>XX.X</td><td>XX.X</td><td>XX.X</td></piii(m5)<>	>= Ratio1	XX	XX	XX.X	XX.X	XX.X	ХХ	XX	XX.X	XX.X	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with available results

n/% = number/percentage of subjects with concentration within the specified range

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PII(M3) = Post-vaccination dose 2 at Month 3 for Co-Ad group

PIII(M5) = Post-vaccination dose 3 at Month 5 for Control group (considered as post dose 2 for HZ/su in Control group)

Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to

PI(M2) for Control group has to be considered

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 35 Listing of potential Immune Mediated Diseases (pIMDs) reported as identified by predefined list of preferred terms and/or by investigator assessment up to end of study <Exposed Set>

Group	Patient ID	Country	Age at onset (Y)	Gender	Race	Primary System Organ Class	Preferred term	Dose	Day of onset	Relation	Serious pIMD based on Investigator?	SAE (Y/N)	Outcome	pIMD Source

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 36 Listing of all SAEs up to end of study <Exposed Set>

Group	Sub. No.	Sex	Country	Race	Age at onset (Year)	Verbatim	Preferred term	Primary System Organ Class	MED type	Dose	Day of onset	Duration	Intensity	Causality	Outcome

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 37 Listing of suspected HZ cases from first administered dose up to end of study <Exposed Set>

Group		Previous dose	Day on-set	Duration	Preferred	AE description	Medical advice	Medically attended visit	Intensity	Causality	Outcome
	No.				term						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

11-JUN-2019 Page 57 of 65

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 38 Listing of (S)AEs and solicited adverse events leading to study or treatment discontinuation <up to month 5><up to end of study> <Exposed Set>

Type of discontinuation: <study/treatment

Group	Subject number	Gender	Country	Race	AE Description	SAE (Y/N)	Causality	Outcome	Vaccination and visit
									Vaccination: x at visit x

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 39 Maximum intensity of solicited <local, general> adverse event ongoing beyond the 7-day (Days 1-7) post-vaccination period following each dose and overall <Exposed Set>

				<each group></each 	<each group></each
			Time to resolution	Value or	
Dose	Adverse event	Туре	(days)	n	n
<each dose=""></each>	<each adverse<="" td=""><td>All</td><td>N</td><td>XX</td><td>XX</td></each>	All	N	XX	XX
	event>		n	xx	xx
			q1	XX.X	XX.X
			median	xx.x	xx.x
			q3	XX.X	XX.X
		Grade 3	N	ХХ	XX
			n	xx	xx
			q1	XX.X	XX.X
			median	xx.x	xx.x
			q3	XX.X	XX.X
		Grade 3*Related	N	XX	XX
			n	xx	xx
			q1	XX.X	XX.X
			median	XX.X	XX.X
			q3	XX.X	XX.X
OVERALL/DOSE	<each adverse="" eve<="" td=""><td>nt><each type=""></each></td><td>N</td><td>XX</td><td>XX</td></each>	nt> <each type=""></each>	N	XX	XX
			n	XX	XX
			q1	XX.X	XX.X
			median	XX.X	XX.X
			q3	XX.X	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Time to resolution: number of days beyond the end of the follow-up period

N = number of *adverse events* that were ongoing after the follow-up period

n = number of adverse events that were ongoing after the follow-up period with a complete end date

q1 = 25th percentile

q3= 75th percentile

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 40 Number and percentage of doses reporting the occurrence of <grade 3> unsolicited adverse events classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination> within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

		Each gro		oup	
				_	5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL
At least one adverse event					
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)				
,	Teething (10043183)				
	Vomiting (10047700)				
General disorders and administration site conditions (10018065)	Pyrexia (10037660)				
Immune system disorders (10021428)	Seasonal allergy (10048908)				
Infections and infestations (10021881)	Conjunctivitis (10010741)				
	Otitis media (10033078)				
	Paronychia (10034016)				
	Tonsillitis (10044008)				
	Tonsillitis streptococcal (10044013)				
	Viral upper respiratory tract infection				
	(10047482)				
Injury, poisoning and procedural complications (10022117)	7				
,	Face injury (10050392)				
	Head injury (10019196)				
Skin and subcutaneous tissue disorders (10040785)	Miliaria (10027627)				

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13. Dose 2: HZ/su. Dose 3: HZ/su

At least one **adverse event** = at least one **adverse event** experienced (regardless of the MedDRA Preferred Term) N = number of administered doses

n/% = number/percentage of doses followed by the adverse event

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 41 Number and percentage of subjects reporting the occurrence of <serious adverse events, potential Immune Mediated Disease> classified by MedDRA Primary System Organ Class and Preferred Term from <first vaccination up to 30 days post last vaccination, from 30 days post last vaccination dose up to end of study, from first vaccination up to study end> <,including number of events><Exposed Set>

			(Ad =				Co I	ntr N =	
						5% CI				ć	95% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%	LL	UL	n*	n	% I	LL	UL
At least one adverse event											i
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)										
Cardiac disorders (10007541)	Acute myocardial infarction (10000891)										
	Atrial fibrillation (10003658)										
	Cardiac failure congestive (10007559)										
	Tachycardia (10043071)										
	Ventricular tachycardia (10047302)										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the **adverse event** at least once

n* = Number of events reported

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Please note that n* will be used to present pIMD for CTRS posting.

Template 42 Global Summary of <serious adverse events, potential Immune
Mediated Disease> <with causal relationship with vaccination>
reported from <first vaccination up to 30 days post last vaccination,
from 30 days post last vaccination dose up to end of study, from
first vaccination up to study end> <Exposed Set>

	Co-Ad	Control	Total
Number of subjects with at least one <sae, pimd=""> reported</sae,>			
Number of doses followed by at least one <sae, pimd=""></sae,>			
Number of <sae, pimd=""> classified by MedDRA Preferred Term*</sae,>			
Number of <sae, pimd=""> reported**</sae,>			

Co-Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

^{*} **Adverse events** reported by a subject after a given dose and classified by the same Preferred Term are counted once

^{**} **Adverse events** reported by a subject after a given dose and classified by the same Preferred Term and the same start date of the event, are counted once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 43 Vaccine response rates for anti-gE antibody concentrations at one month post dose 2 of HZ/su vaccine <PPS for analysis of immunogenicity, Exposed Set>

			•	Each gro	Each group>						
					95	5% CI					
Antibody	Pre-vaccination										
Timing	status	N	n	%	LL	UL					
<each antibody=""></each>	S-	XXXX	XXXX	XX.X	XXX.X	XXX.X					
•	S+	XXXX	XXXX	XX.X	XXX.X	XXX.X					
	Total	XXXX	XXXX	XX.X	XXX.X	XXX.X					

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

S- = seronegative subjects (antibody <concentration> < <cut off> <unit>) at pre-vaccination

S+ = seropositive subjects (antibody <concentration>≥ <cut off> <unit>) at pre-vaccination

Total = subjects either seropositive or seronegative at pre-vaccination

Vaccine response defined as:

Vaccine response defined as:

For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml)

For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

N = number of subjects with both pre- and post-vaccination results available


n/% = number/percentage of responders

<95>% CI = exact <95>% confidence interval, LL = Lower Limit, UL = Upper Limit

Please note – To calculate the vaccine response, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to PI(M2) for Control group has to be considered

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 44 Reverse cumulative distribution curves for <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> in each group at baseline and <post dose 2 of HZ/su vaccine, post dose of Prevenar 13> <PPS for analysis of immunogenicity, Exposed Set>



Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Note: This graph is provided as an example. The same graph will be provided in colour for each time point and each assay comparing the values of the groups

Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3) for Co-Ad and PI(M2) and PIII(M5) for Control group.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 45 Number and percentage of subjects <with><experiencing> fatal SAEs classified by MedDRA Primary System Organ Class and Preferred Term <who died><with onset of fatal SAE> <during the period starting> <from first vaccination up to 30 days post last vaccination dose vafter 30 days post last vaccination dose up to study end><from first vaccination until the study end><during the entire study period> <Exposed Set>

			_	o-A N =					ntrol V =		
					5% CI			;	95% CI		
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL		
At least one adverse event											
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)										
Cardiac disorders (10007541)	Acute myocardial infarction (10000891)										
	Atrial fibrillation (10003658)										
	Cardiac failure congestive (10007559)										
	Tachycardia (10043071)										
	Ventricular tachycardia (10047302)										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one adverse event = at least one adverse event experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group n/% = number/percentage of subjects reporting the adverse event at least once 95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Template 46 Summary of subject disposition from enrolled set to randomized set

	Total N=XXX
	n %
Number of subjects who signed an informed consent	
Withdrawals prior to randomization	xxx xx.x
<withdrawal 1="" reason=""></withdrawal>	xxx xx.x
<withdrawal 2="" reason=""></withdrawal>	xxx xx.x
	xxx xx.x
	xxx xx.x
Number of subjects included in randomized set	

N = Number of subjects

n = number of subjects enrolled by center

% = n / Number of subjects with available results x 100

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 47 Summary of subject disposition from Randomised Set to Per Protocol Set

		up 1> KXX	<group N=XX</group 		Tota N=XX	
	n	%	n %	6	n	%
NUMBER OF SUBJECTS						
INCLUDED IN RANDOMISED SET						
Withdrawals	xxx	XX.X	XXX	XX.X	XXX	XX.X
<withdrawal 1="" reason=""></withdrawal>	xxx	XX.X	xxx	xx.x	xxx	XX.X
<withdrawal 2="" reason=""></withdrawal>	xxx	XX.X	xxx	XX.X	xxx	XX.X
Eliminations	ххх	xx.x	xxx	xx.x	xxx	XX.X
<elimination 1<="" reason="" td=""><td>xxx</td><td>XX.X</td><td>xxx</td><td>XX.X</td><td>xxx</td><td>XX.X</td></elimination>	xxx	XX.X	xxx	XX.X	xxx	XX.X
(code)>	xxx	XX.X	xxx	XX.X	xxx	XX.X
<elimination 2<="" reason="" td=""><td></td><td></td><td></td><td></td><td></td><td></td></elimination>						
(code)>						
	xxx	XX.X	xxx	XX.X	XXX	XX.X
NUMBER OF SUBJECTS						
INCLUDED IN EXPOSED						
SET						
Elimination 1						
NUMBER OF SUBJECTS						
INCLUDED IN PER						
PROTOCOL SET						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Number of subjects

n = number of subjects enrolled by center

% = n / Number of subjects with available results x 100

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Amendment 1

Template 48 Listing of subjects who died during the entire study period and their fatal SAEs <Enrolled Set>

Group	No.	Sex	Country	Race	Age at Onset (Year)	Verbatim	Preferred term	Primary System Organ Class	type	prior to onset of fatal SAE	Days between onset of fatal SAE and previous dose	prior to death	Days between death and previous dose	SAE Duration	SAE Causality
No Group	-PPD							1		0	-	0	-		
										0	-	0	-		
										1	XX	1	XX		
										1	XX	2	XX		
										1	XX	1	XX		
										1	XX	1	XX		

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

No Group= Enrolled not vaccinated

MED = Medical Advice type (HO: hospitalisation, ER: emergency room visit, MD: medical practice visit)

11-JUN-2019 Page 65 of 65

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

gsk GlaxoSmithKline	Statistical Analysis Plan					
Detailed Title:	A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with <i>Prevenar13</i> in adults aged 50 years and older.					
eTrack study number and Abbreviated Title	204487 (ZOSTER-059 PRI) Statistical Analysis Plan – Final					
Scope:	All analyses planned per protocol.					
Date of Statistical Analysis Plan	Final: 13-APR-2018					
Co-ordinating author:	(Study Statistician), PPD (Project Statistician)					
Reviewed by:	Clinical and Epidemiology Project Lead) PPD (Clinical and Research Development Lead) PPD (Clinical and Epidemiology Scientist) (Lead statistician) (Lead statistical analyst) (Scientific writer) PPD (Regulatory Affair) (SERM Expert Scientist) PPD (Medical Affairs) PPD (Public disclosure representative) PPD (Lead Scientific writer) (Public disclosure representative) (Lead Scientific writer)					
Approved by:	Clinical and Epidemiology Project Lead) PPD (Clinical and Research Development Lead) PPD (Lead statistician) PPD (Scientific writer) PPD (Lead stat Analyst)					

APP 9000058193 Statistical Analysis Plan Template (Effective date: 14 April 2017)

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

TABLE OF CONTENTS

				PAGE
LIS	T OF A	ABBREVIA	ATIONS	10
1.	DOC	JMENT H	ISTORY	12
2.	STUD	Y DESIG	N	12
3.	OBJE 3.1. 3.2.	Co-Prim	nary objectivesary objective	14
4.		POINTS Primary	endpointsary endpoints	15 15
5.	ANAL 5.1.		— p (— -)	16 16
	5.2.	Criteria 5.2.1. 5.2.2.	for eliminating data from Analysis Sets	17 17
	5.3.		nt protocol deviation not leading to elimination from per- analysis set	20
6.	STAT 6.1.	Demogr 6.1.1.	ANALYSES aphy Analysis of demographics/baseline characteristics planned in the protocol	20
	6.2.		reAnalysis of exposure planned in the protocol	21 21
	6.3.	-	Analysis of immunogenicity planned in the protocol	21 21 21
		6.3.2.	Additional considerations	
	6.4.	Analysis 6.4.1. 6.4.2.	objectives s of safety Analysis of safety planned in the protocol Additional considerations 6.4.2.1. Combined Solicited and Unsolicited Adverse Events	24 24 25
7.	ANAL	YSIS INT	ERPRETATION	26
8.	CONI	DUCT OF	ANALYSES	27

204487l Statistical Analysis Plan $\,$ 13 Apr 2018l TMF-605547 l2.0

CONFIDENTIAL

			204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final
	8.1. 8.2.	Sequence of analyses Statistical considerations for interim analyses	27 27
9.	CHAN	GES FROM PLANNED ANALYSES	27
10.	LIST C	OF FINAL REPORT TABLES, LISTINGS AND FIGU	JRES28
11.		X 1 STANDARD DATA DERIVATION RULE AND	
	METH	ODS	28
	11.1.	Standard data derivation	28
		11.1.1. Dose number	
		11.1.2. Immunogenicity	
		11.1.3. Safety	
	11.2.	Statistical Method References	
	11.3.	Number of decimals displayed:	32
12.		X 2: STUDY SPECIFIC MOCK TFL	
	12.1.	List of individual data listing	33
		Template of Tables and Figures	

204487l Statistical Analysis Plan $\,$ 13 Apr 2018l TMF-605547 | 2.0

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

LIST OF TABLES

		PAGE
Table 1	Study groups and epochs foreseen in the study	13
Table 2	Study groups and treatment foreseen in the study	13
Table 3	Blinding of study epochs	13
Table 4	Power to demonstrate VRR objective and non-inferiority of the immunogenicity of HZ/su and Prevenar13 co-administered compared to Control group	23
Table 5	Analysis and disclosure plan for the planned analysis	27

204487l Statistical Analysis Plan $\,$ 13 Apr 2018l TMF-605547 l2.0

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

LIST OF FIGURES

		PAGE
Figure 1	Overview of Study Design	12

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

LIST OF TEMPLATES

		PAGE
Template 1	Number of subjects by country and center <exposed set=""></exposed>	34
Template 2	Number of enrolled subjects by country	34
Template 3	Number of enrolled subjects by age category	34
Template 4	Number of subjects by country and age category <exposed set=""></exposed>	35
Template 5	Number of subjects vaccinated, completed and withdrawn with reason for withdrawal – <end active="" end="" of="" phase,="" study=""> <exposed set=""></exposed></end>	35
Template 6	Visit attendance <exposed set=""></exposed>	35
Template 7	List of subjects withdrawn from vaccination with reason for withdrawal	36
Template 8	Number of subjects enrolled into the study as well as the number excluded from PPS analyses of immunogenicity with reasons for exclusion	36
Template 9	Percentage of subjects with serological results who were eliminated from PPS for immunogenicity	36
Template 10	Deviations from specifications for age and intervals between study visits for Co-Ad group <exposed for="" immunogenicity="" pps="" set,=""></exposed>	37
Template 11	Deviations from specifications for age and intervals between study visits - for Control group <exposed for="" immunogenicity="" pps="" set,=""></exposed>	37
Template 12	Summary of demographic characteristics <exposed for="" immunogenicity="" pps="" set,=""></exposed>	38
Template 13	Minimum and maximum activity dates <exposed set=""></exposed>	38
Template 14	Study Population <exposed set=""></exposed>	39
Template 15	Exposure to study vaccines <exposed set=""></exposed>	39
Template 16	Compliance in completing solicited symptoms information <exposed set=""></exposed>	40
Template 17	Incidence and nature of <grade 3="" 3,="" grade="" related,=""> symptoms (<unsolicited and="" only="" solicited="" solicited,="">) reported <during (days="" 1-7)="" 1-7),="" 7-day="" beyond="" the=""> post-vaccination period following each dose and overall</during></unsolicited></grade>	40

CONFIDENTIAL 204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final Template 18 Incidence of solicited local symptoms reported during the 7-day (Days 1-7) post-vaccination period by study vaccine following each dose and overall <Exposed Set>......41 Template 19 Incidence of solicited general symptoms reported during the 7day (Days 1-7) post-vaccination period following each dose and Summary of temperature value by half degree increment Template 20 reported during the 7-day (Days 1-7) post-vaccination following Template 21 Percentage of subjects reporting the occurrence of <grade 3> unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination, with medically attended visit>, within the 30-day (Days 1-30) post-vaccination period < Exposed Set>......44 Template 22 Global Summary of <grade 3> unsolicited signs and symptoms reported <with causal relationship with vaccination, with medically attended visit> within the 30-day (Days 1-30) postvaccination period <Exposed Set>......44 Number and percentage of subjects starting a concomitant Template 23 medication during the 30- day (Days 1-30) post vaccination period by dose and overall < Exposed Set >45 Template 24 Number of days with <local, general> solicited symptoms <during the 7 days (Days 1-7), beyond the 7-days (Days 1-7) of post vaccination period following each dose and overall <- Prevenar 13 vaccine, - HZ/su vaccine> <Exposed Set>46 Template 25 Solicited and unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 30day (Days 1-30) post-vaccination period including number of Template 26 Number (%) of subjects with <serious adverse events from <first vaccination dose up to 30 days post last vaccination, 30 days post last vaccination up to study end, first vaccination dose up to study end>, including number of events reported < Exposed Set>47

Template 27

Template 28

Template 29

Number (%) of subjects reported solicited local symptoms during the 7-day (Days 1-7) post-vaccination period following each dose

Number (%) of subjects reported solicited general symptoms during the 7-day (Days 1-7) post-vaccination period following

Number and percentage of subjects with <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> equal to

and across dose <Exposed Set>......48

each dose and across dose < Exposed Set >49

	CONTIDENTIAL	204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final
	or above <cut-off> and <gmcs, gmt=""> <pps exposed="" fimmunogenicity,="" set=""></pps></gmcs,></cut-off>	or analysis of
Template 30	Vaccine response rates for anti-gE antibody El concentrations in Co-Ad group at one month p HZ/su vaccine – primary objective <pps ar="" exposed="" for="" immunogenicity,="" set=""></pps>	ost dose 2 of nalysis of
Template 31	Adjusted ratios of GMCs between groups (Corby Co-Ad group) for anti-gE antibody ELISA cone month post dose 2 of HZ/su vaccine <pps exposed="" immunogenicity,="" set=""></pps>	oncentrations at S for analysis of
Template 32	Adjusted ratios of GMTs between groups (Conby Co-Ad group) for anti-pneumococcal <x> a one month post Prevenar 13 vaccine <pps exposed="" for="" immunogenicity,="" set=""></pps></x>	ntibody titres at analysis of
Template 33	Mean Geometric Increase (MGI) of anti-gE and concentrations from baseline to one month post vaccine <pps analysis="" for="" immunogenicity,<="" of="" td=""><td>st dose 2 of HZ/su</td></pps>	st dose 2 of HZ/su
Template 34	Descriptive statistics of fold increase from base post dose 2 of HZ/su vaccine for anti-gE antibot concentration <pps analysis="" for="" immunoger="" of="" set=""></pps>	ody ELISA nicity, Exposed
Template 35	Distribution of fold increase from baseline to or dose 2 of HZ/su vaccine for anti-gE antibody E concentrations <pps analysis="" for="" immunoge="" of="" set=""></pps>	LISA enicity, Exposed
Template 36	Listing of potential Immune Mediated Diseases as identified by predefined list of preferred term investigator assessment up to end of study <e< td=""><td>ns and/or by</td></e<>	ns and/or by
Template 37	Listing of all SAEs up to end of study <expose< td=""><td>d Set>54</td></expose<>	d Set>54
Template 38	Listing of suspected HZ cases from first adminent of study <exposed set=""></exposed>	•
Template 39	Listing of dropouts due to AEs, SAEs and solid to end of study <exposed set=""></exposed>	• •
Template 40	Maximum intensity of solicited <local, general=""> ongoing beyond the 7-day (Days 1-7) post-vac following each dose and overall <exposed set<="" td=""><td>cination period</td></exposed></local,>	cination period
Template 41	Percentage of doses reporting the occurrence unsolicited symptoms classified by MedDRA P Organ Class and Preferred Term <with causal="" vaccination=""> within the 30-day (Days 1-30) posperiod <exposed set=""></exposed></with>	rimary System relationship to st-vaccination

204487l Statistical Analysis Plan $\,$ 13 Apr 2018l TMF-605547 l2.0

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 42	Percentage of subjects reporting the occurrence of <serious adverse="" disease="" events,="" immune="" mediated="" potential=""> classified by MedDRA Primary System Organ Class and Preferred Term from <first 30="" days="" dose="" end="" first="" from="" last="" of="" post="" study="" study,="" to="" up="" vaccination="" vaccination,=""> <exposed set=""></exposed></first></serious>	57
Template 43	Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose <exposed set=""></exposed>	58
Template 44	Global Summary of <serious adverse="" disease="" events,="" immune="" mediated="" potential=""> <with causal="" relationship="" vaccination="" with=""> reported from <first 30="" days="" dose="" end="" first="" from="" last="" of="" post="" study="" study,="" to="" up="" vaccination="" vaccination,=""> <exposed set=""></exposed></first></with></serious>	59
Template 45	Vaccine response rates for anti-gE antibody concentrations at one month post dose 2 of HZ/su vaccine <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps>	59
Template 46	Reverse cumulative distribution curves for <anti-ge <x="" anti-pneumococcal="" antibody="" concentration,=""> antibody titres> in each group at baseline and <post 13="" 2="" dose="" hz="" of="" post="" prevenar="" su="" vaccine,=""> <pps analysis="" exposed="" for="" immunogenicity,="" of="" set=""></pps></post></anti-ge>	60

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

LIST OF ABBREVIATIONS

AE Adverse event

ANCOVA Analysis of Covariance

AS01_B: MPL, QS21, liposome based Adjuvant System (50 µg MPL and 50 µg

QS21)

CDR Clinical Data Reviewer

CI Confidence Interval Co-Ad: Co-administration

CRDL Clinical Research and Development Lead

CRF Case Report Form

CSR Clinical Study Report

CTRS Clinical Trial Registry Summary

EL.U/ml ELISA unit per milliliter

Eli Type Internal GSK database code for type of elimination code

ELISA Enzyme-linked immunosorbent assay

EoS: End of Study

ES Exposed Set (formally called 'Total Vaccinated Cohort')

FAS Full Analysis Set

GMC Geometric mean antibody concentration

GMT Geometric mean antibody titer

GSK GlaxoSmithKline

IU/ml International units per milliliter

LL Lower Limit of the confidence interval

MedDRA Medical Dictionary for Regulatory Activities

N.A. Not Applicable

PCD Primary Completion Date

PD Protocol Deviation

PPS Per Protocol Set (formally called 'According to Protocol')

SAE Serious adverse event SAP Statistical Analysis Plan

SBIR GSK Biological's Internet Randomization System

SD Standard Deviation

SHS Study Headline Summary

204487 | Statistical Analysis Plan | 13 Apr 2018 | TMF-605547 | 2.0

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

SR Study Report

SUSAR Suspected Unexpected Serious Adverse Reactions

TFL Tables Figures and Listings

TOC Table of Content

UL Upper Limit of the confidence interval

VRR Vaccine response rate

WBR Web-based Randomization


204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

1. DOCUMENT HISTORY

Date Description		Protocol Version	
13-APR-2018	First Version	Amendment 2: 30-JAN-2018	

2. STUDY DESIGN

Figure 1 Overview of Study Design



Vacc: vaccination; BS: blood sample; Pre-Vacc: pre-vaccination; FU: follow-up

Experimental design: Phase IIIB, open-label, randomized, controlled, multi-centric, and multi-country, with two parallel groups.

Duration of the study: The intended duration of the study per subject is approximately 14 months for subjects from the Co-Ad group and approximately 16 months for subjects from the Control group.

• Epoch 001: Primary starting at Visit Day 1 and ending with the phone contact at Month 16.

Primary completion date (PCD): Visit Month 5.

End of Study (EoS): Last testing results released of samples collected at Visit Month 3 (Co-Ad group) or at Visit Month 5 (Control group).

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Study groups:

Table 1 Study groups and epochs foreseen in the study

Study groups	Number of subjects	Age	Epochs Epoch 001
Co-Ad	456	≥ 50 years	Х
Control	456	≥ 50 years	Х

Table 2 Study groups and treatment foreseen in the study

Treatment name	Vaccine/Product name	Study Groups	
		Co-Ad	Control
HZ/su	VZV gE	х	Х
	AS01B	х	х
Prevenar13	Prevenar 13	х	Х

Control: active control.

Vaccination schedule(s):

Co-Ad Group:

- at Visit Day 1: first dose of HZ/su and one dose of Prevenar13,
- at Visit Month 2: second dose of HZ/su.

Control Group:

- at Visit Day 1: one dose of Prevenar13,
- at Visit Month 2: first dose of HZ/su,
- at Visit Month 4: second dose of HZ/su.

Treatment allocation: Subjects to be randomized in a 1:1 ratio at Visit Day 1 to either Co-Ad or Control group. Subjects in each group will be stratified by age with the following approximate distribution (not less than 25% in each age strata):

- 171 subjects in the 50-59 YOA stratum,
- 171 subjects in the 60-69 YOA stratum, and
- 114 subjects in the \geq 70 YOA stratum.

Blinding: open-label.

Table 3 Blinding of study epochs

Study Epochs	Blinding
Epoch 001	open

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

3. OBJECTIVES

3.1. Co-Primary objectives

To determine the vaccine response rate (VRR) to HZ/su (based on humoral immune response) one month after the second vaccine dose, when the first dose of HZ/su is co-administered with *Prevenar13* (Co-Ad group).

Criterion to be used:

The objective is met if the lower limit (LL) of the 95% CI of the VRR for anti-gE antibody concentrations in the Co-Ad group one month after the second vaccine dose is $\geq 60\%$.

If the above objective is met in the Co-Ad group, then the following objective will be evaluated:

To demonstrate non-inferiority of the humoral immune response to two doses of HZ/su at one month after the last vaccine dose, when the first dose of HZ/su is co-administered with *Prevenar13* (Co-Ad group) compared to when two doses of HZ/su are administered subsequent to *Prevenar13* (Control Group).

Criterion for non-inferiority:

One month after the last vaccine dose in each study group, the upper limit (UL) of the 95% confidence interval (CI) for the anti-gE antibodies Geometric Mean Concentration (GMC) ratio between the Control group and the Co-Ad group is <1.5.

If the above non-inferiority objective is met, then the following objective will be evaluated:

To demonstrate non-inferiority of the humoral immune response to *Prevenar13* at one month after the vaccine dose, when *Prevenar13* is co-administered with the first HZ/su dose (Co-Ad group) compared to when *Prevenar13* is administered separately from HZ/su (Control group), for the 13 serotypes included in *Prevenar13* analyzed sequentially.

Criterion for non-inferiority:

One month after the Prevenar13 vaccine dose in each study group, the UL of the 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group is <2.

For the co-primary objectives, fixed sequence testing which allows for full alpha propagation in pre-ordered hypotheses families will be used (see section 6.3.2.1).

3.2. Secondary objective

To evaluate the safety and reactogenicity following administration of HZ/su and *Prevenar13 vaccines*, up to one month post last vaccination and during the whole follow-up period, in the Control group and the Co-Ad group.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

4. ENDPOINTS

4.1. Primary endpoints

HZ/su immunogenicity:

- Vaccine response for anti-gE humoral immunogenicity, as determined by ELISA, in subjects from the Co-Ad group at one month post-dose 2, at Visit Month 3.
- Anti-gE antibody concentrations as determined by ELISA at one month postdose 2, at Visit Month 3 for the Co-Ad group and Visit Month 5 for the Control group.

Pneumococcal vaccine immunogenicity:

• Anti-pneumococcal antibody titers for the 13 following serotypes as determined by MOPA at one month post-dose at Visit Month 1: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

The criteria used to define the VRR is given in Section 11.1.2.

4.2. Secondary endpoints

Occurrence of solicited local and general symptoms:

- Occurrence, duration and intensity of each solicited local symptom within 7 days (Days 1 7) after each vaccination,
- Occurrence, duration, intensity and relationship to vaccination of each solicited general symptom within 7 days (Days 1 7) after each vaccination.

Occurrence of unsolicited AEs:

• Occurrence, intensity and relationship to vaccination of unsolicited AEs within 30 days (Days 1 - 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.

Occurrence of SAEs:

- Occurrence and relationship to vaccination of all SAEs from first vaccination at Day 1 up to 30 days post last vaccination.
- Occurrence and relationship to vaccination of all SAEs during the period starting after 30 days post last vaccination up to study end.

Occurrence of pIMDs:

- Occurrence and relationship to vaccination of any pIMDs from first vaccination at Day 1 up to 30 days post last vaccination.
- Occurrence of any pIMDs during the period starting after 30 days post last vaccination up to study end.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

5. ANALYSIS SETS

5.1. Definition

5.1.1. Exposed Set (ES)*

The Exposed set (ES) will include all subjects with at least one vaccine administration documented:

- The ES for analysis of solicited symptoms will include all subjects with at least one documented administered vaccine
- The ES for analysis of unsolicited AEs, SAEs and pIMDs will include all subjects with at least one vaccine administered.
- The ES for analysis of immunogenicity will include vaccinated subjects for whom immunogenicity data are available.

The ES analysis will be performed per treatment actually administered (at Dose 1).

5.1.2. Per-protocol set (PPS)* for analysis of immunogenicity

The Per-protocol set for analysis of immunogenicity will include all evaluable subjects:

- who meet all eligibility criteria,
- who comply with the procedures and intervals allowed for the analysis,
- who do not meet any of the criteria for elimination during the study,
- for whom data concerning immunogenicity endpoint measures are available.

^{*} Note that in order to align to ICH and cDISC terminology the Total Vaccinated Cohort and the Per- Protocol cohort have been renamed Exposed Set (ES) and Per-Protocol Set (PPS) respectively.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

The intervals allowed for the inclusion in the PPS for analysis of immunogenicity are defined as follow

	Group	Interval	Allowed interval for PPS analysis of immunogenicity
Interval	Co-Ad	HZ/su (Dose 1) – HZ/su (Dose 2)	49-83 Days
between vaccinations	Control	Prevenar13 (Dose 1) – HZ/su (Dose 2)	>= 60 days
	Control	HZ/su (Dose 2) – HZ/su (Dose 3)	49-83 Days
Interval between vaccination	Co-Ad	Prevenar13 (Dose 1) – Visit Month 1 for BS	28-48 Days
and blood sample taken	Co-Ad	HZ/su (Dose 2) – Visit Month 3 for BS	28-48 days
	Control	Prevenar13 (Dose 1) – Visit Month 1 for BS	28-48 Days
	Control	HZ/su (Dose 3)– Visit Month 5 for BS	28-48 days

BS= blood sampling taken

5.2. Criteria for eliminating data from Analysis Sets

Elimination codes are used to identify subjects to be eliminated from analysis. Detail is provided below for each set.

5.2.1. Elimination from Exposed Set (ES)

Code 1030 (Study vaccine not administered at all) and code 900 (invalid informed consent or fraud data) will be used for identifying subjects eliminated from ES

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

5.2.2. Elimination from Per-protocol analysis Set (PPS)

A subject will be excluded from the PPS analysis under the following conditions

Code	Condition under which the code is used
000	
900	Invalid informed consent or fraud data. Subjects excluded from all
	stat analysis Note: Subjects receiving a code 900 should not receive any other elimination
	codes.
1030	Study vaccine not administered AT ALL but subject number
	allocated
	Note: Subjects receiving a code 1030 should not receive any other elimination
1040*	codes
1040*	Administration of concomitant vaccine(s) forbidden in the protocol
	Comment :- Up to 30 days post last dose at Visit Month 3 for co-ad group and up
	to 30 days post last dose at Visit Month 5 for control group.
1050	Randomization failure (subject not randomized in the correct group)
	Comment: To check for manual randomisation, treatment not compatible with one
1070	assigned by SBIR
10/0	 Side, site or route of study vaccine administration wrong or unknown
	- Administration not according to protocol for reason
	specified by the investigator, other than side, site and route
	- Wrong replacement or study vaccine administered (not
	compatible with the vaccine regimen associated to the
	treatment number)
	- Administered study vaccine reported as being the correct
	one but is not compatible with the vaccine regimen
	associated to the treatment number.
1080	Vaccine has been administered (effective treatment number) despite
	a temperature deviation qualified by Status QA GMP NON Use
1090	Expired vaccine administered
1500	Wrong replacement or study vaccine administered (not compatible
	with the vaccine regimen associated to the treatment number).
2010	Protocol violation (inclusion/exclusion criteria)
2040*	Administration of any medication forbidden by the protocol
	Comment: - Up to 30 days post last dose at Visit Month 3 for co-ad group and up
	to 30 days post last dose at Visit Month 5 for control group
2050*	Underlying medical condition forbidden by the protocol
	Comment: - Up to 30 days post last dose at Visit Month 3 for co-ad group and up to 30
	days post last dose at Visit Month 5 for control group
2060*	Concomitant infection related to the vaccine which may influence
	immune response
	Comments that 20 January 1 1 1 1 1 1 2 C
	Comment: Up to 30 days post last dose at Visit Month 3 for co-ad group and up to 30 days post last dose at Visit Month 5 for control group
	20 mays post tust hose at 1 isti month of solution group

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

	Statistical Analysis
Code	Condition under which the code is used
2070*	Concomitant infection not related to the vaccine which may influence immune response
	Comment: Up to 30 days post last dose at Visit Month 3 for co-ad group and up to 30 days post last dose at Visit Month 5 for control group
2080	Subjects did not comply with vaccination schedule (dates of vaccination not corresponding to protocol intervals or unknown vaccination dates)
	Comments: Co-Ad group: DOSE 1 – DOSE 2
	Control group: DOSE 1 – DOSE 2
	DOSE 2 – DOSE 3
2090	Subjects did not comply with blood sample schedule (dates of BS not corresponding to adapted protocol intervals or unknown BS/vaccination dates)
	Comments: Co-Ad group: DOSE 1 – MONTH 1 BS
	DOSE 2 – MONTH 3 BS
	Control group: DOSE 1 – MONTH 1 BS
	DOSE 3 – MONTH 5 BS
2100	Serological results not available post-vaccination (including lost samples, blood sample not done, unable to test, absence of parallelism).
	Please specify the applicable rule:
	elimination code if ALL are missing
	Comment:
	Co-Ad group: Check for availability of anti-gE serological result at Month 3 and for pneumococcal serotype at Month 1
	Control group: Check for availability of anti-gE serological result at Month 5 and for pneumococcal serotype at Month 1
2120	Obvious incoherence or abnormality or error in data (incoherence between CRF and results, wrong labelling)
	Comment:
	Co-Ad group: Check for above condition on anti-gE serological result at Month 3 and on pneumococcal serotype at Month 1
	Control group: Check for above condition on anti-gE serological result at Month 5 and on pneumococcal serotype at Month 1
2500	Incomplete vaccination course.
	Comment: The subject should receive one dose of Prevenar 13 vaccine and 2 doses of Hz/su vaccine

BS = Blood sample

^{*} Attribution of these elimcodes are responsibility of CRDL following review of individual data listings

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

5.3. Important protocol deviation not leading to elimination from per-protocol analysis set

For information on important protocol deviation not leading to elimination from the PPS set, refer to the study protocol deviation and management plan (PDMP).

6. STATISTICAL ANALYSES

Note that standard data derivation rule and stat methods are described in annex 1 and will not be repeated below. All analyses will be presented by study phase when there are data for both active and follow up phases.

6.1. Demography

6.1.1. Analysis of demographics/baseline characteristics planned in the protocol

Demographic characteristics (age, sex, race and ethnicity) will be tabulated per treatment group.

The mean age (plus range and standard deviation [SD]) of the enrolled subjects, as a whole, and per treatment group will be calculated. The distribution of subjects enrolled among the study sites will be tabulated as a whole and per treatment group.

The same tabulations might be performed by age strata (50-59, 60-69 and \geq 70 YOA) if deemed necessary.

6.1.2. Additional considerations

- Following additional tables will be generated: -
 - The number of subjects enrolled into the study as well as the number of subjects excluded from PPS analyses will be tabulated.
 - Withdrawal status will be summarized by group. The numbers of withdrawn subjects will be tabulated according to the reason for withdrawal
- The following table will be performed for CTRS:
 - Percentage of Enrolled subjects by country will be tabulated by group,
 - Percentage of Enrolled subjects in the following age categories ≤64, 65-84, ≥85 will be tabulated by group.
- For computation of age, following rule need to be considered:-
 - Age will be calculated as the number of years between the date of birth and the date of first vaccination.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

- To ensure that the collection of date of birth will not jeopardise the privacy of Personally Identifiable Information (PII), only a partial date of birth (MMYYYY) will be collected.
- Therefore, the 15th of the month will be used to replace the missing date.
- In case the month is missing, the date will be replaced by the June 30th of the year. Analysis of demography will be based on exposed set.

6.2. Exposure

6.2.1. Analysis of exposure planned in the protocol

The number of doses administered will be tabulated.

6.2.2. Additional considerations

None

6.3. Immunogenicity

6.3.1. Analysis of immunogenicity planned in the protocol

The primary analysis will be based on the per-protocol set for analysis of immunogenicity. A second analysis based on the Exposed set will be performed to complement the per-protocol analysis (see section 9 for changes in the planned analysis).

Immunogenicity analyses for confirmatory objectives will be performed by age stratum (50-59, 60-69 and \geq 70 YOA) on PPS, if the number of subjects enrolled is sufficient in each stratum.

6.3.1.1. Within group assessment

The following parameters will be tabulated by vaccine group at each time point when a blood sample result is available:

- Seropositivity with exact 95% CI for all antigens
- GMC/GMT with 95% CI for all antigens
- VRR with exact 95% CI for anti-gE
- Mean Geometric Increase (MGI) with exact 95% CI for anti-gE
- Descriptive statistics (N, mean, SD, min, Q1, median, Q3, max) of Mean Geometric Increase (MGI) for anti-gE
- Distribution of the fold increase i.e. Percentage of subjects with a more than X-fold (e.g. >2, >4, >6, -fold) increase will be tabulated for anti-gE per group with 95%CI.
- Antibody titre/concentration will be displayed using reverse cumulative curves.

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

6.3.1.2. Between group assessment

Following between group comparison will be performed: -

- For the second primary objective for anti-gE, at one month post-dose 2 of HZ/su vaccine:
 - The 95% CI of the group GMCs ratio (Control divided by Co-Ad) will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.
- For third primary objective for each vaccine pneumococcal serotype (according to the pre-specified order in the protocol), one month post-dose of pneumococcal vaccine:
 - The 95% CI of the group MOPA GMT ratios (Control divided by Co-Ad) will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

6.3.2. Additional considerations

Following additional points need to be considered for immunogenicity analysis:-

- Immunogenicity descriptive analyses will be performed by age stratum (50-59, 60-69 and ≥ 70 YOA), if the number of subjects enrolled is sufficient in each stratum.
- Two-sided 95% confidence intervals (CIs) for Seropositivity and VRR will be computed by Clopper-Pearson method [Clopper, 1934]. The differences in percentages and the associated two-sided 95% between the groups CIs for the difference will be constructed using the method of Miettinen and Nurminen [Robert, 1998].
- The two-sided 95% CI for the mean of log-transformed titre/concentration will be first obtained assuming that log-transformed values were normally distributed with unknown variance. The 95% CI for the GMTs/GMCs/MGIs will be then obtained by exponential-transformation of the 95% CI for the mean of log-transformed titre/concentration.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

6.3.2.1. Statistical considerations for confirmatory objectives

For the multiplicity adjustment, all hypotheses have been ranked into three families and one sub-family according to the following power of test:

Table 4 Power to demonstrate VRR objective and non-inferiority of the immunogenicity of HZ/su and Prevenar13 co-administered compared to Control group

Family 1: HZ/su: VVR*(1-sided test with alpha = 2.5%)								
Endpoint	Threshold	VR assumed	Total β	Power				
VRR in Co-Ad	0.60	95%	0.001%	99.99%				
group								
Family 2: HZ/su: non-in	feriority* (1-sided test	with alpha = 2.5%) N=410					
Endpoint	Standard deviation	δ	Total β	Power				
Anti-gE GMC ratio	0.35	1.5	0.001 %	99.99 %				
Family 3: Prevenar13: Non-inferiority* (1-sided test with alpha = 2.5%) N=410								
Endpoint (13 vaccine								
pneumococcal	Standard deviation	δ	Total β	Power				
serotypes)								
3 GMT ratio	0.660	2	0.001%	99.99%				
19A GMT ratio	0.644	2	0.001%	99.99%				
1 GMT ratio	0.798	2	0.029%	99.97%				
18C GMT ratio	0.891	2	0.203%	99.80%				
4 GMT ratio	0.906	2	0.260%	99.74%				
6A GMT ratio	0.919	2	0.320%	99.68%				
5 GMT ratio	0.931	2	0.383%	99.62%				
19F GMT ratio	0.971	2	0.664%	99.33%				
6B GMT ratio	0.995	2	0.891%	99.11%				
7F GMT ratio	1.014	2	1.107%	98.89%				
9V GMT ratio	1.021	2	1.194%	98.81%				
14 GMT ratio	1.045	2	1.530%	98.47%				
23F GMT ratio	1.094	2	2.398%	97.60%				
Global β to show non-infe	eriority		~9%					
Global power				~91%				

VRR: vaccine response rate; gE: Varicella Zoster Virus glycoprotein E; GMT: geometric mean titer; GMC: geometric mean concentration.

For each pneumococcal serotype: non-inferiority limit = 0.301 (=log10(2)), variability for each of the 13 vaccine pneumococcal serotype taken from the EMA assessment report for *Prevenar13* and multiplied by 1.1, power under equal GMT.

Fixed sequence testing which allows for full alpha propagation in pre-ordered hypotheses families will be applied in the following manner:

Family 1:

In the Co-Ad group, for anti-gE, at one month post-dose 2 of HZ/su vaccine:

- The VRR and 95% CI will be computed.

The objective is met if the LL of the 95% CI is \geq 60%.

^{*} Pass 12, alpha = 2.5%, for VRR: Exact test, for non-inferiority one-sided equivalence of means. For gE: non-inferiority limit = 0.176 (=log10(1.5)), power under equal GMC

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Family 2:

For anti-gE, at one month post-dose 2 of HZ/su vaccine:

- The 95% CI of the group GMCs ratio will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

In terms of concentrations, the Co-Ad group will be considered non-inferior to the Control group if the UL of the 95% CI for the GMC ratio of the Control group to the Co-Ad group is <1.5.

Family 3:

For each vaccine pneumococcal serotype (according to the pre specified order), one month post-dose of pneumococcal vaccine:

- The 95% CI of the group MOPA GMT ratios will be computed using an analysis of covariance (ANCOVA) model on the log10 transformation of the concentrations. The pre-vaccination log-transformed antibody concentrations will be included as continuous covariate and the vaccine group and age strata as fixed effects in the model.

In terms of MOPA GMTs, the Co-Ad group will be considered non-inferior to the Control group if the UL of the 95% CI for the MOPA GMTs ratio of the Control group to the Co-Ad group is <2 for each of the 13 vaccine serotypes.

In the ANCOVA models Adjusted Least Squares (LS) means and difference of LS means between the groups will be calculated together with the 2-sided 95% CIs and backtransformed to the original units to provide GMCs and GM ratios.

6.4. Analysis of safety

6.4.1. Analysis of safety planned in the protocol

The analysis for safety will be based on the Exposed set. All safety analyses may also be performed by age strata (50-59, 60-69 and \geq 70 YOA), if the number of subjects enrolled is sufficient in each stratum

When appropriate, tabulations will be presented overall and by time of occurrence relative to last vaccination (e.g. using windows such as Days 1 to 7, Days 1 to 30 and more than 30 days post-vaccination).

The results for the analysis of safety will be tabulated as follows:

• The number and percentage of subjects with at least one local solicited AE, with at least one general solicited AE, and with any solicited AE during the 7-day follow-up

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

period with exact 95% CIs after each vaccine dose and overall by vaccination group will be provided;

- The percentage of subjects reporting each individual solicited local and general AE during the solicited 7-day follow-up period will be tabulated with exact 95% CI;
- For all solicited symptoms, the same tabulation will be performed for grade 3 solicited AEs and for solicited general AEs with relationship to vaccination;
- Number of days with each individual solicited local and general AE during the solicited 7-day follow-up period;
- The proportion of subjects with at least one report of unsolicited AE classified by the MedDRA preferred term and reported up to 30 days after each vaccination will be tabulated with exact 95% CI;
- The same tabulation will be performed for grade 3 unsolicited AEs and for unsolicited AEs with a relationship to vaccination. The proportion of AEs resulting in a medically attended visit will also be tabulated;
- Total number/percentages of doses (per dose and overall) followed by AEs will be tabulated;
- Number of subjects with pIMDs will be tabulated;
- SAEs, including fatalities and withdrawal due to AE(s) will be described in detail.

6.4.2. Additional considerations

- Following additional tables will be generated:-
 - The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 7-day follow-up period will be tabulated with exact 95% confidence interval (CI) after each vaccine dose and overall. The same computations will be done for Grade 3 AEs, for any AEs considered related to vaccination and for any Grade 3 AEs considered related to vaccination.
 - The percentage of subjects with at least one local solicited AE, with at least one general solicited AE and with any AE will also be done for Grade 3 AEs, for any AEs considered related to vaccination and for any Grade 3 AEs considered related to vaccination.
 - Summary of temperature value by half degree increment reported during the 7-day (Days 1-7) post-vaccination following each dose.
 - Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose
 - For fever, the number and percentage of subjects reporting fever by half degree (°C) cumulative increments during the 7-day follow-up period (Day 1-7) will be tabulated for each group after each vaccine dose and overall. Similar tabulations will be performed for Grade 3 (> 39.0°C) causally related fever.
 - List of suspected HZ cases identified during the study will be presented

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

- The number and percentage of subjects starting a concomitant medication during the 30-day post-vaccination period by dose and overall will be presented
- The duration of solicited local symptoms (in days), not limited to the 7-day post-vaccination period, following each dose and overall/dose. The same tabulations after Prevenar13 and HZ/su vaccinations.
- The duration of solicited general symptoms (in days), not limited to the 7-day post-vaccination period, following each dose and overall/dose.
- Solicited local symptoms ongoing beyond the 7-day (Days 1-7) post-vaccination period, following each dose and overall/dose. The same tabulations after Prevenar13 and HZ/su vaccinations.
- Solicited general symptoms ongoing beyond the 7-day (Days 1-7) post-vaccination period, following each dose and overall/dose

6.4.2.1. Combined Solicited and Unsolicited Adverse Events

A summary of subjects with all combined solicited (regardless of their duration) and unsolicited adverse events will be provided. Solicited adverse events will be coded by MedDRA as per the following codes

Solicited symptom	Lower level term name	Corresponding Lower level term code
Pain	Injection site pain	10022086
Redness	Redness at injection site	10022098
Swelling	Swelling at injection site	10053425
Fatigue	Fatigue	10016256
Gastrointestinal symptoms	Gastrointestinal disorder	10017944
Headache	Headache	10019211
Myalgia	Myalgia	10028411
Shivering	Shivering	10040558
Temperature	Fever	10016558

For clintrial.gov and EudraCT posting purposes, a summary of combined solicited and unsolicited non-serious adverse events will be produced by System Organ Class and preferred terms and according to occurrence of each event.

7. ANALYSIS INTERPRETATION

All co-primary objectives will be evaluated using a one-sided Type I error of 2.5% (as already justified by fixed sequential testing procedure, no alpha adjustment needed). The trial will be considered conclusive if all co-primary objectives criteria are met.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

8. CONDUCT OF ANALYSES

8.1. Sequence of analyses

The analysis will be performed in the following steps:

- Analysis of the co-primary immunogenicity objectives will be performed at the end of the active phase on data as clean as possible. A confirmatory re-analysis will be done at the end of the study using the final database. In addition, analyses of secondary objectives will also be performed at the end of the active phase.
- Analyses on safety data will be performed when all data up to study end (i.e., phone contact at Month 14 for Co-Ad group and phone contact at Month 16 for Control group) will be available and cleaned.

An integrated clinical study report containing all data will be written and made available to the investigators.

Table 5 Analysis and disclosure plan for the planned analysis

Description	Analysis ID	Disclosure Purpose (CTRS=public posting, SR=study report, internal)	Dry run review needed (Y/N)	Study Headline Summary (SHS)requiring expedited communication to upper management (Yes/No)	Reference for TFL
End of Active phase	E1_02	CTRS	Y	Υ	See in TFL TOC where POSTING=YES
Final analysis	E1_01	CTRS CSR	Y	Y	All tables from Annex 2 of the SAP13 APR2018

8.2. Statistical considerations for interim analyses

Not applicable

9. CHANGES FROM PLANNED ANALYSES

In protocol, it was specified that the second analysis for immunogenicity on Exposed set will be performed only if, in any study group, the percentage of enrolled subjects with serological results excluded from the per-protocol set for analysis of immunogenicity is 5% or more. At Paul Ehrlich Institute, Germany (PEI) request, a ES analysis will be performed to complement the per-protocol analysis.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

10. LIST OF FINAL REPORT TABLES, LISTINGS AND FIGURES

The TFL TOC provides the list of tables/listings and figures to be included in the study report.

The following group names will be used in the TFLs, in line with the T-domains:

Group order in tables	Group label in tables	Group definition for footnote
1	Co-Ad	Dose 1 : Prevenar 13 + HZ/su, Dose 2: HZ/su
2	Control	Dose 1 : Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

The following sub-group will be used in the TFL, in line with the T-domain

Group Definitions to be used for the sub-group analysis by age (Analysis will be included in the clinical report)

Sub-group order in tables	Sub-group label in tables	Sub-group definition for footnote
1	50-59YOA	Subjects aged 50-59 years
2	60-69YOA	Subjects aged 60-69 years
3	≥70YOA	Subjects aged 70 years and over

YOA = Year of age

Please note that for table presentation in the sub-group analysis, the sequence maintained has to be each treatment group within each age sub-group.

11. ANNEX 1 STANDARD DATA DERIVATION RULE AND STATISTICAL METHODS

11.1. Standard data derivation

11.1.1. Dose number

The study dose number is defined in reference to the number of study visits at which vaccination occurred. More specifically dose 1 refers to all vaccines administered at the first vaccination visit while dose 2 corresponds to all vaccinations administered at the second vaccination visit even if this is the first time a product is administered to the subject.

Associated dose: the associated dose for an event (AE, medication, vaccination) is the most recent study dose given before an event. In case the event takes place on the day a study dose is given, the associated dose will be that of the study dose, even if the event

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

actually took place before vaccination. For instance, if an adverse event begins on the day of the study vaccination but prior to administration of the vaccine, it will be assigned to this dose. In case a study dose is not administered and an event occurs after the subsequent study dose (e.g. 2nd study dose), the associated dose of the event will be study dose associated to the subsequent study dose (e.g. dose 2).

The number of doses for a product is the number of times the product was administered to a subject.

The incidence per dose is the number of visits with vaccine administered at which an event was reported among all visits with vaccine administered.

11.1.2. Immunogenicity

- For a given subject and given immunogenicity measurement, missing or non-evaluable measurements will not be replaced. Therefore, an analysis will exclude subjects with missing or non-evaluable measurements.
- A seronegative subject is a subject whose antibodies concentration/titer is below the cut-off value (cut-off value is defined by the laboratory prior to the analysis).
- A seropositive subject is a subject whose antibodies concentration/titer is greater than or equal to the assay cut-off value.
- The seropositivity rate is defined as the percentage of seropositive subjects.
- The VRR for anti-gE is defined as the percentage of subjects who have at least:
 - a 4-fold increase in the anti-gE antibodies concentration as compared to the prevaccination anti-gE antibodies concentration, for subjects who are seropositive at baseline, or,
 - a 4-fold increase in the anti-gE antibodies concentration as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who are seronegative at baseline.
- The GMC/GMT calculations are performed by taking the anti-log of the mean of the log concentration transformations. Antibody concentrations below the cut-off of the assay will be given an arbitrary value equal to half the cut-off for the purpose of GMC/GMT calculation.
- All CI computed will be two-sided 95% CI.

204487 | Statistical Analysis Plan 13 Apr 2018 | TMF-605547 | 2.0

CONFIDENTIAL

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

11.1.3. Safety

For a given subject and the analysis of solicited symptoms during the 7 day follow-up period after vaccination, missing or non-evaluable measurements will not be replaced. Therefore, the analysis of the solicited symptoms based on the ES will include only vaccinated subjects with documented safety data (i.e., symptom screen completed). More specifically the following rules will be used:

- Subjects who documented the absence of a solicited symptom after one dose will be considered not having that symptom after that dose.
- Subjects who documented the presence of a solicited symptom and fully or
 partially recorded daily measurement over the solicited period will be included
 in the summaries at that dose and classified according to their maximum
 observed daily recording over the solicited period.
- Subjects who documented the presence of a solicited symptom after one dose without having recorded any daily measurement will be assigned to the lowest intensity category at that dose (i.e., 38°C for fever or grade 1 for other symptoms). The subject will only be presented in the subject with symptom experienced and not in specific grade information.
- Doses without symptom sheets documented will be excluded.

For analysis of unsolicited adverse events, such as serious adverse events or adverse events by primary MedDRA term, and for the analysis of concomitant medications, all vaccinated subjects will be considered. Subjects who did not report the event or the concomitant medication will be considered as subjects without the event or the concomitant medication respectively.

Associated dose: The associated dose for an event (e.g., AE, medication, vaccination,...) is the study dose given before an event. In case the event takes place on a day a study dose is given, the associated dose will be that of the study dose even if the event actually took place before. For instance, for a conc. medication started on the day of study dose 2 but before dose 2 administrations, the associated dose will be dose 2

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

The way the percentage of subjects will be derived will depend on the event analysed (see the following table for details). As a result, the denominator (N) will differ from one table to another.

Event	N used for deriving %	Terminology used in the tables for N
Concomitant	All vaccinated subjects	Number of subjects with at least
medication		one administered dose
Solicited local	All vaccinated subjects with	For each dose and overall/subject:
symptom	at least one solicited general	N= number of subjects with at
	symptom documented as	least one documented dose
	either present or absent	For overall/dose:
		N= number of documented doses
Solicited	All vaccinated subjects with	For each dose and overall/subject:
general	at least one solicited local	N= number of subjects with at
symptom	symptom documented as	least one documented dose
	either present or absent	For overall/dose:
		N= number of documented doses
Unsolicited	All vaccinated subjects	Number of subjects with at least
symptom from		one administered dose
day 0 to day X		
SAE	All vaccinated subjects	Number of subjects with at least
		one administered dose

- The maximum intensity of local injection site redness and swelling will be scored at GSK Biologicals as follows:
 - 0:<20 mm
 - $1 : \ge 20 \text{ mm to} \le 50 \text{ mm diameter}$
 - $2:>50 \text{ mm to} \le 100 \text{ mm diameter}$
 - 3 : > 100 mm diameter

Fever is defined as temperature \geq 38.0 C / 100.4 F for oral, axillary, tympanic or rectal route. The preferred route for recording temperature in this study will be oral. For the analysis, temperatures will be coded as follows:

Grade	Temperature (oral, axillary, tympanic or rectal route)
0	< 38°C
1	≥ 38°C - ≤ 38.5°C
2	> 38.5°C - ≤ 39°C
3	> 39°C

Conversion of temperature to °C -

The following conversion rule is used for the conversion of temperature to °C

- Temperature in °Celsius = ((Temperature in °Fahrenheit -32) *5)/9

The result is rounded to 1 decimal digit.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

11.2. Statistical Method References

Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. *Biometrika*. 1934; 26:404-413.

Robert G. Newcombe, interval estimation for the difference between independent proportions: comparison of eleven methods, *Statist Med.* 1998; 17, 873-890.

11.3. Number of decimals displayed:

The following decimal description from the decision rules will be used for the demography, immunogenicity and safety/reactogenicity.

Display Table	Parameters	Number of decimal digits
Demographic characteristics	Mean, median age	1
Demographic characteristics	SD (age)	1
Immunogenicity	Ratio of GMT/C	2
All summaries	% of count, including LL & UL of CI	1
All summaries	% of difference, including LL & UL of CI	2

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

12. ANNEX 2: STUDY SPECIFIC MOCK TFL

The study specific mocks are annexed to this SAP in a separate document.

The data display, title and footnote are for illustration purpose and will be adapted to the study specificity as indicated in the TFL TOC. Note that there may be few changes between the study specific SAP mock TFL and the final TFLs as editorial/minor changes do not require a SAP amendment

12.1. List of individual data listing

Following individual data listing will be generated

Appendix Table I.A - Elimination codes

Appendix Table I.B – Demography

Appendix Table IBii - Physical examination/vital signs

Appendix Table I.Ci - Dates of birth, Informed consent, Vaccination and blood sampling, Contact

Appendix Table I.Cii - Reason for visit not done

Appendix Table I.D - General medical history - Physical examination

Appendix Table I.Ei – Study Conclusion

Appendix Table I.F – Notes (this appendix is provided for info only and should not be used for the clinical report)

Appendix Table I.G / I.H - Vaccination procedure

Appendix Table I.I - Reason for not administration of vaccine

Appendix Table I.J - Reason for non-eligibility

Appendix Table I.Ki – Previous history of vaccination

Appendix Table I.Kii – Previous history of disease

Appendix Table II.Ai - Solicited local adverse events

Appendix Table II.B - Solicited general adverse events

Appendix Table II.Ci - Unsolicited adverse events within (30) days post-vaccination

Appendix Table II.Cii - Unsolicited adverse events after (30) days post-vaccination

Appendix Table II.Di - Concomitant medications

Appendix Table II.Dii - Concomitant vaccinations

Appendix Table III.A – Immunogenicity

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

12.2. Template of Tables and Figures

Template 1 Number of subjects by country and center <Exposed Set>

		<pre><each group=""> N=XXXX N=XXXX</each></pre>		> Total N=XXXX			
Country	Center	n	%	n	%	n	%
<each country=""></each>	<each center=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X
	All	XXX	XX.X	XXX	XX.X	XXX	XX.X

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

Center = GSK Biologicals assigned center number

Template 2 Number of enrolled subjects by country

	<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>			tal XXXX
Country	n	%	n	%	n	%
<each country=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

Template 3 Number of enrolled subjects by age category

	<each group=""> N=XXXX</each>		<each group=""> N=XXXX</each>		Total N=XXXX	
Age category	n	%	n	%	n	%
Adults [18-64 years]	XXX	XX.X	XXX	XX.X	XXX	XX.X
From 65-84 years						
85 years and over						

<each group>:

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

N = number of enrolled subjects

n = number of enrolled subjects included in each group or in total for a given age category or for all age categories

 $% = n/N \times 100$

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 4 Number of subjects by country and age category <Exposed Set>

			<each group=""> N=XXXX</each>				Total N=XXXX	
Country	Age category	n	%	n	%	n	%	
<each country=""></each>	50-59YOA	XXX	XX.X	XXX	XX.X	XXX	XX.X	
	60-69YOA							
	≥70YOA							
	All	XXX	XX.X	XXX	XX.X	XXX	XX.X	

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

50-59YOA = Subjects aged 50-59 years

60-69YOA = Subjects aged 60-69 years

≥70YOA = Subjects aged 70 years and over

n = number of subjects in a given center or country

N = total number of subjects

 $% = n/N \times 100$

Template 5 Number of subjects vaccinated, completed and withdrawn with reason for withdrawal – <end of active phase, study end> <Exposed set>

	<each group=""> N=XXXX</each>	<each group=""> N=XXXX</each>	Total N=XXXX
	n	n	n
Number of subjects vaccinated	XXX	XXX	XXX
End of study status			
[EACH CATEGORY]	XXX	XXX	XXX
Reasons for withdrawal:			
[REASONS]	XXX	XXX	XXX

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

Vaccinated = number of subjects who were vaccinated in the study

Completed = number of subjects who completed last study visit

Withdrawn = number of subjects who did not come for the last study visit

Template 6 Visit attendance < Exposed set>

		<each g<br="">N=X</each>	
Visit	Status	n	%
INFORMED CONSENT	Completed		
RANDOMIZATION	Completed		
<each visit=""></each>	Attended		
	Not attended yet		
	Permanent discontinuation prior to this visit		
	Not attended		
CONCLUSION	Completed		

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

N = Number of subjects in each group or in total

Conclusion = date of last visit or withdrawal

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 7 List of subjects withdrawn from vaccination with reason for withdrawal

Group	Sub. number	Dose	Decision	Reason	comment
Co-Ad					
Control					

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

Template 8 Number of subjects enrolled into the study as well as the number excluded from PPS analyses of immunogenicity with reasons for exclusion

	Total			-	each roup]
Title	n	S	%	n	s
Total enrolled Set					
Subjects eliminated from stat analyses (code 900)					
Study vaccine dose not administrated but subject					
number allocated (code 1030)					
Exposed Set					
<each elimination="" for="" from="" immuno<="" pps="" reason="" td=""><td></td><td></td><td></td><td></td><td></td></each>					
(code)>					
PPS for immunogenicity					

Co Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

Note: Subjects may have more than one elimination code assigned

n = number of subjects with the elimination code assigned excluding subjects who have been assigned a lower elimination code number

s = number of subjects with the elimination code assigned

% = percentage of subjects in the considered PPS relative to Total Exposed Set

Template 9 Percentage of subjects with serological results who were eliminated from PPS for immunogenicity

	[each gro	oup]
Number of subjects in Total Exposed Set with serological results available		
Number of subjects with serological results eliminated from PPS for immunogenicity		
Percentage of subjects with serological results eliminated from PPS for immunogenicity		

Co_Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 10 Deviations from specifications for age and intervals between study visits for Co-Ad group <Exposed Set, PPS for immunogenicity>

		Age	Dose:1-PI (M1)		Dose:1- Dose:2	Dose:2-PII (M3)		Dose:2- PHC (M14)	
Group		Protocol	Protocol	Protocol	Protocol	Protocol	Adapted	Protocol	
		from ≥ 50 years	from 30 to 42 days	from 28 to 48 days	from 49 to 83 days	from 30 to 48 days	from 28 to 48 days	from 335 to 395 days	
Co-Ad	N								
	n								
	%								
	range								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Adapted = interval used for defining PPS for immunogenicity

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PI (M1) = Blood sample at Month 1, post-vaccination Dose 1

PII (M3) = Blood sample at Month 3, post-vaccination Dose 2

PHC (M14) = Phone Contact MONTH 14

Note that the exact age is unknown since only the month and year of birthdate are recorded. Accordingly the age estimated using the middle of the month may be inexact by one month

Template 11 Deviations from specifications for age and intervals between study visits - for Control group <Exposed Set, PPS for immunogenicity>

		Age	Dose:1-PI(M1)		Dose:1-Dose:2		Dose:2- Dose:3	Dose:3-PIII(M5)		Dose:3- PHONE CONT M16
Group		Protocol	Protocol	Adapted	Protocol	Adapted	Protocol	Protocol	Adapted	Protocol
_		from ≥ 50	from 30 to	from 28 to	from 60 to	≥ 60	from 49 to	from 30 to	from 28 to	from 335 to
		years	42 days	48 days	83 days	days	83 days	48 days	48 days	395 days
Control	N			•	·	Ĭ	•		•	
	n									
	%									
	range									

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adapted = interval used for defining the ATP cohorts for immunogenicity

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PI(M1) = Blood sample at Month 1, post-vaccination Dose 1

PIII(M5) = Blood sample at Month 5, post-vaccination Dose 3

PHC (M16) = Phone Contact Month 16

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 12 Summary of demographic characteristics <Exposed Set, PPS for immunogenicity>

	<each group=""> N=XXXX</each>			<each group=""> N=XXXX</each>		otal XXXX
	Value or n	%	Value or n	%	Value or n	%
Age in Years at <timepoint></timepoint>						
N with data	XXX		XXX		XXX	
Mean	XXX.X		XXX.X		XXX.X	
SD	XXX.X		XXX.X		XXX.X	
Median	XXX.X		XXX.X		XXX.X	
Minimum	XXX		xxx		XXX	
Maximum	XXX		xxx		XXX	
Gender						
<each gender=""></each>	XXX	XX.X	xxx	XX.X	XXX	XX.X
	XXX	XX.X	xxx	XX.X	XXX	XX.X
Ethnicity						
<each ethnicity=""></each>	XXX	XX.X	xxx	XX.X	XXX	XX.X
•••	xxx	XX.X	xxx	XX.X	XXX	XX.X
Geographic Ancestry						
<each ancestry="" geographic=""></each>	XXX	XX.X	xxx	XX.X	XXX	XX.X
	XXX	XX.X	xxx	XX.X	XXX	XX.X
Age category						
<each age="" category=""></each>	XXX	XX.X	XXX	XX.X	XXX	XX.X
Country						
<each country=""></each>	XXX	XX.X	xxx	XX.X	XXX	XX.X
	XXX	XX.X	XXX	XX.X	xxx	XX.X

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = total number of subjects

n/% = number / percentage of subjects in a given category

Value = value of the considered parameter

N with data = number of subjects with documentation of the corresponding data

SD = standard deviation

Template 13 Minimum and maximum activity dates <Exposed Set>

Group	Activity number	Activity Description	Minimum date	Maximum date
Co-Ad	10	VISIT DAY 1		
	20	VISIT MONTH 1		
	30	VISIT MONTH 2		
	40	VISIT MONTH 3		
	70	PHONE CONTACT MONTH 14		
Control	10	VISIT DAY 1		
	20	VISIT MONTH 1		
	30	VISIT MONTH 2		
	50	VISIT MONTH 4		
	60	VISIT MONTH 5		
	80	PHONE CONTACT MONTH 16		

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 14 Study Population < Exposed Set>

	<each group=""> N=XXXX</each>	<each group=""> N=XXXX</each>	Total N=XXXX
Number of subjects			
Planned, N	xxx	XXX	XXX
Randomised, N <cohort name=""></cohort>	XXX	XXX	XXX
Completed, n (%)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<unknown></unknown>	XXX	XXX	XXX
Demographics			
N <cohort name=""></cohort>	XXX	XXX	XXX
Females:Males	XXX:XXX	XXX:XXX	XXX:XXX
Mean Age, <unit> (SD)</unit>	xxx.x (xxx.x)	xxx.x (xxx.x)	xxx.x (xxx.x)
Median Age, <unit> (minimum, maximum)</unit>	xxx (xxx,xxx)	xxx (xxx,xxx)	xxx (xxx,xxx)
<most category="" frequent="" of="" race=""></most>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<second category="" frequent="" most="" of="" race=""></second>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)
<third category="" frequent="" most="" of="" race=""></third>	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Total number of subjects

SD = Standard deviation

Template 15 Exposure to study vaccines <Exposed Set>

	•	<each group=""> N=XXXX n %</each>		group>	Total N=XXXX	
Number of subjects receiving	n			n %		%
Exactly 1 Dose						
Exactly 2 Doses						
Exactly 3 Doses						
At least 1 Dose						
Total number of doses administered during the study						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects in each group or in total included in the considered cohort

n = number of subjects/doses in the given category

% = percentage of subjects in the given category

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 16 Compliance in completing solicited symptoms information <Exposed Set>

			<each gr<="" th=""><th>oup></th><th></th><th><each groเ<="" th=""><th>ıb></th></each></th></each>	oup>		<each groเ<="" th=""><th>ıb></th></each>	ıb>
DOSE	Symptom information	N	n	Compliance (%)	N	n	Compliance (%)
DOSE <each dose="" number=""></each>	General SS						
	Local SS						
TOTAL	General SS Local SS						

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N=Number of administered doses

n = number of doses with SS returned

General SS = Symptom screens used for the collection of general solicited AEs

Local SS = Symptom screens used for the collection of local solicited AEs

Compliance (%) = $(n / N) \times 100$

Template 17 Incidence and nature of <grade 3, related, grade 3 related, > symptoms (<unsolicited and solicited, solicited only>) reported <during the 7-day (Days 1-7), beyond the 7-day (Days 1-7)> post-vaccination period following each dose and overall

		<e< th=""><th>Ea</th><th>ch</th><th>gro</th><th>up></th><th><₽</th><th>a</th><th>ch</th><th>gro</th><th>up></th></e<>	Ea	ch	gro	up>	<₽	a	ch	gro	up>
						6 CI					6 CI
Dose	Symptoms	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Any symptom										
	General symptoms										
	Local symptoms										
Dose 2	Any symptom										
	General symptoms										
	Local symptoms										
Dose 3	Any symptom										
	General symptoms										
	Local symptoms										
Overall/dose	Any symptom										
	General symptoms										
	Local symptoms										
Overall/subject	Any symptom										
	General symptoms										
	Local symptoms										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects presenting at least one type of symptom for overall/dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 18 Incidence of solicited local symptoms reported during the 7-day (Days 1-7) post-vaccination period by study vaccine following each dose and overall <Exposed Set>

						Co-A	رم.			(Contr	ol .	
							95%	6 CI				95%	6 CI
Dose	Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Pain	HZ/su	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
		Prevenar13	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
	Redness (mm)	HZ/su	All										
	,		>50										
			>100										
			Medical advice										
		Prevenar 13	All										
			>50										
			>100										
			Medical advice										
	Swelling (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar 13	All										
			>50										
			>100										
			Medical advice										
Dose 2													
Dose 3													
Overall/Dose													
Overall/Subject													
	Provenar 13± H7	lou Doso 2: UZ	lou		1	1	1	1	l	1	l	1	1

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the type of symptom at least once following the corresponding dose For Overall/dose:

N = number of documented dose

n/% = number/percentage of doses followed by at least one type of symptom

For Overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the type of symptom at least once

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 19 Incidence of solicited general symptoms reported during the 7-day (Days 1-7) post-vaccination period following each dose and overall <Exposed Set>

				•	<each gr<="" th=""><th colspan="3">roup></th></each>	roup>		
							5 % CI	
Dose	Symptom	Type	N	n	%	LL	UL	
Dose 1	Fatigue	All						
		Grade 3						
		Related						
		Grade 3*Related						
		Medical advice						
	Gastrointestinal symptoms	All						
		Grade 3						
		Related						
		Grade 3*Related						
		Medical advice						
	Haeadache	All						
		Grade 3						
		Related						
		Grade 3*Related						
		Medical advice						
	Myalgia	All						
		Grade 3						
		Related						
		Grade 3*Related						
		Medical advice						
	Shivering	All						
		Grade 3						
		Related						
		Grade 3*Related						
		Medical advice						
	Fever (Oral) (°C)	All (≥38.0)						
		>38.0						
		>38.5						
		>39.0						
		>39.5						
		>40.0						
		Related						
		>39.0*Related						
		Medical advice						
Dose 2								
Dose 3								
Overall/Dose								
Overall/Subject								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the symptom at least once following the corresponding dose For Overall/dose:

N = number of documented dose

n/% = number/percentage of doses followed by at least one type of symptom

For Overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the type of symptom at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

Template 20 Summary of temperature value by half degree increment reported during the 7-day (Days 1-7) post-vaccination following each dose <Exposed Set>

					Cc	-Ad			(Co	ntro	l
							% CI					% CI
Dose	Symptom	Type	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Temperature/(*) (°C)	All										
		≥35.0										
		>35.5										
		>36.0										
		>36.5										
		>37.0										
		>37.5										
		>38.0										
		>38.5										
		>39.0										
		>39.5										
		>40.0										
Dose 2	Temperature/(*) (°C)	All										
		≥35.0										
		>35.5										
		>36.0										
		>36.5										
		>37.0										
		>37.5										
		>38.0										
		>38.5										
		>39.0										
		>39.5										
		>40.0										
Dose 3	Dogg 1: Drovener 12											

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with at least one documented dose

 $\ensuremath{\text{n}}\xspace\%$ = number/percentage of subjects reporting the symptom at least once

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

*=Temperature is defined on oral, axillary or tympanic

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 21 Percentage of subjects reporting the occurrence of <grade 3> unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination, with medically attended visit>, within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

			ach	gro	oup	
						5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n'	'n	%	LL	UL
At least one symptom						
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)					
	Teething (10043183)					
	Vomiting (10047700)					
General disorders and administration site conditions (10018065)	Pyrexia (10037660)					
Immune system disorders (10021428)	Seasonal allergy (10048908)					
Infections and infestations (10021881)	Conjunctivitis (10010741)					
	Otitis media (10033078)					
	Paronychia (10034016)					
	Tonsillitis (10044008)					
	Tonsillitis streptococcal (10044013)					
	Viral upper respiratory tract infection					
	(10047482)					
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)					
,	Face injury (10050392)					
	Head injury (10019196)					
Skin and subcutaneous tissue disorders (10040785)	Miliaria (10027627)					

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Please note the n* will only be presented for the CTRS posting with the time interval as per the secondary endpoint

Template 22 Global Summary of <grade 3> unsolicited signs and symptoms reported <with causal relationship with vaccination, with medically attended visit> within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

	Co-Ad	Control	Total
Number of subjects with at least one unsolicited symptom reported			
Number of doses followed by at least one unsolicited symptom			
Number of unsolicited symptoms classified by MedDRA Preferred Term*			
Number of unsolicited symptoms reported**			

Co-Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13. Dose 2: HZ/su. Dose 3:HZ/su

^{*} Symptoms reported by a subject after a given dose and classified by the same Preferred Term are counted once

^{**} Symptoms reported by a subject after a given dose and classified by the same Preferred Term and the same start date of the event, are counted once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 23 Number and percentage of subjects starting a concomitant medication during the 30- day (Days 1-30) post vaccination period by dose and overall <Exposed Set>

				<each g<="" th=""><th>roup></th><th></th></each>	roup>	
					(95% CI
Dose	Туре	N	n	%	LL	UL
Dose 1	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Dose 2	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Dose 3	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					
Overall/Dose	Any					
	Any in anticipation of study					
	vaccine reaction					
	Any chronic use					
Overall/Subject	Any					
	Any in anticipation of study vaccine reaction					
	Any chronic use					

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = total number of subjects with the corresponding administered dose

n/% = number/percentage of subjects took the specified type of concomitant medication at least once during the considered period

For Overall/dose:

N = number of administered doses

n/% = number/percentage of doses after which the specified type of concomitant medication was taken at least once during the considered period

For Overall/subject:

N = total number of subjects with at least one administered dose

n/% = number/percentage of subjects who took the specified type of concomitant medication at least once during the considered period

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 24 Number of days with <local, general> solicited symptoms <during the 7 days (Days 1-7), beyond the 7-days (Days 1-7) of> post vaccination period following each dose and overall <- Prevenar 13 vaccine, - HZ/su vaccine> <Exposed Set>

			<co-ad group=""></co-ad>	<control group=""></control>
Dose	Symptom	Statistic	value	value
<each dose=""></each>	<each symptoms=""></each>	n	XXXX	XXXX
		Mean	XX.X	XX.X
		Minimum	XX.X	XX.X
		Q1	XX.X	XX.X
		Median	XX.X	XX.X
		Q3	XX.X	XX.X
		Maximum	XX.X	XX.X
Overall/Dose	<each symptoms=""></each>	n	XXXX	XXXX
		Mean	XX.X	XX.X
		Minimum	XX.X	XX.X
		Q1	XX.X	XX.X
		Median	XX.X	XX.X
		Q3	XX.X	XX.X
		Maximum	XX.X	XX.X

Co-Ad group = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control group = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of doses with symptom

Q1= 25th percentile

Q3= 75th percentile

Please note the table by vaccine will only be done for local symptom and not for general symptom

Template 25 Solicited and unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 30-day (Days 1-30) post-vaccination period including number of events - SAE excluded <Exposed Set>

		<eac< th=""><th>h grou N =</th><th>ıp></th></eac<>	h grou N =	ıp>
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%
At least one symptom				
<each soc=""></each>	<each pt="" term=""></each>			

<each group>:

Co-Ad group = Dose 1: Prevenar+ HZ/su, Dose 2: HZ/su

Control group = Dose 1: Prevenar, Dose 2: HZ/su, Dose 3: HZ/su

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n* = number of events reported

n/% = number/percentage of subjects reporting the symptom at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 26 Number (%) of subjects with <serious adverse events from <first vaccination dose up to 30 days post last vaccination, 30 days post last vaccination up to study end, first vaccination dose up to study end>, including number of events reported <Exposed Set>

			<ea< th=""><th>ch gro N =</th><th>up></th></ea<>	ch gro N =	up>
Type of Event	Primary System Organ Class	Preferred Term (CODE)	n*	n	%
SAE	At least one symptom				
	<each soc=""></each>	<each pt="" term=""></each>			
Related SAE	At least one symptom				
	<each soc=""></each>	<each pt="" term=""></each>			
Fatal SAE	At least one symptom				
	<each soc=""></each>	<each pt="" term=""></each>			
Related fatal SAE	At least one symptom				
	<each soc=""></each>	<each pt="" term=""></each>			

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with the administered dose

n* = number of events reported

n/% = number/percentage of subjects reporting the symptom at least once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 27 Number (%) of subjects reported solicited local symptoms during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <Exposed Set>

						Co-A	d			(Contr	ol	
							95%	6 CI				95%	6 CI
Dose	Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Pain	HZ/su	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
		Prevenar	All										
			Grade 2 or 3										
			Grade 3										
			Medical advice										
	Redness (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar	All										
			>50										
			>100										
			Medical advice										
	Swelling (mm)	HZ/su	All										
			>50										
			>100										
			Medical advice										
		Prevenar	All										
			>50										
			>100										
			Medical advice										
Dose 2													
Dose 3													
Overall/Dose													
Overall/Subject													
	Prevenar 13+ HZ	leu Doco 2: H	7/eu		•		•					•	

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the type of symptom at least once following the corresponding dose For Across dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 28 Number (%) of subjects reported solicited general symptoms during the 7-day (Days 1-7) post-vaccination period following each dose and across dose <Exposed Set>

					<each gr<="" th=""><th>oup></th><th></th></each>	oup>	
							5 % CI
Dose	Symptom	Туре	N	n	%	LL	UL
ose 1	Fatigue	All					
	_	Grade 3					
		Related					
	Gastrointestinal symptoms	All					
		Grade 3					
		Related					
	Headache	All					
		Grade 3					
		Related					
	Myalgia	All					
		Grade 3					
		Related					
	Shivering	All					
		Grade 3					
		Related					
	Fever (Oral) (°C)	All (≥38.0)					
		>39.0					
		Related					
Dose 2	Fatigue						
	Gastrointestinal symptoms						
	Headache						
	Myalgia						
	Shivering						
	Fever (Oral) (°C)						
Across Dose							

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

For each dose:

N = number of subjects with the corresponding documented dose

n/% = number/percentage of subjects reporting the symptom at least once following the corresponding dose For Across dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 29 Number and percentage of subjects with <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> equal to or above <cut-off> and <GMCs, GMT> <PPS for analysis of immunogenicity, Exposed Set>

				≥	cut-o	ff ur	it	<g< th=""><th>MC, GN</th><th>IT></th><th></th><th></th></g<>	MC, GN	IT>		
						95%	6 CI		95%	6 CI		
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL	Min	Max
<anti-ge antibody, anti- pneumococcal <x> antibody titres></x></anti-ge 	Co-Ad	PRE										
		PI(M1)										
		or PII(M3)										
	Control	PRE or PI(M2)										
		PI(M1)										
		or PIII(M5)										

<each group>:

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

GM<C,T> = geometric mean antibody <concentration, titre> calculated on all subjects

N = Number of subjects with available results

95% CI = 95% confidence interval; LL = lower limit, UL = upper limit

n/% = number/percentage of subjects with <concentration, titre> equal to or above specified value

MIN/MAX = Minimum/Maximum

PRE= Pre-vaccination at Day 1

PII(M3) = Post-vaccination dose 2 at Month 3

PI(M1) = Post-vaccination dose 1 at Month 1

PI(M2) = Post-vaccination dose 1 at Month 2

PIII(M5) = Post-vaccination dose 3 at Month 5

Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3) for Co-Ad and PI(M2) and PIII(M5) for Control group.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 30 Vaccine response rates for anti-gE antibody ELISA concentrations in Co-Ad group at one month post dose 2 of HZ/su vaccine – primary objective <PPS for analysis of immunogenicity, Exposed Set>

			Co-Ad		
				959	% CI
Antibody	N	n	%	LL	UL
Anti-gE antibody	XXXX	XXXX	XX.X	XXX.X	XXX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Total = subjects either seropositive or seronegative at pre-vaccination

Vaccine response defined as:

Vaccine response defined as:

For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml)

For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

N = number of subjects with both pre- and post-vaccination results available

n/% = number/percentage of responders

<95>% CI = exact <95>% confidence interval, LL = Lower Limit, UL = Upper Limit

Template 31 Adjusted ratios of GMCs between groups (Control group divided by Co-Ad group) for anti-gE antibody ELISA concentrations at one month post dose 2 of HZ/su vaccine <PPS for analysis of immunogenicity, Exposed Set>

	Control				Co-Ad			Adjusted GMC ratio (Control / Co-Ad)			
	95% CI*					95%	CI*		95	% CI	
N	N Adjusted GMC LL UL			N	Adjusted GMC	LL	UL	Value	LL	UL	

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adjusted GMC = geometric mean antibody concentration adjusted for vaccine group, age and baseline concentration N = Number of subjects with both pre- and post-vaccination results available

95% CI* = 95% confidence interval for the adjusted GMC (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

95% CI = 95% confidence interval for the adjusted GMC ratio (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 32 Adjusted ratios of GMTs between groups (Control group divided by Co-Ad group) for anti-pneumococcal <X> antibody titres at one month post Prevenar 13 vaccine <PPS for analysis of immunogenicity, Exposed Set>

	Contro	ol			Co-Ad	k		Adjuste (Cont	ed GMT rol / Co	
	95% CI*					95%	CI*		95% CI	
N	Adjusted GMT	LL	UL	N	Adjusted GMT	LL	UL	Value	LL	UL

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Adjusted GMT = geometric mean antibody titre adjusted for vaccine group, age and baseline concentration

N = Number of subjects with both pre- and post-vaccination results available

95% CI* = 95% confidence interval for the adjusted GMT (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

95% CI = 95% confidence interval for the adjusted GMT ratio (Ancova model: adjustment for vaccine group, age and baseline concentration - pooled variance); LL = lower limit, UL = upper limit

Template 33 Mean Geometric Increase (MGI) of anti-gE antibody ELISA concentrations from baseline to one month post dose 2 of HZ/su vaccine <PPS for analysis of immunogenicity, Exposed Set>

							MGI		
								9	5% CI
Antibody	Group	N	Time point description	GMC	Time point description	Ratio order	Value	LL	UL
<antibody></antibody>	Co-Ad		PII(M3)		PRE	PII(M3)/PRE			
-	Control		PIII(M5)		PI(M2)	PIII(M5)/PI(M2)			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = Number of subjects with available results at the two considered time points

MGI = Geometric mean of the within -subject ratios of the post-vaccination reciprocal anti-gE concentration to the Day 1 reciprocal anti-gE concentration

GMC = geometric mean antibody concentration

95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit

PRE= Pre-vaccination at Day 1

PII(M3) = Post-vaccination dose 2 at Month 3 for Co-Ad group

PI(M2) = Post-vaccination dose 1 at Month 2 for Control group (considered as pre for HZ/su in Control group)

PIII(M5) = Post-vaccination dose 3 at Month 5 for Control group (considered as post dose 2 for HZ/su in Control group)

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 34 Descriptive statistics of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentration <PPS for analysis of immunogenicity, Exposed Set>

		Ea	ach Gro N=	up
			9	5% CI
Parameters	Parameter	Value	LL	UL
Anti-gE antibody	n			
	nmiss			
	Mean			
	SD			
	Min			
	Q1			
	Median			
	Q3			
	Max			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with available results

Nmiss = number of subjects with missing results

SD = Standard Deviation

Q1, Q3 = First and third quartiles

Min/Max = Minimum/Maximum

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to PI(M2) for Control group has to be considered

Template 35 Distribution of fold increase from baseline to one month post dose 2 of HZ/su vaccine for anti-gE antibody ELISA concentrations <PPS for analysis of immunogenicity, Exposed Set>

				<e< th=""><th>ach gr</th><th>oup></th><th></th><th></th><th><e< th=""><th>ach gr</th><th>oup></th><th></th></e<></th></e<>	ach gr	oup>			<e< th=""><th>ach gr</th><th>oup></th><th></th></e<>	ach gr	oup>	
					_	95	% CI					% CI
Antibody	Timing	Fold change	N	n	%	LL	UL	N	n	%	LL	UL
<each antibody=""></each>	<pii(m3)></pii(m3)>	≥2	XX	XX	XX.X	XX.X	XX.X	XX	XX	XX.X	XX.X	XX.X
-		≥4		į								
		≥6						Ì				
		≥8										
		≥10										
		≥12										
		≥14										
	<piii(m5)< td=""><td>>= Ratio1</td><td>XX</td><td>хх</td><td>XX.X</td><td>XX.X</td><td>XX.X</td><td>xx</td><td>хх</td><td>XX.X</td><td>XX.X</td><td>xx.x</td></piii(m5)<>	>= Ratio1	XX	хх	XX.X	XX.X	XX.X	xx	хх	XX.X	XX.X	xx.x

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

N = number of subjects with available results

n/% = number/percentage of subjects with concentration within the specified range

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PII(M3) = Post-vaccination dose 2 at Month 3 for Co-Ad group

PIII(M5) = Post-vaccination dose 3 at Month 5 for Control group (considered as post dose 2 for HZ/su in Control group)
Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to

Please note – To calculate the fold increase, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to

PI(M2) for Control group has to be considered

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 36 Listing of potential Immune Mediated Diseases (pIMDs) reported as identified by predefined list of preferred terms and/or by investigator assessment up to end of study <Exposed Set>

Group	Patient	Country	Age	Gender	Race	Primary	Preferred	Dose	Day	Relation	Serious	SAE	Outcome	pIMD
	ID		at			System	term		of		pIMD based	(Y/N)		Source
			onset			Organ			onset		on			
			(Y)			Class					Investigator?			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 37 Listing of all SAEs up to end of study <Exposed Set>

(Group	Sub.	Sex	Country	Race	Age	Verbatim	Preferred	Primary	MED	Dose	Day	Duration	Intensity	Causality	Outcome
		No.				at		term	System	type		of				
						onset			Organ							
L						(Year)			Class			onset				
I	·															

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 38 Listing of suspected HZ cases from first administered dose up to end of study <Exposed Set>

	Group S	Sub.	Previous dose	Day on-set	Duration	Preferred	AE description	Medical advice	Medically	attended visit	Intensity	Causality	Outcome
	I	No.				term							
Ī													

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

13-APR-2018 Page 54 of 60

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 39 Listing of dropouts due to AEs, SAEs and solicited symptoms up to end of study <Exposed Set>

Group	Study-	Country	Gender	Race	AE Description	SAE	Causality	Outcome	Type of discontinuation
	Subject No.								

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Template 40 Maximum intensity of solicited <local, general> symptoms ongoing beyond the 7-day (Days 1-7) post-vaccination period following each dose and overall <Exposed Set>

				<each group></each 	<each group></each
			Time to resolution	Value or	Value or
Dose	Symptom	Туре	(days)	n	n
<each< td=""><td><each symptom=""></each></td><td>All</td><td>N</td><td>XX</td><td>XX</td></each<>	<each symptom=""></each>	All	N	XX	XX
DOSE>			n	xx	хх
				XX.X	XX.X
			median	XX.X	XX.X
			q 3	XX.X	XX.X
		Grade 3	N	ХХ	XX
			n	xx	xx
				XX.X	XX.X
			median	XX.X	XX.X
			q 3	XX.X	XX.X
		Grade 3*Related	N	ХХ	XX
			n	xx	xx
			_	XX.X	XX.X
			median	XX.X	XX.X
			q 3	XX.X	XX.X
	<each symptom=""></each>	<each type=""></each>	N	xx	XX
SE			n	хх	XX
				XX.X	XX.X
				XX.X	XX.X
			q3	XX.X	XX.X

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Time to resolution: number of days beyond the end of the follow-up period

N = number of symptoms that were ongoing after the follow-up period

n = number of symptoms that were ongoing after the follow-up period with a complete end date

q1 = 25th percentile

q3=75th percentile

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 41 Percentage of doses reporting the occurrence of <grade 3> unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term <with causal relationship to vaccination> within the 30-day (Days 1-30) post-vaccination period <Exposed Set>

			acł I =	gr	oup
					5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL
At least one symptom					
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)				
,	Teething (10043183)				
	Vomiting (10047700)				
General disorders and administration site conditions (10018065)	Pyrexia (10037660)				
Immune system disorders (10021428)	Seasonal allergy (10048908)				
Infections and infestations (10021881)	Conjunctivitis (10010741)				
, ,	Otitis media (10033078)				
	Paronychia (10034016)				
	Tonsillitis (10044008)				
	Tonsillitis streptococcal (10044013)				
	Viral upper respiratory tract infection				
	(10047482)				
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)				
, , , , , , , , , , , , , , , , , , , ,	Face injury (10050392)				1
	Head injury (10019196)				1
Skin and subcutaneous tissue disorders (10040785)	Miliaria (10027627)				

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses followed by the symptom

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 42 Percentage of subjects reporting the occurrence of <serious adverse events, potential Immune Mediated Disease> classified by MedDRA Primary System Organ Class and Preferred Term from <first vaccination up to 30 days post last vaccination, from 30 days post last vaccination dose up to end of study, from first vaccination up to study end> <Exposed Set>

			Co-Ad N =					trol =			
				95% CI							95% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n*	n	%	LL	UL	n*	n %	6 LL	UL	
At least one symptom											
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)										
Cardiac disorders (10007541)	Acute myocardial infarction (10000891)										
	Atrial fibrillation (10003658)										
	Cardiac failure congestive										
	(10007559)										
	Tachycardia (10043071)										
	Ventricular tachycardia (10047302)										

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13. Dose 2: HZ/su. Dose 3: HZ/su

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects included in the considered cohort in each group

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Please note that n* will be used to present pIMD for CTRS posting.

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 43 Summary of temperature value by half degree increment taken by different routes reported during the 7-day (Days 1-7) post-vaccination following each dose <Exposed Set>

					Co-Ad			Control								
										95 % CI		95		95	% CI	
Dose	Symptom	Route	Type	N	n	%	LL	UL	N	n	%	LL	UL			
Dose 1	Temperature (°C)	Oral	≥35.0													
			>35.5													
			>36.0													
			>36.5													
			>37.0													
			>37.5													
			>38.0													
			>38.5													
			>39.0													
			>39.5													
			>40.0													
		Axillary	≥35.0													
			>35.5													
		>36.0														
		>36.5														
		>37.0														
		>37.5														
			>38.0													
			>38.5													
			>39.0													
			>39.5													
			>40.0													
Dose 2	Temperature (°C)	Oral	≥35.0													
	, , ,		>35.5													
			>36.0													
			>36.5													
			>37.0													
		>37.5														
		>38.0														
		>38.5														
			>39.0													
			>39.5													
			>40.0													
Dose 3																
C- Ad-	Daga 1, Drayanar 13) . 117/a	<u> </u>	<u> </u>	<u> </u>	<u>L.</u>		1	<u> </u>	<u> </u>	<u> </u>					

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su For each dose:

N = number of subjects with at least one documented dose n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit *=Temperature is defined on oral, axillary or tympanic

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 44 Global Summary of <serious adverse events, potential Immune
Mediated Disease> <with causal relationship with vaccination>
reported from <first vaccination up to 30 days post last vaccination,
from 30 days post last vaccination dose up to end of study, from
first vaccination up to study end> <Exposed Set>

	Co-Ad	Control	Total
Number of subjects with at least one <sae, pimd=""> reported</sae,>			
Number of doses followed by at least one <sae, pimd=""></sae,>			
Number of <sae, pimd=""> classified by MedDRA Preferred Term*</sae,>			
Number of <sae, pimd=""> reported**</sae,>			

Co-Ad = Dose 1: Prevenar 13 + HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3:HZ/su

Template 45 Vaccine response rates for anti-gE antibody concentrations at one month post dose 2 of HZ/su vaccine <PPS for analysis of immunogenicity, Exposed Set>

		<each group=""></each>							
					95	% CI			
Antibody	Pre-vaccination								
Timing	status	N	n	%	LL	UL			
<each antibody=""></each>	S-	XXXX	XXXX	XX.X	XXX.X	XXX.X			
-	S+	XXXX	XXXX	XX.X	XXX.X	XXX.X			
	Total	XXXX	XXXX	XX.X	XXX.X	XXX.X			

Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

S- = seronegative subjects (antibody <concentration> < <cut off> <unit>) at pre-vaccination

S+ = seropositive subjects (antibody <concentration>≥ <cut off> <unit>) at pre-vaccination

Total = subjects either seropositive or seronegative at pre-vaccination

Vaccine response defined as:

Vaccine response defined as:

For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml)

For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

N = number of subjects with both pre- and post-vaccination results available

n/% = number/percentage of responders

<95>% CI = exact <95>% confidence interval, LL = Lower Limit, UL = Upper Limit


Please note – To calculate the vaccine response, result at PII(M3) compared to PRE-for Co-Ad and PIII(M5) compared to PI(M2) for Control group has to be considered

^{*} Symptoms reported by a subject after a given dose and classified by the same Preferred Term are counted once

^{**} Symptoms reported by a subject after a given dose and classified by the same Preferred Term and the same start date of the event, are counted once

204487 (ZOSTER-059 PRI) Statistical Analysis Plan Final

Template 46 Reverse cumulative distribution curves for <anti-gE antibody concentration, anti-pneumococcal <X> antibody titres> in each group at baseline and <post dose 2 of HZ/su vaccine, post dose of Prevenar 13> <PPS for analysis of immunogenicity, Exposed Set>



Co-Ad = Dose 1: Prevenar 13+ HZ/su, Dose 2: HZ/su

Control = Dose 1: Prevenar 13, Dose 2: HZ/su, Dose 3: HZ/su

Note: This graph is provided as an example. The same graph will be provided in colour for each time point and each assay comparing the values of the groups

Please note to consider PRE and PI(M1) for both group for pneumococcal antibody. For gE antibody, PRE and PII(M3) for Co-Ad and PI(M2) and PIII(M5) for Control group.